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HIV 
The human immunodeficiency virus (HIV) preferentially targets, 
infects and kills CD4+ lymphocytes, which are essential for initiating 
an immune response against invading micro-organisms. Ultimately 
the immune response becomes severely compromised and 
opportunistic infections and virus-related cancers develop, at which 
stage the acquired immune deficiency syndrome (AIDS) is apparent. 
The time between HIV infection and the development of AIDS shows 
enormous variety, with less than two years in some individuals to 
more than ten years without treatment [1]. This is influenced by 
multiple factors, including the hosts immune response, nutritional 
status and pharmacologic prophylaxis [2,3,4].  
Early in the twentieth century the virus likely transferred from an 
animal source to humans [5]. Observations were made in the 1970s 
when African doctors noted an increase in wasting and infections 
associated with a failing immune system. The disease took its toll in 
many villages and became known to the African public as “slim 
disease”. Western physicians and scientists remained unaware of the 
epidemic until the first reports of an unusual cluster of Pneumocystis 
carinii pneumonia were made in New York in 1981 [6].  Although HIV 
was already identified as the cause for AIDS in 1984 [7], only in 1996 
a major breakthrough was made in treatment, when a combination of 
anti-retroviral drugs was shown to dramatically increase life-
expectancy among HIV patients. Currently, these anti-retroviral 
treatments (ART) are almost universally available in developed 
countries. However, despite major efforts since the G8 summit in 
2005, globally only one out of three patients in need of ART have 
access to the intervention [8]. For those who are not eligible, and 
those who do not have access to the treatment, adjuvant 
interventions to reduce the progression of HIV would fill a significant 
void in the range of treatment options.   
HIV and the intestinal microbiota 
In a healthy state, the interplay between the intestinal microbiota 
and the host is symbiotic in nature. Microbes are provided with a 
range of habitats and in turn supply energy, provide nutrients, and 
prevent colonization of the host by pathogens [9]. In this setting, the 
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immune system has to balance permissive, tolerogenic responses to 
food antigens and commensal microbes with inducing potentially 
damaging inflammatory responses to ward off pathogens.  
Infection with HIV has a disruptive impact on this physiological 
interplay. In the early stages of disease, the virus preferentially 
infects and depletes immune cells associated with the intestinal 
immune system, including CD4+ lymphocytes and dendritic cells 
[10,11,12]. Their infection is likely due to the relatively high 
expression of HIV co-receptors as a result of their activated state 
[13,14]. The intestinal epithelial cells are also affected by the 
infection leading to a reduced barrier function and compromised 
mucosal regeneration mechanisms [15,16]. The net result is an 
increased risk of gastro-intestinal infections at all stages of HIV 
infection and a high prevalence of gastro-intestinal disorders with 
unknown etiology [17,18]. 
Furthermore, the breakdown of the intestinal immune system 
results in an aberrant microbiota with higher levels of pathogens such 
as Pseudomonas aeruginosa and Candida albicans and reduced or 
undetectable levels of Bifidobacterium and Lactobacillus species 
[19,20]. Collectively these changes can lead to leakage of microbial 
products, including lipopolysaccharide (LPS) and bacterial DNA, to the 
peripheral circulation of HIV patients [15,16]. Increased serum levels 
of microbial products have been associated with enhanced levels of 
inflammatory cytokines and immune cell activation [21,22,23]. This, 
in turn, can be a factor for enhanced HIV progression [21,24].  
The composition of the intestinal microbiota and its interplay with 
the immune system could have an impact on leakage of microbial 
products from the intestinal tract and the associated inflammatory 
response. If modulating it by using beneficial microbes (probiotics) 
can influence these factors, this could have an impact on HIV 
progression.  
The intestinal microbiota and probiotics 
Probiotics, defined as “live microorganisms which, when 
administered in adequate amounts, confer a health benefit on the 
host” [25], have been studied in several conditions related to a 
compromised intestinal epithelial barrier and an aberrant intestinal 
microbiota. Although most of these studies have been conducted 
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among persons without HIV, some of these findings can be applied to 
HIV subjects. For example, various trials have been conducted among 
critically ill patients to assess whether a probiotic formulation could 
impact a compromised intestinal epithelial barrier and reduce leakage 
of bacterial products to the peripheral circulation. A product, 
combining probiotic strains with a prebiotic [Synbiotic 2000 Forte], 
was shown to reduce the rates of bacteria detected in the 
bloodstream and mortality [26], findings which were confirmed in 
consecutive trials [27,28,29]. In addition, these studies also showed 
an enhanced intestinal immune defense with an increased secretion 
of fecal IgA.  Among non-critically ill patients, similar observations 
were made [30,31]. However, the evidence is not conclusive, as  
three other randomized clinical trials using L. acidophilus La-5 and 
Bifidobacterium lactis Bb-12 [32,33] or L. plantarum 299v [34] 
reported no reduction in leakage of microbial products to the 
peripheral circulation. This suggests strain specific effects or the need 
of prebiotics for efficacy.  
Specific probiotic strains have been shown to modify the intestinal 
microbiota at least temporarily in a range of populations [35,36,37]. 
Furthermore, they can interfere with the colonization and proliferation 
of pathogens in the intestinal tract in various ways; by enhancing the 
secretion of pathogen-specific IgA [38], inducing β-defensin 
production by the host [39], or secreting bactericidal compounds 
themselves [40,41]. The net effect is reduced adhesion and invasive 
properties of intestinal pathogens [42,43]. As a result, certain 
probiotic strains have been firmly established as having the ability to 
prevent or treat gastro-intestinal infections (reviewed in [44]). 
Probiotics to modify the intestinal microbiota in 
HIV 
Although the application of probiotics to prevent gastro-intestinal 
infections and potentially reduce a compromised state of the 
intestinal barrier bears promise, only a few studies have assessed the 
potential of probiotics for HIV. The first small trials concluded that 
supplementation with L. rhamnosus GG or L. reuteri to a level of 1010 
cfu/day was safe and not associated with adverse events [20,45]. 
These were followed by randomized controlled trials assessing the 
potential for specific strains to reduce the progression of HIV. One 
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study of 77 children in Brazil showed an increase of 118 CD4+cells/µl 
among those receiving B. bifidum and Streptococcus thermophilus for 
two months compared to a decrease of 42 CD4+cells/µl among the 
placebo group (p = 0.05) [46]. Another study of 24 HIV patients in 
Nigeria showed after four weeks of L. rhamnosus GR-1 and L. reuteri 
RC-14 an increase of 6.7 CD4+cells/µl compared to a decrease of 2.2 
CD4+cells/µl among the placebo group (p < 0.05) [47].  
However, the impact of probiotics on the immune function has not 
been evaluated during follow-up periods of more than two months. 
Therefore, this thesis aims to answer the following question: What is 
the long-term impact of probiotic use on the immune function 
of HIV patients? 
HIV and the vaginal microbiota 
The quantitative composition of microorganisms living on the 
vaginal epithelium has a major impact on the health of a woman. The 
composition is determined by multiple factors, including the nutrients 
available in the vaginal tract, the ability of organisms to ascend from 
the rectum and the host immune response. High levels of estrogen in 
reproductive age women result in glycogen being deposited on the 
vaginal epithelium. This complex sugar molecule is mainly 
metabolized by Lactobacillus species with concurrent production of 
organic acids [48]. The resulting low pH creates an environment 
inhospitable to many pathogenic organisms [49]. 
For reasons poorly understood, a shift can occur from a vaginal 
microbiota dominated by lactobacilli and characterized by a low pH, 
to a complex mix of anaerobic bacteria and a higher pH [50]. This 
condition is termed bacterial vaginosis (BV) and is diagnosed by the 
clinical Amsel criteria or the microbiological Nugent score [51,52].  
Among women with HIV, the condition is highly prevalent and its 
resulting higher pH disrupts physiological mechanisms that might 
inactivate or contain the virus [49,53,54,55]. The physiologically 
aberrant environment associated with BV results in an increased risk 
of viral transmission from the host to the vaginally born child or to a 
sexual partner [56]. In addition, BV appears to be more recalcitrant 
to antibiotic treatment in HIV patients and treatment is ineffective in 
reducing shedding of viral HIV particles from the vaginal tract 
[57,58].  
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An understanding of the vaginal microbiota among women living 
with HIV is important as different micro-organisms may represent 
distinct risk-profiles in the transmission of HIV or severity of BV.  
Therefore, a study was undertaken to answer the following question: 
Which micro-organisms constitute the vaginal microbiota 
among women with HIV? 
Probiotics to modify the vaginal microbiota in 
HIV 
Conventional antibiotic treatment for BV has a cure rate of 50 – 
80% among women not infected with HIV. However, more than half 
of women have recurrent BV within six months after antibiotic 
treatment [59,60]. The rate of recurrence is higher among women 
living with HIV, with antibiotic cure rates being negligible [57]. In an 
attempt to provide an adjunct treatment for BV, some effort has been 
made to select lactobacilli from a healthy vaginal microbiota with the 
ability to modify the vaginal microbiota of women with BV. Of those, 
L. rhamnosus GR-1, L. reuteri RC-14 and to a lesser extent L. 
crispatus CTV-5 are the most thoroughly studied [61,62].  L. 
rhamnosus GR-1 and L. reuteri RC-14 have been shown to persist in 
the vagina for up to 21 days after vaginal application [63,64,65]. 
Using molecular techniques, Morrelli and co-workers confirmed that 
the probiotic strains could reach the vagina after oral ingestion [66]. 
Consecutive studies then showed that oral application of L. 
rhamnosus GR-1 and L. reuteri RC-14 could improve the vaginal 
microbiota of healthy women in terms of reduced Nugent score’s 
[67,68,69,70]. Also, application of the probiotic strains in addition to 
metronidazole treatment was shown to improve the cure-rate of BV. 
For example, one randomized controlled trial conducted among 125 
African women with BV showed that combining metronidazole with L. 
rhamnosus GR-1 and L. reuteri RC-14 had a cure rate of 88% versus 
40% among those not additionally supplemented (p < 0.001) [71]. 
The improved cure rate of antibiotics in combination with the 
probiotic strains was confirmed in a Brazilian trial [72].  
This concept has great potential for women living with HIV, who 
bear many of the health consequences of BV. However, no studies 
have been conducted evaluating this concept in such populations, nor 
has the long term impact of this strategy been assessed. A study was 
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designed to answer the following question: Can probiotics prevent 
or improve the cure rate of BV among women with HIV? 
Overview of the thesis 
Several studies have been undertaken to answer the research 
questions.  In part I (chapter 2 – 3) the question “What is the long-
term impact of probiotic use on the immune function of HIV 
patients?” is addressed.  Chapter 2 provides a systematic 
assessment of the effectiveness of nutritional interventions in 
reducing the progression of HIV. Chapter 3 describes a conceptual 
framework for the use of probiotics to impact HIV progression. 
Chapter 4 evaluates the effectiveness of probiotics in preserving the 
immune function among a cohort of Tanzanian users with HIV. A 
randomized controlled trial is described in chapter 5 to evaluate the 
impact of 25 weeks probiotic use on the immune function of HIV 
patients.  
The second research question on “Which microorganisms 
constitute the vaginal microbiota among women with HIV?” is 
addressed in part II (chapter 6 – 7).  In chapter 6 an in depth 
assessment of the vaginal microbiota among HIV infected women is 
performed and chapter 7 describes the characteristics of the 
methodology developed to analyze the vaginal microbiota.  
The third research question on "Can probiotics prevent or improve 
the cure rate of BV among women with HIV?" is addressed in part III 
(chapter 8 – 9). A critical assessment of the studies that have been 
conducted to assess the impact of probiotic supplementation on the 
vaginal microbiota is provided in chapter 8. This is followed, in 
chapter 9, by the description of a randomized controlled trial on the 
impact of probiotics on the cure rate of BV among women with HIV. 
 The thesis concludes with a general discussion, along with 
conclusions and recommendations in chapter 10.  
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Abstract 
Low serum concentrations of micronutrients, intestinal 
abnormalities, and an inflammatory state have been associated with 
HIV progression. These may be ameliorated by micronutrients, N-
acetyl cysteine, probiotics, and prebiotics. This review aims to 
integrate the evidence from clinical trials of these interventions on 
the progression of HIV. Vitamin B, C, E, and folic acid have been 
shown to delay the progression of HIV. Supplementation with 
selenium, N-acetyl cysteine, probiotics, and prebiotics has 
considerable potential, but the evidence needs to be further 
substantiated. Vitamin A, iron, and zinc have been associated with 
adverse effects and caution is warranted for their use.  
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Introduction 
Infections caused by the Human Immunodeficiency Virus (HIV) are 
one of the leading public health concerns around the world. Over 33 
million people are living with HIV and nearly three million became 
infected during 2008 [1]. While antiretroviral therapies (ART) are 
almost universally available in developed countries, only since the G8 
summit in 2005 have they been made more readily accessible to 
patients in developing countries [2]. As there is considerable risk for 
developing ART-induced toxic effects and metabolic dysfunction, the 
therapy is initiated only when the immune function is compromised 
(<350 CD4 cells/µL). For patients who have not developed severe 
immune deficiency, there is a significant void in methods to provide 
improved health. HIV causes certain dietary complications, including 
increased resting energy expenditure [3,4], enhanced oxidative 
stress [5], and a deleterious impact on the gastrointestinal system 
[6] that may require interventions specifically targeted to HIV. 
Therefore, the provision of a balanced and adequate diet is of prime 
importance for people living with HIV [7].  
Vitamins and minerals (referred to as micronutrients) have 
received widespread and recent attention as potential interventions to 
delay HIV progression [8]. Although micronutrient interventions for 
people living with HIV have been thoroughly reviewed [9], to our 
knowledge, no review articles have integrated the evidence of the 
potential of various bioactive components, such as N-acetyl cysteine, 
probiotics, and prebiotics with micronutrients for this population. 
These interventions could potentially delay the progression of HIV 
and therefore postpone the moment that a patient becomes immune-
compromised, and thus eligible for ART. Moreover, they could act in a 
complementary fashion with the ART, once the latter is initiated. 
Therefore, we present an assessment of randomized controlled trials 
(RCT) that evaluates the impact of micronutrients, N-acetyl cysteine, 
probiotics, and prebiotics on mortality, CD4 count, or HIV viral load 
among people living with HIV. Although this review emphasizes 
results from trials, it also briefly explores results from observational 
studies.  
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Micronutrients 
The use of micronutrients among people living with HIV is 
widespread and comes from the concept that the virus causes a 
diverse range of nutrient abnormalities (reviewed in [10]). The 
depletion of micronutrients may occur through increased metabolic 
requirements, enhanced excretion, and intestinal mal-absorption 
(reviewed in [11]).  
Early studies of micronutrients tested the effect of single vitamins 
or minerals on delaying the progression of HIV. While some successes 
were reported, the focus has now turned to multivitamin/mineral 
supplementation as a more comprehensive approach to delaying HIV 
progression. The levels of micronutrients consumed by people living 
with HIV are often much higher than recommended by the Dietary 
Reference Intakes, potentially leading to adverse events [12]. 
Therefore, health care professionals should be aware of the beneficial 
and potential adverse effects of micronutrients in order to make 
informed, safe, and practical decisions for people living with HIV.  
Vitamin A 
Vitamin A is essential for normal immune function, the 
maintenance of mucosal surfaces, and haematopoiesis [13]. Also, 
vitamin A supplementation is recognized for its ability to decrease 
morbidity and mortality rates for some infectious diseases [14]. 
Vitamin A deficiency has consistently been associated with an 
increase in mother-to-child transmission of HIV (MTCT) [15]. 
However, there is conflicting evidence coming from observational 
studies on HIV progression and vitamin A where in one study, a 
cohort (n = 179) of HIV infected drug users, reported increases in 
mortality and lower CD4 counts associated with lower serum vitamin 
A levels [16]. In contrast, another observational study of HIV-infected 
men (n = 311) did not find a relationship between lower serum 
retinol (vitamin A) status and HIV disease progression or CD4 count 
[17].  
There seems to be a potential role for vitamin A in children living 
with HIV. During an RCT in Tanzania, 687 children without signs of 
vitamin A deficiency who were admitted to the hospital with 
pneumonia were randomized. Some were given a large dose of 
vitamin A (400,000 IU) at baseline and again at four and eight 
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months post-discharge. Among those, 58 were diagnosed with HIV 
and naïve to ART. Overall, a 49% reduction in mortality (p = 0.05) 
and a 92% reduction in diarrhea-related death (p = 0.01) was 
observed. These effects were more profound among the sub-group of 
children with HIV with a reduction in mortality of 53% (p = 0.04) and 
a reduction of 68% in AIDS related deaths (p = 0.05) [18]. Another 
RCT among 181 ART naïve HIV-infected children (15–36 months) in 
Uganda found similar results. Vitamin A supplementation (60 mg 
retinol) at three month intervals for a median of 17.8 months reduced 
mortality rates by 46% (p = 0.04), as well as persistent cough and 
chronic diarrhea. No effects were noted on CD4 count or HIV viral 
load [19]. Thus, there are potential benefits conferred by vitamin A 
supplementation for reducing the morbidity and mortality of children 
living with HIV in developing countries.  
Women living with HIV are at increased risk for experiencing 
adverse pregnancy outcomes, such as preterm birth and the delivery 
of low-birth-weight infants. Moreover, women can transmit the virus 
to their newborns through intrauterine, delivery, or breastfeeding 
routes. Research on the role of vitamin A in birth outcomes is critical 
as low levels of the vitamin have been associated with adverse 
pregnancy outcomes and vertical transmission of HIV [15]. To 
evaluate the effect of vitamin A supplementation on MTCT, RCTs were 
conducted among ART naïve pregnant women in South Africa, 
Malawi, and Tanzania. In South Africa, an RCT among 728 pregnant 
women showed that daily Vitamin A supplementation (5000 IU and 
30 mg β-carotene) and a large dose at delivery (200,000 IU) did not 
reduce MTCT or mortality among women and infants, although among 
those infants born pre-term, vitamin A was associated with a 
reduction in MTCT [20]. In the Malawian RCT, pregnant women with 
HIV (n = 697) were randomized to receive daily vitamin A (3 mg 
retinol) or placebo. Infants whose mothers were in the vitamin A 
group had a higher birth weight (p = 0.05) and fewer incidences of 
anemia at six weeks, from 41% to 23% (p = < 0.001). This trial, 
however, did not show vitamin A supplementation to have an effect 
on MTCT [21]. Another trial among HIV-infected pregnant women in 
Tanzania (n = 1078) did not show any effects of vitamin A 
supplementation (30 mg β-carotene plus 5000 IU vitamin A) on 
improved pregnancy outcomes. In contrast, vitamin A 
supplementation appeared to increase the MTCT of HIV by an 
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additional 38% compared to the placebo (p = 0.009) [22]. 
Furthermore, vitamin A did not have any effect on HIV-associated 
mortality or CD4 count during a median 71 months of follow-up 
among the women [23,24].  
In conclusion, two studies have indicated a potential benefit of 
vitamin A supplementation for children with HIV in developing 
countries who are naïve to ART. However, these benefits need to be 
confirmed in larger RCTs with HIV progression, mortality, and 
morbidity as primary outcomes. With respect to maternal 
supplementation, little evidence exists to support the use of vitamin A 
supplements in HIV-positive pregnant women. Rather, the possibility 
that maternal vitamin A supplementation could increase the risk of 
vertical transmission warrants caution for its use among this 
population. The notion that vitamin A supplementation reduced the 
benefits of multivitamin supplementation indicates that no profound 
benefits may exist for supplementing vitamin A among adults. 
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Vitamin B, C, E and Folic Acid 
B-vitamins are essential components of our immune system. 
Riboflavin deficiency hampers the generation of a humoral antibody 
response, vitamin B-6 deficiency reduces the maturation of 
lymphocytes, and vitamin B-12 deficiency impairs the function of 
neutrophils [25]. It is therefore not surprising that among people 
living with HIV, higher serum levels and intake of B vitamins have 
been associated with improved survival. In a large cohort study of 
people living with HIV in the US (n = 241), the highest quartile of 
intake for each B-group vitamin was independently associated with 
improved survival over the course of an eight-year follow-up: B1, 
(relative hazard (RH) = 0.60), B2 (RH = 0.59), B6, (RH = 0.45), and 
niacin (RH = 0.57) [26]. Higher serum levels of vitamin B12 were 
also associated with delayed HIV progression [27]. These results 
were confirmed in a matched case-control study within a cohort of 
South African HIV patients. The median survival time of patients 
using vitamin B supplements (264 weeks) was significantly longer 
than of those not taking B vitamins (144 weeks) (p = 0.0014) [28].  
In several observational studies, vitamins C and E were found to 
be lower among people living with HIV [5,10]. These findings were 
confirmed by the group of Baum et al., who compared the nutrient 
levels of 108 HIV-infected gay men, almost all with high CD4 counts, 
to a similar group of HIV-negative controls. In this seminal study, 
they found that deficiencies of vitamins B6, B12, A, E, and zinc were 
highly prevalent in the HIV-infected cohort. Thus, the conclusion was 
that HIV-infected individuals most likely require micronutrient intake 
in multiples of the DRI in order to maintain normal serum levels [29]. 
Lower levels of vitamin C and E were also related to significantly 
higher levels of oxidative stress [5], which presumably leads to 
increased viral replication [30]. In longitudinal studies, the dietary 
intake of vitamin E [31] and higher vitamin E serum levels [17] were 
associated with higher CD4 counts and a reduced risk of HIV 
progression [32].  
These findings were the impetus for studies assessing whether 
exogenous supplementation of vitamins could reduce oxidative stress 
and therefore potentially reduce HIV viral load. A pilot RCT (n = 49) 
among HIV patients receiving ART showed that the group receiving 
vitamin E (800 IU) and C (1000 mg) for three months had 
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significantly less oxidative stress (reduction of plasma peroxides and 
malondialdehyde) and a trend was seen (p = 0.1) towards a 
reduction of the viral load (-0.45 log10 copies/ml) compared to the 
placebo group (+0.50 log10 copies/mL) [33]. A study in Uganda with 
a short follow-up period of six weeks did not find a benefit of 
supplementation. The RCT (n = 141) among ART naïve HIV patients 
admitted with diarrhea showed that supplementation with a 
combination of vitamin A (10,500 IU), E (300 mg), Selenium (150 
µg), and Zinc (200 mg) for two weeks did not reduce the length of 
time with diarrhea. Moreover, no effects were seen on mortality or 
CD4 count after the six weeks of follow-up. Low serum levels of 
vitamin A and E were confirmed to be predictors of mortality in this 
study, but exogenous supplementation did not increase these levels 
[32]. The expectation to see an effect of supplementation within such 
a short time-frame might have been unrealistic, as an impact on HIV 
progression is typically assessed over longer periods of time.  
The first long term study with HIV progression and mortality as 
primary outcome was conducted in Tanzania. A specific multivitamin 
combination of vitamins B, C, E, and folic acid (20 mg B1, 20 mg B2, 
25 mg B6, 100 mg B3, 50 µg B12, 500mg C, 0.8mg folic acid) was 
repeatedly shown to increase CD4 and CD8 counts, lower viral loads, 
and reduce mortality among ART naïve HIV infected women [34]. The 
large RCT (n = 1075) among pregnant women showed an increase in 
CD4 count from baseline (between 12 and 27 weeks gestation) to six 
weeks postpartum of 176 cells/µL vs. 112 cells/µL (p = < 0.001) in 
the placebo group. At 30 weeks postpartum, there was still a 
significant difference with an increase of 99 CD4 cells/µL in the 
multivitamin group vs. an increase of 59 CD4 cells/µL in the placebo 
group (p = 0.05), in addition to an increase in CD8 and CD3 cells. 
Furthermore, there were significant reductions in fetal death (Relative 
Risk (RR) = 0.61), low birth weight (RR = 0.56), and severe preterm 
birth (RR = 0.61) with multivitamin supplementation [34]. Long term 
(71 months) follow-up of this cohort showed that only 67 of 271 
(25%) women receiving multivitamins died or developed stage 4 
disease compared to 83 of 276 (30%) receiving placebo (RR = 0.71, 
P = 0.04). Moreover, women receiving multivitamin had on average a 
CD4 count of 48 cells/µL higher than the placebo group (p = 0.01), 
and a significantly lower viral load (p = 0.02) [24]. Multivitamins also 
reduced the risk of wasting (RR = 0.66, p = 0.02) and the incidence 
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of weight loss episodes amongst HIV infected women [35]. 
Interestingly, women with impaired immunological (low lymphocyte 
count) and nutritional status (low haemoglobin levels) at baseline had 
reduced transmission of the virus from mother to child (RR = 0.37, p 
= 0.02) and decreased child mortality after 24 months (RR = 0.82, p 
= 0.08) when given multivitamins [22]. These results suggest that 
this particular multivitamin supplement (20 mg B1, 20 mg B2, 25 mg 
B6, 100 mg B3, 50 µg B12, 500mg C, 0.8 mg folic acid) can be safely 
administered to pregnant women and has considerable immunological 
benefits.  
To assess the impact of the same multivitamin formula and 
selenium (200 µg daily for six weeks) on the infectivity (vaginal HIV 
shedding) of ART naïve women with HIV, an RCT (n = 400) was 
launched in Kenya. Although a relatively short intervention period of 
six weeks was used and the primary outcome was infectivity, the 
study confirmed the beneficial effects of the multivitamin supplement 
on the CD4 count (a mean of 23 cells/µL higher than placebo) and 
CD8 count (a mean of 74 cells/µL higher than placebo). However, the 
trial showed a potential increase of HIV infectivity amongst women 
receiving supplements as the odds of detecting HIV infected vaginal 
epithelial cells increased 2.5 fold (p = 0.001), as well as the quantity 
of vaginal HIV RNA (p = 0.004) [36].  
In Bangkok, an RCT (n = 481) was conducted with an intervention 
using similar concentrations of vitamin B, C, E, and folic acid (24 mg 
B1, 15 mg B2, 40 mg B6, 30 µg B12, 400mg C, 3 mg A, 0.1 mg folic 
acid), but with the addition of vitamin A, zinc, and various other 
micronutrients (table 2.). Overall, a trend was seen towards a 
reduced mortality in the multivitamin group (RR = 0.53, p = 0.1) and 
a significant reduction among subgroups of those with a CD4 count 
<200 (RR = 0.37, p = 0.05) and <100 (RR = 0.26, p = 0.03). 
However, no effect was seen on viral load and CD4 count [37].  
A multivitamin combining vitamins A, B, C, D, E, zinc, copper, 
selenium, iodine, and folic acid with concentrations approximately 10 
times lower than the Tanzanian combination was tested within a 
cluster randomized trial in Zambia. Households (n = 500 individuals) 
were randomized to receive the multivitamin combination for an 
average of 3.3 years [45]. No differences were seen in terms of CD4 
count or diarrhea incidence amongst those living with HIV who are 
ART naïve (n = 135). However, a significant difference in mortality 
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was reported, as 20% (12/61) died during follow-up with placebo as 
compared to 5% (4/74) amongst the multivitamin supplemented 
group (p = 0.03 by log-rank test). 
In the United States, an RCT (n = 40) among HIV patients treated 
with ART who displayed related neurotoxicity, tested the impact of an 
intervention combining vitamins B, C, E, and folic acid in a daily dose 
approximately 6 times higher than the Tanzanian multivitamin 
combination and with the addition of vitamins A, D, zinc, N-acetyl 
cysteine (1.2g), and various other minerals (Table 2). The 
intervention group experienced an increase in CD4 count from a 
baseline of 65 cells/µL after 12 weeks of supplementation, as 
compared to -6 cells/µL in the placebo group. However, no 
differences were seen in viral load or neuropathy scores [38]. 
In summary, several well designed RCTs have shown a 
considerable benefit of supplementation of vitamins B, C, E, and folic 
acid (20 mg B1, 20 mg B2, 25 mg B6, 100 mg B3, 50 µg B12, 500 mg 
C, 0.8mg folic acid) to ART naïve HIV patients. Although in 
subpopulations a decrease in MTCT has been reported, further studies 
are needed to assess if the potential increase in infectivity is present 
and may enhance HIV transmission. Furthermore, as one trial has 
shown potential for this approach among an ART-treated population, 
these results need to be confirmed by larger RCTs with long term 
follow-up.  
Vitamin D 
The interest in vitamin D and the immune system has been 
catalyzed by the discovery of vitamin D receptors in peripheral blood 
mononuclear cells involved in immune system regulation [39]. 
Vitamin D is involved in immune-related diseases, such as Ulcerative 
Colitis and Crohn’s Disease, and has recently gained attention for its 
mediating role in innate immunity and the body’s response to 
intracellular micro-organisms, such as Mycobacterium tuberculosis 
[40]. The role of vitamin D in HIV progression is less well understood. 
In Tanzania, an observational study (n = 1078) was conducted within 
a trial to assess the effects of the vitamin D status of pregnant 
women on adverse pregnancy outcomes, MTCT, and child mortality 
[41]. Children born to mothers with low vitamin D levels had a 64% 
greater risk of dying during follow-up and an overall 46% higher risk 
of contracting HIV. In this observational study of vitamin D status’ 
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effects on child morbidity and mortality, a non-linear relationship was 
found between vitamin D levels and MTCT (p = 0.01), where the risk 
of MTCT decreased as the levels of vitamin D increased [41]. The only 
RCT with findings on vitamin D and HIV progression to date was 
conducted in Guinea-Bissau. The trial (n = 367) among Tuberculosis 
(TB) patients assessed the impact of supplements of vitamin D every 
four months (100,000 IU of oral cholecalciferol) over a 12-month 
period [42] on mortality and the clinical severity of TB (Table 2). 
Vitamin D did not appear to improve the severity of tuberculosis, nor 
was there an impact on mortality in both the complete group and the 
sub-group infected with HIV (n = 135) [42]. Therefore, there is 
insufficient evidence to recommend vitamin D use among people 
living with HIV. Larger RCTs are warranted, as there might be 
considerable potential. 
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Iron 
Iron deficiency is the most common nutritional deficiency in the 
world, and is a condition mainly affecting women. Among people 
living with HIV, anemia (defined as low haemoglobin) is highly 
prevalent and is associated with increased mortality [46,47] and 
enhanced HIV progression [47]. Although anemia can generally be 
treated by iron supplementation, various clinical observations have 
raised the concern that iron supplementation may adversely affect 
HIV progression and increase mortality [48]. Firstly, in a 
retrospective study among thalassemia major patients (n = 64), the 
rate of progression of HIV was significantly faster amongst those 
receiving lower doses of the iron chelating agent, desferrioxamine, 
and who have higher serum ferritin concentrations [49,50]. Second, 
the concurrent administration of low doses of iron with dapsone for 
the prophylaxis of Pneumocystis carinii pneumonia in HIV-positive 
patients was associated with an increased risk of mortality in a 
randomized study among 196 HIV patients [51]. In contrast, the 
administration of Dapsone for the prophylaxis of Pneumocystis carinii 
without a low dose of iron did not lead to excess mortality in another 
trial [52]. Thirdly, a study on polymorphisms of haemoglobin-binding 
haptoglobin indicated that the haptoglobin 2-2 polymorphism is 
associated with higher iron stores and shortened survival among HIV 
patients [53]. Finally, a retrospective study of iron load in bone 
marrow macrophages among HIV patients suggested that high iron 
stores were associated with a shorter survival in HIV-positive patients 
[54]. As none of these observations could provide conclusive 
evidence for an adverse effect of iron on HIV progression, two 
prospective studies were conducted. Within a larger RCT of non-
anemic participants (n = 181), a subpopulation of ART naïve HIV 
patients (n = 45) was studied to assess the effect of daily 60 mg iron 
supplementation (twice weekly for 4 months) on HIV viral load (table 
3). In this small study, no increase in HIV viral load could be detected 
[55]. In the United States, an RCT was conducted among female drug 
users infected with Hepatitis C Virus (n = 485) and among them, a 
subgroup co-infected with HIV (n = 138), of whom 50 were treated 
with ART. An assessment was made on whether iron supplementation 
Nutritional interventions and HIV progression 
 | 37  
(18 mg daily) would increase HIV viral load and reduce anemia over a 
12-month period. At follow-ups, the proportion with anemia in the 
iron group was only 21% vs. 31% in the placebo group (P = 0.03) at 
6 months and, respectively, 26% versus 30% (P = 0.5) at 12 
months. Furthermore, no increase in HIV viral load could be detected 
[56]. This study could exclude a large increase in HIV viral load due 
to iron supplementation, but was not powered to detect small 
increases over a larger period of time. Furthermore, the conclusions 
from this study cannot readily be extrapolated to other HIV 
populations. It remains to be determined what the influence is of iron 
supplementation among patients who are receiving ART. Given the 
potential adverse role of iron in HIV progression, caution is warranted 
for iron supplementation among HIV infected populations. Routine 
supplementation without a specific indication is contra-indicated. 
Zinc 
Various studies have investigated the role of zinc in HIV disease 
progression. The immunologic consequences of zinc deficiency are 
manifold, given the involvement of the mineral in basic cellular 
processes, which are essential in immunological mechanisms [57]. 
Consequently, zinc deficiency has been associated with a higher 
susceptibility to infectious diseases, such as pneumonia, malaria, and 
diarrhea [58]. There is evidence that zinc deficiency amongst people 
living with HIV may account for an improper maturation of CD4 count 
cells mediated through low levels of the zinc-dependent hormone, 
thymuline. This may lead to a less effective immune response and a 
higher susceptibility to opportunistic infections [59]. However, 
evidence for the relationship between zinc status and HIV is 
inconclusive. In an observational study of asymptomatic HIV-infected 
men in the United States, high zinc intake has been shown to be 
significantly associated with faster HIV progression and an increased 
mortality amongst men [17,60]. In contrast, another observational 
US cohort study of HIV positive men suggested that higher serum 
zinc levels were inversely associated with mortality [61].  
A first interventional study was conducted in Italy among 57 
Zidovudine treated HIV patients that had developed or were at risk of 
developing AIDS (Table 4.). Those supplemented daily with zinc (45 
mg) for 30 days experienced, at follow-up, a lower frequency of 
opportunistic infections after 24 months and an increase in CD4 count 
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after four months (compared to the controls) [59]. To assess the 
safety of daily zinc supplementation (10 mg) to ART naïve children 
with HIV, an RCT (n = 96) was conducted in South Africa. This trial 
did not show any apparent benefit of zinc supplementation. No 
differences were found in CD4 count, viral load, or haemoglobin 
concentration, while supplementation was found to be safe [62]. This 
trial was followed by the largest study to date on zinc 
supplementation for people living with HIV and was aimed at 
assessing the potential benefits of zinc supplementation on pregnancy 
outcomes. The study population of the RCT (n = 400) consisted of 
pregnant ART naïve women with HIV in Tanzania [63]. All women 
received the multivitamin supplement (discussed in the section on 
vitamins B, C, E, and folic acid) and were randomized to receive, in 
addition, either a placebo or a 25 mg daily dosage of zinc between 
recruitment and six weeks after delivery. The results showed no 
differences in pregnancy outcomes, HIV transmission, CD4 or CD8 
count, and viral load. However, zinc supplementation was inversely 
associated with haemoglobin levels, and was related to a threefold 
increase in the probability of wasting (RR = 2.7, p = 0.03) [64].  
In conclusion, although an initial trial has shown potential benefits 
of zinc supplementation among ART treated patients, these results 
have not been replicated in a trial among ART naïve pregnant women. 
Further research is warranted to assess whether there is a potential 
role for zinc among HIV patients treated with ART.  
Selenium 
The trace selement selenium has been suggested to be a key 
nutrient for people living with HIV. Lower serum concentrations of 
selenium in both adults and children infected with HIV have been 
linked to increased mortality [65] and an increased viral load 
[66,67,68]. The role of selenium in immunity and antioxidant defence 
may be the underlying mechanism of an enhanced HIV progression 
with lower levels of the micronutrient [69]. These observational 
findings instigated clinical trials to assess whether selenium 
supplementation could have an impact on HIV viral load, CD4 counts, 
or HIV progression (Table 5). An earlier pilot RCT among ART treated 
HIV patients (n = 52) showed that selenium supplementation (100 
µg) could enhance the antioxidant status of HIV patients [70]. A 
larger RCT (n = 186, of which 124 were receiving ART) showed that 
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daily supplementation with selenium (200 µg) did not affect CD4 
count levels or viral load after two years of follow-up. However, a 
smaller proportion (25%) among the selenium group experienced a 
substantial decline in CD4 count (>50 cells/µL) when compared to the 
placebo group (46%, p = 0.01). In addition, the relative risk of being 
admitted at a hospital was 2.4-times lower among the selenium 
supplemented group in comparison to the placebo group (p = 0.008) 
[71]. In a more recent RCT among 262 HIV-infected patients (192 
receiving ART), nine-month supplementation with selenium (200 µg 
daily) resulted in an increase in CD4 count (p = 0.04) and a decrease 
in viral load (p = 0.02) [72].  To assess the impact of selenium 
supplementation on mother and child mortality, a large RCT (n = 
913) was conducted amongst pregnant women in Tanzania. Daily 
selenium (200 µg) supplementation until six months post partum did 
not affect CD4 count, viral load, or overall mother and child mortality. 
However, at six weeks after delivery, a reduction of 57% in child 
mortality was found (p = 0.05) amongst the selenium supplemented 
group [73]. The authors concluded that the lack of a beneficial effect 
of selenium supplementation on HIV progression may have been due 
to the low prevalence of ART use and selenium deficiency amongst 
their study population or because of a reduced effect of selenium 
amongst patients already supplemented with micronutrients [73].  
At present, there is no support for providing selenium supplements 
to HIV patients who are not selenium deficient and who are already 
receiving a high-dose multivitamin. Although two RCTs have shown 
that selenium supplementation can potentially reduce the viral load 
and enhance the immunological status of patients treated with ARTs, 
well designed trials with a long term follow-up and an appropriate 
sample size among similar populations are needed to substantiate the 
evidence for the use of selenium. 
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N-acetyl Cysteine  
Glutathione (GSH) is a principal regulator of oxidative stress, 
which occurs in the intracellular space and on cellular membranes. 
HIV-infected people tend to have abnormal GSH levels in various 
components of the immune-system, including CD4 cells. In vitro 
studies have shown that lower intracellular GSH levels decrease cell 
survival and increase NF-ĸB activation and consequently, HIV 
replication. Observational studies have linked GSH deficiency directly 
to patient survival [74]. Various interventions have been tested to 
increase GSH levels to normal among HIV patients. N-acetyl cysteine 
(NAC), a pro-drug used to replenish GSH after paracetamol 
intoxication, was shown to restore normal GSH levels among HIV 
patients [74-76].  
One of the first RCTs was conducted by Herzenberg et al., who 
randomized HIV patients (n = 246, mixed ART status) with low GSH 
levels to NAC supplementation (3.2–8 g daily) or to a placebo for 
eight weeks, followed by an open label treatment of two years (Table 
6). The results suggested that those using NAC were more likely to 
survive during follow-up (RR = 1.8, p = 0.02), but no CD4 count or 
viral load data were collected [74]. A smaller RCT (n = 45) among 
ART naïve HIV patients taking NAC supplementation (400 mg) for 
four months showed significantly reduced TNF-α levels, but no effect 
upon CD4 count during the study. However, it was noted that the 
NAC supplemented group had a less profound decline in CD4 count 
when compared to the 36 months before randomization (p = <0.05) 
[75]. Another RCT (n = 29) assessing the effect of daily NAC 
supplementation (0.6–3.6 g) during 7 months did not show 
differences in CD4 and CD8 counts, although an increase in natural 
killer (NK) cell activity (p = <0.05) was noted [76]. A controlled 
cross-over study (n = 24) showed a trend towards an increased CD4 
count and CD4/CD8 ratio during daily supplementation of NAC (600 
mg) when combined with selenium (500 µg) [77]. Serum GSH 
concentrations were not affected by supplementation.  
Another approach to replenishing GSH levels is through the 
supplementation of whey protein, which is a source of the amino acid, 
cysteine. This intervention was shown to be effective in enhancing 
GSH levels in a small RCT amongst patients receiving ART (n = 30) 
[78]. The effectiveness of whey protein on CD4 count levels was 
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assessed in a larger RCT, which was also amongst ART treated 
patients (n = 59). In this study, the whey supplemented group (40 g 
daily) had an increase of CD4 count of 31 cells/µL, compared to 15 
cells/µL amongst the placebo group during the 12-week follow-up (p 
= 0.03) [79].  
Replenishing GSH stores with either NAC or whey protein appears 
to have a beneficial impact upon the immune function of people living 
with HIV. These results are promising and warrant the conduct of a 
large RCT to assess either of the effects of these supplements upon 
the progression of HIV.  
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Probiotics  
Recent findings suggest that the mucosal immune system is 
rapidly and preferentially [80] depleted of CD4 cells during initial HIV 
infection. This is associated with an enhanced intestinal epithelial 
permeability, as evidenced by increased levels of lipopolysaccharides 
(LPS) [81]. Plasma LPS levels correlate with systemic inflammation, 
which may drive HIV replication and consequently, progression of the 
disease [82]. Also, HIV is associated with increased markers of 
intestinal inflammation [83] and has been shown to elicit a Th-2 
skewed immune response, which may inhibit an effective antiviral 
response [84,85]. The gut microbiota of people living with HIV is 
dramatically different than that of healthy populations. The former 
group have a notable reduction of both lactobacilli and bifidobacteria, 
while pathogenic species, such as Candida albicans and Pseudomonas 
aeruginosa, are more prominent [83,86].  
Probiotics are defined as “live micro-organisms, which, when 
administered in adequate amounts, confer a health benefit on the 
host” [87]. Studies indicate that specific probiotic strains may reduce 
epithelial permeability [88-91], down-regulate systemic and mucosal 
inflammation [92,93,94], and regulate “allergy-like” Th-2 responses 
[95]. Therefore, specific probiotic strains may potentially ameliorate 
HIV-induced changes to the mucosal and systemic immune systems.  
To test this hypothesis, a small RCT (n = 77, of which 42 were 
receiving ART) was conducted in Brazil amongst children living with 
HIV. After daily supplementation of candidate probiotic containing 
strains of Bifidobacterium bifidum and Streptococcus thermophilus 
(2.5 × 1010 colony forming units) for two months, the CD4 count 
among the treatment group increased +118 cells/µL versus a 
decrease of −42 cells cells/µL among the placebo group (p = 0.05). 
However, the viral load was not measured, and no reduction in 
diarrhea incidence was shown [96]. Encouraging results were also 
reported in a small RCT (n = 24) among HIV infected women in 
Nigeria (table 7). After four weeks of Lactobacillus rhamnosus GR-1 
and Lactobacillus reuteri RC-14 supplementation, the probiotic group 
experienced an increase of +6.7 CD4 cells/µL, compared to a 
decrease of −2.2 CD4 cells/µL among the placebo group (p = 0.05) 
[97]. Although preliminary results are encouraging for probiotic 
supplementation for people living with HIV, the trials conducted to 
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date have not had sufficiently large sample sizes or length of follow-
up to substantiate the evidence for increases in CD4 count or clinical 
parameters of HIV progression.  
Prebiotics  
A prebiotic is defined as “a selectively fermented ingredient that 
allows specific changes, both in the composition or activity, in the 
gastrointestinal microflora that confers benefits upon host well-being 
and health” [98]. Specific prebiotic formulations have been shown to 
reduce intestinal permeability [99], down-regulate mucosal 
inflammation [100], and enhance a systemic Th1 immune profile 
[101,102]. A recently conducted RCT (n = 57) was the first to show 
the potential of prebiotic supplementation amongst a population living 
with HIV. Participants were randomized to receive a placebo, a single 
dose (15g), or a double dose (30g), of a specific mixture of galacto-
oligosacharides (GOS), which are long-chain fructans and pectin-
derived oligosaccharides. The prebiotic intervention resulted in 
increased bifidobacterial levels and reduced numbers of the 
pathogenic Clostridium histolyticum cluster [103]. Furthermore, the 
prebiotic intervention was associated with reduced CD4+/CD25+ cell 
activation and an improved Natural Killer (NK) cell activity. Effects on 
CD4 count or viral load were not reported [104]. Prebiotics can be 
supplemented with probiotics (once combined, they are referred to as 
synbiotics). A large RCT in Malawi (n = 795) testing the effect of 
SynbioticForte 2000 (Table 5) on malnutrition also included a 
proportion of HIV infected children (n = 361). Although there was no 
improvement in nutritional cure, there was an overall reduction in 
outpatient mortality, including a trend towards a reduced mortality 
among the subgroup of HIV infected children [105]. In conclusion, 
the application of prebiotics to reverse HIV induced intestinal changes 
has considerable potential, and further design and testing of products 
specifically for HIV is warranted. 
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Conclusions  
The beneficial effects of supplementation with vitamins B, C, E, 
and folic acid to HIV patients have been firmly established, and 
enough evidence exists to recommend the Tanzanian supplement to 
pregnant women with HIV in developing countries. The potential 
beneficial effects of this multivitamin supplement among HIV patients 
who are being treated with ARTs and among male HIV patients 
remain to be determined.  
Among children living with HIV, evidence indicates that vitamin A 
is beneficial in reducing morbidity and mortality in developing 
countries. Further large RCTs with HIV progression and mortality as 
primary outcomes are warranted to substantiate these findings. 
Among pregnant women with HIV, there is little evidence to 
recommend vitamin A supplementation. The potential increase in 
MTCT found in one study due to vitamin A supplementation warrants 
caution for its use among this population.  
Only one RCT has been conducted to date to assess the effect of 
vitamin D on HIV progression. The vitamin did not show apparent 
benefits. This might have been due to an insufficient dose or a 
relatively small sample size of the sub-population co-infected with 
HIV. Therefore, a large RCT with HIV progression as the primary 
outcome and a potentially different dose would be of great value. 
A small RCT on zinc has provided some evidence of beneficial 
effects among patients treated with ART. However, a study among 
ART-naïve pregnant women did not show similar results. In contrast, 
supplementation of zinc was associated with an increased risk of 
wasting and anemia. Until these concerns are addressed by further 
research, caution is warranted for the use of zinc among people living 
with HIV.  
No apparent adverse effects on HIV progression have been 
detected with low-dose iron supplementation. However, the studies 
conducted do not exclude more subtle adverse effects of iron 
supplementation on HIV progression. Therefore only an RCT with a 
sufficient sample size to detect more subtle changes would be able to 
rule out potential adverse effects of iron.  
Small studies have indicated beneficial effects of selenium, NAC, or 
whey protein on HIV progression. However, these findings need to be 
confirmed by larger, well designed RCTs. Furthermore, probiotics and 
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prebiotics have limited preliminary data for their use among people 
living with HIV and further research is warranted.  
An integrated approach that combines micronutrients with the 
various functional food components may have the greatest potential 
to delay HIV progression. A large multicenter trial, recently conducted 
in Europe, provides a prime example for this approach. The RCT 
among ART naïve patients (n = 370) showed that a novel formulation 
(not fully disclosed, but including prebiotic oligosaccharides with NAC, 
bovine colostrum, omega-3 poly-unsaturated fatty acids and a 
combination of vitamins and minerals) slowed down the decline of the 
CD4 count with 28 cells/µL in the intervention group, compared to 
−68 cells/µL among the placebo group after one year of 
supplementation (p < 0.05) [106]. This is very encouraging, although 
the formulation would be expensive and perhaps not so readily 
available to people living in developing countries.  
It should be emphasized that an adequate micronutrient intake 
among people living with HIV is best achieved through an adequate 
diet [7]. On the other hand, various interventions have been shown 
to have beneficial effects in dosages not feasible to be obtained from 
a diet or not naturally present in high concentrations in food. 
Therefore, in addition to a diet-based approach, the development of 
functional food interventions specifically for people living with HIV are 
much needed. 
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Abstract 
The intestinal immune system is severely affected by HIV and 
circulating microbial products from the intestinal tract that provide an 
ongoing source of systemic inflammation and concomitant viral 
replication. In addition, HIV-infected individuals can have a 
deregulated immune response which may hamper the anti-viral 
capacity of the host. Various probiotic organisms and prebiotic agents 
have been shown to enhance intestinal epithelial barrier functions, 
reduce inflammation and support effective Th-1 responses. As these 
characteristics may benefit HIV patients, this review aims to provide 
a theoretical framework for the development of probiotic and 
prebiotic interventions specifically for this population. 
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Intestinal defenses and homeostasis  
The gastro-intestinal tract provides a range of habitats for 
microbes that have either co-evolved with the human species as 
symbionts or as potential pathogens. The different compartments of 
the tract host approximately 500 to 1000 bacterial species [1], 
totaling 1013 – 1014 cells. Collectively, these organisms represent at 
least 100 times more genes than the human genome. This complex 
microbial population influences an estimated 10% of all metabolites 
in our body [2], and could be regarded as ’the neglected organ’. In 
various eukaryotic species, including humans, the relation between 
bacterial communities and their host is mutualistic and symbiotic in 
nature [3]. The symbiotic benefits in humans include energy supply, 
nutrient metabolism and prevention of colonization by opportunistic 
pathogens [4]. 
In order to benefit from this symbiotic relationship, the immune 
system has to balance permissive, tolerogenic responses to food 
antigens and commensal microbes with potentially damaging, 
inflammatory responses to ward off pathogens. This delicate balance 
is maintained by the constant interplay between the microbiota, the 
intestinal barrier and the mucosal immune system and is a 
prerequisite for normal gut homeostasis. Imbalance of this system 
may lead to autoimmune inflammation or infectious pathology.  
The first barrier against pathogenic infection and damaging 
inflammatory responses against commensal bacteria is a degree of 
physical separation between the intestinal bacteria and the host. An 
important component of this barrier are intestinal epithelial cells (IEC) 
that form a physical barrier on the body’s largest surface area for 
interaction with microbes. The epithelium is also home to mucus-
producing goblet cells and antimicrobial-peptide-producing Paneth 
cells [1]. Collectively, these cells produce a mucus layer that 
selectively limits the contact between bacteria and host cells, a 
mechanism which is thought to limit damaging inflammatory 
responses [5]. 
Despite this physical barrier, sampling and recognition of the 
intestinal content is a crucial function of the intestinal immune system 
that is necessary to mount appropriate immune responses. An 
important mechanism for IEC and immune cells to interact with 
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commensal and pathogenic bacteria is the recognition of microbe-
associated molecular patterns (MAMP) by germline-encoded pattern 
recognition receptors (PRR). The best described PRR are Toll-like 
receptors (TLR), which have been found on a wide range of cell types. 
The TLR detect various conserved microbial structures such as 
lipoteichoic acid (LTA) (TLR-2), lipopolysaccharide (LPS) (TLR-4), 
flagellin (TLR-5) and CpG DNA (TLR-9) (Reviewed in [6]). Interaction 
of commensal microbes with TLRs appears to be essential for IEC 
integrity  [7]. Other important PRR groups include the sugar-binding 
lectins and NOD protein families. NOD proteins are located in the 
cytoplasm of IEC and are activated upon invasion. While NOD-1 is 
located within all IEC, another variant, NOD-2, is only expressed in 
Paneth cells and plays a role in the synthesis of cryptidin and 
defensin [8].  
Specialized structures for sampling intestinal content are present 
in the Gut Associated Lymphoid Tissues (GALT). These include Peyer’s 
patches (PP) in the small intestine and lymphoid follicles in the colon 
which are covered by follicle-associated epithelium, containing non-
mucus producing microfold (M-) cells. These cells are devoid of 
microvilli and are specialized in antigen transport into the PP, where 
the antigens are taken up by antigen presenting cells (APC) [9]. 
Dendritic cells (DC), the main APCs in PP, interact with T- and B-
lymphocytes to induce suitable adaptive immune responses, 
depending on the type of stimulus. Therefore, PPs are major inductive 
sites of mucosal adaptive immune responses (reviewed in [10]). After 
activation, lymphocytes home to the lamina propria (LP) or intestinal 
epithelium to perform effector functions. The heterogeneous 
population of intestinal Intra-Epithelial Lymphocytes (iIEL) is thought 
to regulate the intestinal epithelial barrier integrity and regeneration, 
and reduce damage due to local immune responses [11].  
Furthermore, the LP contains DCs that can sample luminal content by 
extending dendrites through the intracellular epithelial tight junctions, 
providing a mechanism to sample intestinal content outside of PP as 
well [12]. DCs are central regulators of adaptive immune responses, 
initiating either effector responses or inducing tolerance. The many 
different DC subpopulations that are present within the mucosal 
immune system each have different functional characteristics 
(reviewed in [13]). In the absence of inflammatory signals 
commensal microorganisms induce tolerogenic maturation of DCs, 
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leading to the induction of various types of regulatory T-cells (Treg), 
including CD4+CD25+Foxp3+ lymphocytes [14], or hyporesponsive T-
cells [15]. The maintenance of the Treg population is dependent on 
IL-2, IL-10 and TGF-β levels, which in turn is dependent on 
continuous background activation by commensal micro-organisms 
[16]. In addition, intestinal DCs are potent inducers of IgA synthesis 
in B-cells, which has anti-pathogenic effects but also prevents 
commensal bacteria from penetrating the host [17].  IgA accounts for 
>70% of our body’s total immunoglobulin production. Several grams 
of secretory IgA (sIgA) are secreted in the intestinal lumen daily, 
which exerts considerable immunological pressure on the intestinal 
microbiota [18]. 
Reciprocally, the intestinal bacteria have a major influence the 
immune system as well.  Studies comparing germ-free with 
microbially colonized mice have shown that the presence of microbes 
is crucial for the normal development of GALT as well as other 
secondary immune organs. In the GALT, the absence of bacteria 
leads to a multitude of effects, including limited development of 
Peyer’s patches, reduced B-cell activation and IgA production and 
reduced numbers of intestinal intraepithelial lymphocytes (iIEL). 
Moreover, epithelial function is also affected, as evidenced by 
reductions in IEC turnover and changes in mucus production [19].  
The effects of commensal bacteria on the immune system are 
dualistic in nature. On the one hand, mechanisms are induced that 
maintain tolerance and/or prevent inflammation. This includes IgA 
production, β-defensin production in the epithelium [20, 21], 
enhanced epithelial barrier integrity through TLR signaling [7], Treg 
induction and even immunosuppressive effects [22-24]. On the other 
hand, exposure to commensal bacteria induces the expansion of 
inflammatory lymphocyte populations, including cytotoxic intestinal 
Intra-Epithelial Lymphocytes (IEL) and IL-17 producing CD4+ T-
helper (Th17) cells [25, 26]. Especially Th17 and other IL-17 
producing cells have been implicated in many inflammatory and 
autoimmune conditions [27-29], however, they have also been shown 
to play important roles in protective mucosal responses against extra-
cellular bacteria and fungi (reviewed in [30]). It is interesting to note 
that the induction of Treg and Th17 populations share a dependency 
on TGF-β signaling. Furthermore, both populations are relatively 
abundant in the LP. Therefore, it is thought that both types of T-cells 
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are induced by signals from the intestinal bacteria and the balance 
between these opposing cell types is determined by the specific host-
microbe interactions [31].  
Commensal bacteria are able to influence the mucosal immune 
system not only through cell-cell interactions, but also through the 
secretion of immune-modulatory molecules. For example; adenosine 
triphosphate (ATP), which enhances the polarization of Th-17 T-
lymphocytes [32]; polysaccharide A (PSA), which induces maturation 
of Th-17 cell populations [33]; and DNA, which induces IFN-α 
syntheses and favors IEC integrity [34]. Furthermore, the intestinal 
epithelium is also constantly exposed to inflammatory molecules such 
as LPS and peptidoglycans. Despite this continuous exposure, the 
intestinal immune system is unique in its ability to maintain tolerance 
in the presence of a multitude of immune triggers while minimizing 
the risk of systemic infection.  
In summary, the net effects of the interplay between the 
commensal microbiota and the mucosal immune system are 
enhanced mucosal defense mechanisms, balanced by an inhibition of 
potentially damaging, inflammatory immune responses. In the 
absence of pathogenic stimuli, virulence factors or chronic 
inflammation, the host-microbe interaction leads to a predominance 
of tolerogenic mechanisms and intestinal homeostasis. 
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Figure 1. Normal mucosal defenses and homeostasis. The commensal microbiota 
induces a state of non-responsiveness through interaction with dendritic cells (DC) and 
subsequent induction of the T-regulatory phenotype and secretion of IL-10 and TGF-β. 
There is a limited uptake of bacterial antigens such as lipopolysaccharide (LPS), 
polysaccharide-A (PSA) and DNA, that induce intestinal defense systems such as the 
excretion of α-defensin and secretory IgA. Recognition of bacterial ligands also occurs 
by membrane bound toll-like receptors (TLR) and nod-like receptors (NLR) present in 
endosomes. 
The result of HIV infection on the host-microbe 
interface 
HIV infection has a disruptive impact on the physiological interplay 
between the commensal microbiota and immune system: CD4+ cells 
associated with the mucosal immune system are rapidly depleted 
after HIV infection [35, 36], including reduced numbers of DCs [37], 
a change in the composition of iIEL [38] and depletion and anergy of 
gamma-delta T-lymphocytes [39]. These detrimental changes on the 
mucosal immune system have severe consequences for the 
(immunological) function of the intestine and are associated with 
compromised epithelial repair mechanisms and enhanced epithelial 
permeability [40, 41].  The net result is an increased risk of gastro-
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intestinal infections at all stages of HIV infection [42] and a high 
prevalence of gastro-intestinal disorders with unknown etiology [43]. 
Chronic immune activation and inflammation have long been 
described as characteristic features of progressive HIV disease, while 
the source of inflammation has remained unidentified. Indeed, 
increased B-cell activation, increased T-cell turnover, and increased 
pro-inflammatory cytokines are observed with HIV infection. In this 
pro-inflammatory state, the replication of HIV is markedly enhanced 
[44] and activation of the Nuclear Factor (NF) κB transcription factor 
plays a crucial role in this phenomenon [45]. Strikingly, the degree of 
systemic immune activation, indicated by the expression of the 
immune activation marker CD38 on CD8+ cells, is a better predictor 
of HIV progression than viral load or CD4+ count alone [46]. 
Recently, it has been suggested that the gut might be a source of 
chronic inflammation. The hypothesis is that dysfunction of the 
mucosal immune response due to preferential depletion of intestinal 
mucosal immune cells including effector CD4+ cells and DCs [36, 37, 
47]  may affect systemic immune activation through the increased 
translocation of microbes and bacterial products from the intestinal 
tract [48]. The resultant pro-inflammatory environment [40] may 
then cause further damage to the gut barrier function, augmenting 
bacterial translocation and subsequently fuelling systemic 
inflammation. Evidence indeed suggests that bacterial translocation 
affects the activation state of the immune system, and in turn HIV 
progression.   
Some HIV infected individuals, termed “non-progressors” have a 
low HIV viral load even without treatment and maintain a low degree 
of systemic inflammation [49, 50]. A mechanism that appears to 
contribute to the control of the virus is a capacity to maintain the 
integrity of the gut barrier and to mount an attenuated response to 
bacterial products and thus potentially reduce bacterial translocation 
[40, 51]. In non-progressors, serum LPS has been shown to be lower 
than those with progressive HIV infection [48]. One week of 
treatment with a ‘gut sterilizing’ antibiotic regimen markedly reduced 
serum LPS levels in macaques, concomitant with a reduction of fecal 
Gram-negative bacteria and inflammatory markers. However, after 
two weeks of antibiotics, plasma LPS had increased again, apparently 
due to growth of other bacterial species in the gut [48]. Although 
anti-retroviral treatment (ART) has been shown to enhance epithelial 
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barrier functions [52], the efficiency of CD4+ recovery may still be 
compromised by bacterial translocation [53]. Future studies will need 
to focus on the role of the epithelial barrier and the microbiota 
composition along with translocation in the progression of HIV.  
The intestinal microbiota has been shown to play important roles in 
other disease conditions. Bacterial translocation occurs during surgery 
[54], plays a role in alcohol induced liver cirrhosis [55], in 
exacerbation of graft versus host disease (GVHD) [56] and in 
inflammatory bowel disease (IBD) [57, 58]. Furthermore, correlations 
between the microbiota composition and disease have been shown for 
IBD [59] and obesity [60]. Strikingly, the transplantation of a gut 
microbiota from obese mice (ob-/ob-) to bacteria-free mice resulted 
in obesity in the recipients [61], suggesting that the microbiota may 
be a mediator of specific conditions. Lessons from such studies that 
focus on microbiota-disease interactions may help to provide more 
insight in the role of an aberrant microbiota in HIV-infected subjects.  
The intestinal microbiota of HIV patients appears to contain higher 
levels of pathogens such as Pseudomonas aeruginosa and Candida 
albicans [62] and reduced or undetectable levels of Bifidobacterium 
and Lactobacillus species [63]. In the macaque model, colitis is very 
common after Simian Immunodeficiency Virus (SIV) infection, 
resulting in a reduced microbial diversity and an increased proportion 
of Campylobacteriaceae  [64]. If the aberrant microbiota among HIV 
patients more easily translocates and provides an inflammatory 
stimulus for HIV replication, therapeutic modification of the gut 
microbiota might have a beneficial impact on HIV progression. 
 
Table 1. Evidence implicating the intestinal microbiota and 
epithelial cell barrier as a factor in HIV progression 
• Aberrant intestinal microbiota among HIV patients with fewer lactobacilli and 
bifidobacteria, and higher numbers of pathogenic P. aeruginosa, and C. albicans 
present (48, 49). 
• Antibiotics can temporarily reduce bacterial translocation in SIV infected 
macaques (37). 
• Increased bacterial translocation among HIV progressors and those not 
effectively responding to ARV (37, 39). 
• Enhanced epithelial inflammation and scarring of GALT among HIV progressors 
(26, 33). 
• Increased epithelial permeability with HIV at all stages of infection (27). 
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Several lines of evidence suggest that HIV modulates systemic 
immunity by skewing the Th1/Th2 balance towards Th2 responses. 
Recently, it was suggested that the induction of T helper-2 (Th-2) 
cytokine synthesis [65, 66] and the gradual increase of IL-4 and IgE 
[67, 68] observed after HIV infection, might be due to a Th-2 
response to viral proteins such as gp-120, p24 and p17 [69].  It is 
well known that HIV patients suffer from high rates of allergies [70] 
and the ability of subgroups of HIV patients to maintain a vigorous 
Th-1 response and higher levels of IFN-γ is associated with increased 
survival [71, 72]. An HIV-triggered Th-2-skewed state of the immune 
system could compromise immunological control of HIV replication 
and lead to reduced protection to opportunistic infections. This 
immune imbalance may also aggravate inflammation and barrier 
dysfunction in the gut, as the  increase in IL-4 production can 
compromise the antimicrobial function of Th-17 cells [73] that line 
the intestine.  
Probiotics 
Probiotics, defined as “live micro-organisms which, when 
administered in adequate amounts, confer a health benefit on the 
host” [74], have been studied in a myriad of conditions related to 
intestinal dysbiosis, including IBD, infectious diarrhea, allergy and 
surgery. Relevant research from these fields and studies on probiotic 
interventions among people living with HIV and safety considerations 
are now discussed.  
Effects on gut barrier function 
Supplementation of probiotic strains may enhance or restore the 
beneficial interactions between the commensal enteric flora and the 
host in health and disease conditions, leading to an enhanced barrier 
function and reduced bacterial translocation. Effects have been 
described in animal and human studies that may have relevance for 
HIV-infected subjects. For example, the Gram-negative probiotic 
strain Escherichia coli Nissle 1917 was shown to enhance the 
intestinal epithelial integrity via the induction of epithelial tight 
junctions proteins (ZO-1 and ZO-2) [75, 76]. Prior administration of 
candidate probiotic strains Lactobacillus acidophilus (ATCC19258) and 
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Streptococcus thermophilus (ATCC4356) to IEC has been shown to 
reduce the epithelial permeability induced by TNF-α and IFN-γ, 
suggesting that the impact of inflammation can be reduced [77]. It 
appears that these various protective mechanisms occur through the 
production of as yet uncharacterized proteins [78] or through direct 
interaction of microbes with IEC through TLR-4, TLR-5 and TLR-9 
[34]. That the enhancement of the epithelial barrier might also 
translate to a reduction in bacterial translocation was shown in a 
murine model of enterohemorrhagic shock. In this model, prior 
challenge with L. rhamnosus LMG P-22799 reduced bacterial 
translocation and systemic inflammation [79], as did use of 
Bifidobacterium adolescentis in a murine model of burn wounds [80]. 
Furthermore, allergy-associated intestinal hyper-permeability [81] as 
well as alcohol-induced loss of gut barrier function has been found to 
be reversed by application of L. rhamnosus GG, resulting in less 
intestinal and liver inflammation in the latter [82].  
In human clinical studies, probiotics have been applied to reduce 
bacterial translocation among different patient populations with 
varying degrees of success. A randomized controlled trial (RCT) 
among 65 critically-ill patients showed reduced rates of infections, 
sepsis and mortality with a combination of probiotics and prebiotics 
(Synbiotic 2000 Forte) [83]. In consecutive trials, the same product 
was shown to increase fecal IgA [84], reduce the incidence of 
bacteremia  [85] and lower the rate of post-operative infections [86].  
Two other RCT using different synbiotic preparations showed similar 
results. L. casei Shirota and L. breve Yakult given with Galacto-
oligosaccharides (GOS) supplementation (15 gr/day) before biliary 
cancer surgery, resulted in reduced inflammatory markers and post-
operative complications [87]. Another RCT with L. acidophilus La-5 
and B. lactis Bb-12 combined with oligofructose (15gr/day) resulted 
in a reduced incidence of bacterial translocation [88]. However, the 
evidence is not conclusive as  three other RCTs using L. acidophilus 
La-5 and B. lactis Bb-12 [89, 90] or L. plantarum 299v [91] reported 
no reduction in bacterial translocation. This suggests that there may 
be strain specific effects or that prebiotics are needed for efficacy.  
Effects on mucosal and systemic immunity 
The loss of tolerance in the intestine due to a defect in GALT 
homeostasis can have a detrimental impact on the gut barrier 
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function. Specific probiotic strains have been shown to enhance the 
recovery of GALT homeostasis. For example, administration of 
Escheria coli Nissle 1917 in wild type mice, but not in TLR-2 knock-
out mice, ameliorated experimental colitis and reduced pro-
inflammatory cytokine expression, suggesting a TLR-2 dependant 
pathway  [92].  This response can be mediated by specific 
components of probiotic organisms. DNA from probiotic organisms 
modulates TLR-9 and elicits a different response from immune and 
epithelial cells than DNA from pathogenic organisms [93]. In HT-29 
cells subjected to pro-inflammatory cytokines, challenge with DNA 
from the VSL#3 probiotic mixture could reduce the expression of the 
pro-inflammatory IL-8 cytokine and delayed NF-κB activation [94]. In 
IL-10 deficient mice, the administration of the probiotic mixture 
VSL#3 led to a reduction in mucosal TNF-α and IFN-γ release and 
improved the histological disease in a TLR-9 dependent manner [94].  
Another way of restoring GALT homeostasis is through the 
induction of regulatory mechanisms to down-regulate inflammation. 
Induction of regulatory mechanisms by specific probiotics appears to 
be partly dependent on modulation of DCs [95]. Some probiotic 
organisms induce DCs to express a regulatory T-cells (CD4+FoxP3+) 
inducing phenotype  [16, 96]. This induces tolerance that is partly 
mediated through IL-10 and TGF-β production. Recently, it was 
demonstrated that ingestion of a specific probiotic mixture (IRT-5) 
could induce CD4+FoxP3+ cells in mesenteric lymph nodes. 
Interestingly, probiotics alone, without the presence of DCs could not 
convert this effect. Administration of the probiotic micture also 
induced both T-cell and B-cell hypo responsiveness, down-regulated 
both Th-1 and Th-2 functions, and reduced the secretion of pro-
inflammatory cytokines in GALT [97]. The biological relevance of 
these changes was verified in an IBD model. Administration of 
probiotics in this model was shown to enhance GALT homeostasis and 
severity of disease. The therapeutic effects were associated with an 
enrichment of CD4+Foxp3+ T-cells in inflamed regions [97]. 
O’mahony et al. demonstrated that challenge with Lactobacillus 
salivarius or Bifidobacterium infantis of DCs from mesenteric lymph 
nodes induced secretion of IL-10. This was in contrast to challenge 
with Salmonella strains, which induced the secretion of pro-
inflammatory IL-12. Strikingly, DCs from peripheral blood did not 
show a differential response to lactobacilli or Salmonella strains [98], 
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suggesting that the response of DCs depends on their immunological 
compartment. In the intestine, tolerogenic effects of T-regulatory 
cells and anti-inflammatory effects may improve barrier function and 
intestinal homeostasis. Furthermore, a reduction in the chronic 
inflammatory state may reduce immune activation and potentially 
affect disease progression [48]. 
Systemically, specific probiotics have also been shown to induce a 
T-regulatory phenotype and counter-balance a Th-1 or Th-2 dominant 
state in vivo and in vitro [95, 99, 100]. The induction of a T-
regulatory phenotype frequently occurred together with increased 
levels of anti-inflammatory IL-10 [101, 102]. A prime example of the 
clinical effects of IL-10 induction comes from an RCT of 77 adults with 
an abnormal IL-10/IL-12 ratio and concurrent irritable bowel 
syndrome (IBS). B. infantis 35624 was shown to normalize the IL-
10/IL-12 ratio in parallel with a reduction in clinical symptoms [103]. 
In Crohn’s disease, a Th-1 mediated condition,  a strain of L. 
rhamnosus decreased after 2 weeks of supplementation both the 
syntheses of the Th-1 parameter IFN-γ and IL-2, which is essential 
survival and proliferation factor for effector T-cells [104]. Remarkably 
was that IL-4, a potent Th-2 cytokine, was also reduced with 
probiotic supplementation. Hence, the effects of probiotic 
supplementation were unlikely due to mere Th-1/Th-2 skewing and 
are best explained by the induction of a regulatory DC phenotype 
with the ability to induce a general hypo-responsiveness. In a study 
of children with atopic dermatitis, a Th-2-dominant condition, an up-
regulation of IL-10 was noted after supplementation with L. 
rhamnosus GG [105]. These findings might be valuable in relation to 
HIV management, as both the induction of T-regulatory cells and 
anti-inflammatory effects can potentially be of benefit to HIV 
patients.  
In vitro evidence indicates that several probiotic candidate strains 
can down-regulate the production of Th-2 cytokines and chemokines 
[106, 107] and modulate DCs to skew T-cell polarization toward a 
Th1-response [108]. The ability of probiotics to skew the immune 
system away from a Th-2 dominant state has been studied to some 
extent in humans, albeit in HIV uninfected subjects. An RCT of 230 
children with cow’s milk allergy showed that L. rhamnosus GG 
ingestion could reduce symptoms of atopic eczema and dermatitis 
[109] and up-regulate IFN-γ, indicative of a more pronounced Th-1 
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response [110, 111]. Moreover, L. rhamnosus GG was shown to up-
regulate IL-6, involved in the mucosal response to stress [112] but 
also epithelial IgA production and mucosal protein syntheses [113], 
suggesting a direct effect of L. rhamnosus GG on IECs. Two other 
RCT’s have shown similar results [114, 115] but one study in children 
did not confirm this outcome [116]. In addition to the ability of 
probiotics to improve barrier function and aspects of intestinal 
homeostasis, specific probiotic strains may therefore be able to skew 
away from a HIV-induced Th-2 predominance  
Effects on intestinal microbiota and infections 
Probiotics can interfere with the function and proliferation of 
pathogens in the gastro-intestinal tract in various ways. They can 
enhance the secretion of pathogen-specific IgA [117], induce β-
defensin secretion [118] or secrete bactericidal proteins [119] and 
reduce the adhesion and invasion of pathogens [120, 121]. Antibiotic-
like compounds such as reuterin produced by L. reuteri  exhibit broad 
spectrum effects against Gram-positive, Gram-negative bacteria as 
well as fungi, yeast and protozoa [119], while non-reuterin producing 
strains such as L. reuteri RC-14 produce signaling molecules that 
down-regulate Staphylococcus aureus toxin production [122]. These 
characteristics could be beneficial for Acquired Immune Deficiency 
Syndrome (AIDS) as L. reuteri was shown to prevent 
cryptosporidiosis in a murine AIDS model [123].  
Use of probiotics can lead to at least temporary modification of the 
intestinal microbiota. For example, in an RCT of 69 preterm babies, B. 
lactis Bb-12 significantly increased the levels of bifidobacteria and 
lactobacilli while reducing the numbers of enterobacteria and 
clostridia [124]. In 36 adults receiving triple therapy for Helicobacter 
pylori infection, the addition of L. acidophilus CUL60 and CUL21 and 
Bifidobacterium spp. decreased the intestinal load of C. albicans, 
facultative anaerobes and enterobacteria [125]. Moreover, genomic 
and metabolic studies suggests that probiotic microbes change the 
behavior of the intestinal microbiota [126].   
The application of probiotics for the prevention and treatment of 
gastro-intestinal infections has been well established and might be 
especially useful among people living with HIV. A Cochrane review 
concluded that probiotics are a useful adjunct to lower the occurrence 
and reduce the length of episodes of infectious diarrhea (reviewed in 
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[127]). Synbiotics (probiotics combined with prebiotics) have also 
been shown to reduce diarrhea associated with ARV use [128] but 
these findings could not be confirmed by a cross-over study [129].  
Although the application of probiotics to prevent gastrointestinal 
infections and the concomitant inflammatory state among HIV 
patients bears promise, no studies have so far been conducted to 
assess its potential.  
Probiotic interventions in HIV  
A limited number of studies suggest that the probiotic benefits 
could be translated to people living with HIV. One RCT of 77 children 
in Brazil showed an increase of 118 CD4+cells/µl among those 
receiving B. bifidum and S. thermophilus for two months compared to 
a decrease of 42 CD4+cells/µl among the placebo group [130]. An 
RCT of 24 HIV patients in Nigeria showed after four weeks of L. 
rhamnosus GR-1 and L. reuteri RC-14 an increase of 6.7 CD4+cells/µl 
compared to a decrease of 2.2 CD4+cells/µl among the placebo group 
[131]. A large RCT in Malawi (n = 795) testing the effect of 
SynbioticForte 2000 on malnutrition also included a proportion of HIV 
infected children (n = 361) [132]. Although there was no 
improvement in nutritional cure, there was an overall reduction in 
outpatient mortality including a trend towards a reduced mortality 
among the subgroup of HIV infected children.  
Safety 
Among HIV patients, several studies have been conducted to 
assess the safety of probiotic interventions.  When treated with L. 
reuteri SD2112, no safety concerns arose among moderately immune 
compromised HIV patients (>350 CD4+cells/µl) [63]. In another 
study of severe immune compromised HIV patients (<200 CD4+ 
cells/µl) no safety concerns were detected with use of L. rhamnosus 
[129]. To date, five case studies of lactobacillemia have been 
reported in end-stage AIDS patients. Of these, three patients were 
reported to have central venous catheters and one patient to have 
pneumonia, all of whom had extremely low CD4 counts (<55 
CD4+cells/µl) [133-135]. Currently, no indication exists to avoid oral 
probiotic use in HIV populations, but close monitoring of safety 
parameters is recommended. 
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Figure 2. Potential benefits of probiotics and prebiotics in HIV-induced 
intestinal pathogenesis. HIV infection induces effects and positive feedback 
mechanisms that induce a loss of intestinal homeostasis and promote replication of 
the virus (triangles). Pro- and prebiotics may ameliorate the HIV-induced intestinal 
problems through effects on the microbiota and its metabolism, on various cells of the 
immune system (as represented by the arrow pointing at the sampling DC) and on 
intestinal epithelial cells. 
Prebiotics 
Altered microbe-host interaction 
Prebiotics were defined most recently as “a non-viable food 
component that confers a health benefit on the host associated with 
modulation of the microbiota” [136], although the term is often used 
less strictly for components that modify the composition or 
metabolism of the intestinal microbiota. Prebiotics can modify host-
microbe interactions via the microbiota and its metabolism, host 
epithelial and other cells, as well as by modifying receptor expression 
and bacterial adhesion. As alluded to earlier, prebiotics are candidate 
agents to improve the intestinal homeostasis in HIV-infected 
individuals. Since prebiotics do not contain bacteria but provide 
substrate for the intestinal microbiota, their fermentation depends on 
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the organisms present in the host.  Prebiotic fructans and galacto-
oligosaccharides (GOS) increase the percentage of ‘beneficial 
bacteria’ through selective fermentation as shown in a variety of 
human target groups, including infants [137, 138], healthy 
volunteers [139] and seniors [140]. The fermentation of fructans and 
GOS increases the production of short-chain fatty acids (SCFA), 
lactate and other bacterial metabolites [141, 142]. SCFA are known 
to have a plethora of effects on the intestinal milieu, epithelial cells as 
well as local immune cells. Various prebiotics induce differential 
effects on SCFA production and the ratios of butyrate, acetate and 
propionate [143]. The degree of specificity of prebiotic agents 
enables the potential development of specific prebiotics optimized to 
target HIV-specific issues. Relevant potential benefits for HIV patients 
are discussed in the next sections, focusing both on the effects of 
prebiotic intervention and on the effects of purified bacterial 
metabolites such as SCFA. 
Effects on barrier function 
As described previously, decreased barrier function and increased 
bacterial translocation is described in HIV-infected subjects. Prebiotics 
have been shown to influence barrier function via various 
mechanisms. A combination of fermentable fibers has been shown to 
significantly reduce endotoxemia over a 30-day intervention period in 
an RCT of 55 cirrhosis patients [144]. Animal studies using alcohol-
induced liver damage showed similar beneficial results preventing 
intestinal dysbiosis with an oat-based prebiotic intervention [145].  
There appear to be several mechanisms whereby prebiotics can 
enhance intestinal barrier function. Recently, Cani and coworkers 
[146] have shown that a prebiotic-induced increase in glucagon-like 
peptide-2 (GLP-2) played an important role in the beneficial effects of 
prebiotic intervention in ob/ob mice on a high-fat diet. Increased 
intestinal barrier function and expression of tight-junction proteins 
were observed, leading to reductions of hepatic markers of oxidative 
stress and inflammation, as well as reduced levels of systemic 
inflammatory mediators and endotoxemia [146]. The production of 
SCFA during fermentation of prebiotic agents can also lead to an 
improved barrier function. Butyrate in particular is an energy source 
for intestinal epithelial cells and, through the modulation of intestinal 
prostaglandins it stimulates mucus production [147]. Recently, 
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butyrate was shown to enhance intestinal barrier function in vitro by 
regulating the assembly of tight junctions in Caco-2 cells [148]. 
Effects on gastrointestinal infections 
A few human studies have shown that prebiotics can reduce 
gastrointestinal infections, a functional characteristic that may 
potentially be used to counteract the HIV-increased prevalence of 
gastro-intestinal infections [42]. Fructan supplementation for 30 days 
reduced diarrhea relapse rates in an RCT among 140 patients with 
Clostridium difficile-associated diarrhea [149]. In addition, fructan 
supplementation showed a tendency to reduce traveler’s diarrhea in 
an RCT of 244 healthy volunteers [150]. In a 12-month open-label 
intervention trial among 342 infants, a formula containing a specific 
combination of GOS and a long-chain fructan induced significant 
reductions in gastroenteritis and acute diarrhea [151]. The same 
combination of oligosaccharides was shown to reduce the number of 
fecal pathogens and increase intestinal IgA production in infants; two 
mechanisms by which prebiotics could reduce intestinal infections 
[152, 153].  
SCFAs can contribute though acidification of the intestinal content 
and growth inhibition of acid-sensitive pathogens [154]. Butyrate 
stimulates the production of antimicrobial peptides, such as 
cathelicidins, which are able to kill a variety of potential pathogenic 
bacteria [155].  
Prebiotic oligosaccharides can have anti-pathogenic effects that are 
independent of the intestinal microbiota and its metabolism. Human 
milk oligosaccharides are known to exhibit receptor-decoy 
functionality, based on the molecular structure and sugar moieties of 
the oligosaccharides [156], leading to binding of oligosaccharides to 
potential pathogens and preventing their adherence to the intestinal 
lining. Similarly, GOS and pectin-derived oligosaccharides can inhibit 
adherence of specific pathogens to epithelial cells in vitro, 
demonstrating that this mechanism is not limited to oligosaccharides 
of mammalian origin [157, 158]. Studies on HIV-infected adults and 
infants are required to better determine the efficacy of prebiotics 
against diarrhea, especially in developing countries where such 
infections can be lethal.  
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Local anti-inflammatory and immunomodulatory effects 
IBD is characterized by intestinal inflammation in which the 
microbiota plays an important role, a situation not dissimilar to the 
HIV-induced inflammation in the gut. Small-scale studies using 
fructan-based pre- and synbiotic intervention in ulcerative colitis (UC) 
patients have shown beneficial effects on histological inflammation 
scores, and on mRNA expression of inflammatory mediators in biopsy 
samples [159, 160]. Similarly, a small, open-label study showed anti-
inflammatory effects of fructan supplementation in moderate Crohn’s 
disease patients. In that case, lamina propria biopsies showed that 
the intervention modulated the phenotype of intestinal DCs, 
enhancing IL-10 production and expression of TLR-2 and TLR-4 
[161]. This suggested that the anti-inflammatory effects are related 
to changes in microbe-host interactions.  
Many preclinical data using prebiotics in IBD models show 
corresponding results (reviewed in [162]). In mechanistic studies 
using different chemically-induced inflammation models, it was shown 
that the beneficial effects of prebiotic intervention could be 
reproduced in part or completely by infusing lactic acid bacteria 
intragastrically and/or SCFA into distal parts of the large intestine.  
Recent animal studies confirm that the expression of PRRs in 
epithelial and immune cells can be modified by prebiotics and by 
butyrate in vitro [163, 164]. However, the molecular mechanisms 
remain to be elucidated. Whereas butyrate was found to reduce LPS 
and TNF-α-induced NF-κB activation in a colonic epithelial cell line 
[165, 166] these results were partly contradicted in a different 
colonic cell line [163]. A recent study indicatedthat NF-κB may be 
modulated directly by unfermented oligosaccharides. Pectin derived 
acidic oligosaccharides reduced NF-κB in vitro and reduced HIV-1 viral 
production in vitro [167]. 
Another molecular target for SCFA-induced modulation of 
inflammation are the G-protein-coupled receptor 41 and 43 (GPR-43), 
that are most efficiently activated by acetate and propionate [168-
170]. GPR-43 is expressed mainly in innate immune cells and is 
critically important in the resolution or reduction of inflammation in a 
variety of mouse models. These mechanisms highlight the potential of 
prebiotic anti-inflammatory capacities, which could lead to an 
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amelioration of chronic inflammation and possibly immune activation 
in HIV-infected subjects [48].  
Modulation of systemic immunity 
In addition to local effects of prebiotics in the gut, systemic 
immunomodulatory effects of prebiotics have been described that are 
relevant for HIV-infected individuals. A 10-week cross-over study 
with GOS in 44 healthy, elderly subjects showed simultaneous 
bifidogenic and systemic immunomodulatory effects. The 
phagocytosis capacity and natural killer cell activity of circulating 
white blood cells was increased, whereas the production of 
inflammatory cytokines was reduced [140]. Furthermore, specific 
prebiotic interventions have been shown to modulate the 
immunological balance, consistent with a shift away from a Th2-
dominant state. For example, a specific combination of GOS and 
short-chain fructans was shown to reduce the incidence of atopic 
dermatitis and allergy-related symptoms in infants at risk for allergy 
[171]. Correspondingly, changes in the antibody class and isotype 
ratios suggestive of a Th1 shift were detected [172]. The ability to 
induce this shift is thought to be beneficial in HIV patients, as it might 
result in more effective anti-viral control and a better immunological 
defense against opportunistic pathogens [69, 173].  
Effects of the specific combination of GOS and long-chain fructans 
in multiple mouse models are also consistent with a shift from Th2 to 
Th1 responses, as allergic responses were reduced and Th1-
dependent vaccine-specific DTH responses were enhanced [174-176]. 
In addition to modifying the microbiota, prebiotics may also mediate 
effects via the carbohydrate structures on immune cells. Very low-
level systemic bioavailability of short-chain fructans have been 
described in the urine of healthy volunteers [177], suggesting the 
potential for direct systemic effects through interactions with lectins, 
galectins or other sugar-binding molecules. 
Prebiotic intervention in HIV-infected individuals 
A limited number of studies that have used prebiotics in HIV-
infected individuals indicate that the benefits described above may be 
relevant for this population. Recently, a prebiotic intervention study 
was performed to investigate potential microbiological and 
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immunological benefits among 57 HIV patients. A 12-week 
intervention with a specific mixture of GOS, long-chain fructans and 
pectin-derived oligosaccharides in HAART-naïve HIV-1 infected 
individuals resulted in increased bifidobacterial levels and reduced 
numbers of the pathogenic Clostridium histolyticum cluster. In 
addition, reduced levels in the pathogenic E. rectale and C. coccoides 
cluster were found [178]. The prebiotic intervention was associated 
with reduced CD4+ T-cell activation, measured as percentage of 
CD4+/CD25+ T-cells. In addition, improved NK-cell cytotoxicity was 
observed [179]. The beneficial effects of this pilot study were 
confirmed in a multi-centre RCT, in which a one-year intervention 
was tested in HIV infected individuals not on ART.  A total of 340 
participants were included in the trial and received the intervention 
product or an isocaloric, isonitrogenous control product. The 
intervention product consisted of the same mixture of prebiotic 
oligosaccharides in combination with bovine colostrum, omega-3 
polyunsaturated fatty acids, and N-acetyl cysteine.  The intervention 
significantly slowed down the decline of the CD4 count as the 
decrease in the intervention group (-28 cells/µl) was lower than the 
decrease in the control group (-68 cells/µl) [180]. These findings are 
very promising and show the potential for nutrition-based strategies 
to become an integral part of disease management.  
Conclusion and future prospects 
The interaction between the gastrointestinal microbiota and the 
human host plays a crucial role in intestinal homeostasis and the 
health status of the host. The gut-associated immune system tightly 
regulates this interaction and, under normal conditions, prevents 
damaging inflammatory reactions by maintaining a tolerogenic state. 
HIV infection has a disruptive impact on the intestinal homeostasis as 
it directly affects the host and indirectly affects the intestinal 
microbiota. The loss of intestinal CD4+ T-cells, epithelial function and 
immune regulation, in combination with a pathogen-enriched 
microbiota composition, leads to an increase in intestinal 
permeability, bacterial translocation and an inflammatory state.  
Pro- and prebiotics are modulators of both microbiota and host 
factors, making them potential agents to ameliorate the intestinal 
problems induced by HIV. Various beneficial effects of pro- and 
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prebiotic interventions have been demonstrated that may translate to 
applications in HIV. These effects include improved barrier function, 
reductions in the translocation of bacterial products, reductions in 
pathogenic load, local and systemic anti-inflammatory effects and 
immunomodulatory effects to restore a proper Th1/Th2 balance. 
Various therapeutic applications of pro- and prebiotics are 
conceivable, such as before initiation of ART, where they could 
potentially help reduce HIV-induced intestinal inflammation, intestinal 
infection or diarrhea. In addition, by reducing systemic inflammation 
and associated immune activation, disease progression may be 
slowed down. Obviously, pro- and prebiotics should not be used as 
alternatives to ARV but might have a role as conjoint therapy 
especially among immunological non-responders to ARV.  
An additional benefit of the pro- and prebiotic is the possible 
application in low-cost interventions of limited complexity, which 
might be especially useful in resource-limited countries [181]. 
Depending on the target group, the oral application of pro- and 
prebiotics makes it possible to combine the intervention with specific 
(micro-) nutrients to prevent specific deficiencies or to aim at multiple 
targets simultaneously. Applied as interventions to improve intestinal 
homeostasis in HIV-infected individuals, pro- and prebiotics have 
potential to contribute beneficially to integrated disease 
management. 
In recent years, promising initial studies encompassing pro- and 
prebiotic interventions have been performed in HIV-infected 
individuals, showing the potential for improvement of intestinal 
homeostasis and potentially a reduction in the decline in CD4 count. 
However, a clear need remains for additional, well-designed double-
blind, randomized studies to provide evidence for the efficacy of 
specific pro- and prebiotic interventions.  
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Abstract 
Goal: To evaluate the long term effect of yogurt supplemented with 
Lactobacillus rhamnosus Fiti on the immune function (CD4 count) of 
people living with HIV/AIDS. 
Background: Gastrointestinal infections as well as the leakage of 
microbial products from the gut have a profound impact on the 
deterioration of the immune system among people living with 
HIV/AIDS. Among persons not infected with the virus, probiotics can 
prevent gastrointestinal infections and restore an effective gut 
barrier, suggesting they might have a beneficial effect on the immune 
function of people living with HIV/AIDS.  
Study: We performed an observational retrospective study over a 
period of three years, with longitudinal comparison of the CD4 count 
within subjects (n=68) before and during probiotic yogurt 
consumption, and compared to a control group of subjects not 
consuming the yogurt (n=82). 
Results: Among the yogurt consumers before use and the non-
consumers an average increase in CD4 count was seen of 0.13 
cells/ųl/day [95% CI; 0.07 - 0.20, p= <0.001]. After commencing 
consumption, yogurt consumers experienced an additional increase of 
0.28 cells/ųl/day [95% CI; 0.10-0.46, p= 0.003]. When adjusting for 
length of time using ARV medication the additional increase explained 
by yogurt consumption remained 0.17 cells/ųl/day [95% CI; 0.01-
0.34, p= 0.04]. Treatment with ARV medication was associated with 
an increase of 0.27 cells/ųl/day [95% CI; 0.17-0.38, p= < 0.001]. 
Conclusion: The introduction of probiotic yogurt, made by local 
women in a low-income community in Tanzania, was significantly 
associated with an increase in CD4 count among consumers living 
with HIV.  
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Introduction 
Recent attention on HIV/AIDS care in Africa has focused on 
increasing access to antiretroviral (ARV) medication. Although this is 
important, efforts are also needed to provide safe and affordable 
interventions for those without access to ARV’s or with CD4 counts 
too high to initiate antiretroviral therapy, yet whose quality of life is 
diminished by micronutrient deficiencies, diarrhea and other 
conditions associated with HIV infection. An increased micronutrient 
intake, most notably vitamin B-complex in combination with C and E , 
seems to be an effective intervention that has been associated with a 
reduced mortality and increased CD4 count (1-5).  The WHO 
recommends that an “increased micronutrient intake can be best 
achieved through an adequate diet” (6), favoring food based 
interventions.  
The gut is one of the most severely affected sites by HIV (7, 8). 
Inflammation results in damage to the epithelial barrier, leading to an 
increased leakage of microbial products into the bloodstream. 
Recently it was theorized that this may be an ongoing source of 
systematic immune activation that fuels HIV (9), although this 
association was less clear in an African population (10). Capsule 
proteins of HIV may further facilitate viral replication by eliciting a 
profound Th-2 activation which inhibits an effective immune response 
against the virus (11).  
Probiotic bacteria, ”live microorganisms which when administered 
in adequate amounts confer a health benefit on the host” (12) can 
potentially restore an effective gut barrier (13, 14), thereby reducing 
systemic immune activation. Furthermore, probiotics have been 
shown to up-regulate T-regulatory lymphocytes (15, 16), potentially 
skewing  the immune system away from a Th-2 dominant state (17). 
Probiotic usage has been shown to be safe among people living with 
HIV (18-20) and recent randomised trials in Brazil (21) and Nigeria 
(22) suggest that probiotic use can increase the CD4 count.  
The most commonly used vehicle for supplying probiotics, yogurt, 
is a significant source of vitamin A, B-complex, zinc and high biologic-
quality protein (23) and is therefore an excellent food-based 
intervention to improve micronutrient intake among people living with 
HIV/AIDS. Based on these notions, a community kitchen in Mwanza, 
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Tanzania, was established in 2004 to produce yogurt supplemented 
with Lactobacillus rhamnosus GR-1 (Fiti) to be distributed as an 
adjunct to the diet of people living with HIV. In order to evaluate the 
impact of probiotic yogurt supplementation on immune function (CD4 
count), the following observational study was undertaken. 
Materials and methods 
Study design 
An observational retrospective study was designed with the 
collection of CD4 count measurements from three years prior to the 
date of interview. This allowed longitudinal comparison of the 
development in CD4 count within subjects (before and during 
probiotic yogurt consumption) and between probiotic yogurt 
consumers and non-consumers. Participants were informed about the 
study and gave their written or thumb printed consent prior to 
participation, and all procedures were performed according to the 
Helsinki Declaration as revised in 2000. The study was performed 
during April and May 2008. 
Setting 
Both probiotic yogurt consumers and non-consumers were 
recruited from three probiotic yogurt distribution sites in the urban 
area of Mwanza city (Mabatini, Mahina and Bwiru). At the Mabatini 
site, regular yogurt was produced and supplemented with 
Lactobacillus rhamnosus Fiti which was grown from stock cultures 
stored and harvested at the laboratory of the National Institute for 
Medical Research, Mwanza. Yogurt was served in portions of 200 ml 
containing 109cfu/ml of viable Lactobacillus rhamnosus Fiti.  
Subjects 
The subjects were invited to participate when they were able to 
show their clinical HIV record with at least one CD4 count 
measurement.  All people consuming yogurt at least once a week 
were invited to participate while they were visiting one of the three 
sites to receive their portion of probiotic yogurt. People living with 
HIV who were not consuming yogurt but were visiting one of the sites 
for another nutrition intervention (monthly distribution of maize and 
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beans) were also invited to participate without further standardization 
of the control group. Local leaders or the hospitals had referred both 
yogurt consumers and non-consumers to these nutrition programs 
because of the subject’s lack of adequate nutrition.  
Data collection 
During a structured interview, data was collected pertaining to 
demographics, socioeconomic status (SES), dietary intake through a 
24-hours recall, medication, disease history. Furthermore participants 
were interviewed about the number of days they experienced febrile 
symptoms, diarrhea and cough as well as the average length 
participants were able to work per day. Also they were asked to rate 
the severity of their gastrointestinal symptoms (stomach pain, 
stomach gas, nausea, diarrhea) and its impact on daily life. 
CD4 count measurements three years prior to the interview were 
recorded from the clinical file. The CD4 count measurements were 
determined blinded for probiotic yogurt consumption under the 
National AIDS Control Program at Sekou-Toure regional hospital and 
Weil Bugando university hospital in Mwanza using conventional flow-
cytometry. 
Analyses 
Differences between yogurt consumers and non-consumers were 
detected by comparing characteristics between groups using a Chi-
square test while micronutrient data were compared using a T-test. 
Trends in CD4 count measurements were analyzed, allowing for 
repeated measurements, by using generalized estimating equation 
methods with an Identity link, Poisson variance and an exchangeable 
correlation structure. To adjust for the length of time on ARV 
medication, a variable was created with the number of days since 
date of commencement of ARV treatment at the time of each CD4 
count. This continuous variable was then used to adjust the overall 
trend in time of CD4 count (number of days since first recording in 
clinical file) the effect of yogurt consumption (number of days since 
start of consumption of yogurt), length of time living with HIV 
(number of days since HIV diagnosis) and length of time using ARV 
treatment (number of days since initiation of ARV treatment). 
Chapter 4 
 98 | 
We were interested in the effect of short tem probiotic yogurt 
consumption (70 days) since a randomized controlled trial 
(Hummelen et al. submitted) had indicated different effects before 
and after this period. To allow for this we created a spline variable. 
Wald’s test with robust standard errors was used to compare 
differences between groups. All tests were performed two-sided at 
the α = 0.05 significance level with no adjustments made for multiple 
comparisons. Data was stored in a Microsoft Access database and 
analysed using SPSS version 15.0. 
Results 
A total of 68 yogurt consumers and 82 non-consuming controls 
participated in the study. Demographics, SES and years living with 
HIV were similar between both groups (Table 1). Furthermore the 
proportion of consumers being treated with ARV’s (52 of 68, 76%), 
and non-consumers (57 of 82, 70%) was similar (p=0.3).  Among 
yogurt consumers, 196 CD4 counts were recorded before yogurt 
consumption and 97 measurements were recorded during yogurt 
consumption. Yogurt was consumed for a median [range] of 357 [3 – 
1062] days. Among yogurt consumers 62 of 68 (91%) subjects had 
at least one CD4 count before commencing yogurt intake. In the 
group of 82 subjects who did not consume the yogurt, a total of 233 
CD4 counts were recorded. The probiotic yogurt group had an 
average higher daily intake of calories (2097 vs. 1887 kcal, p= 0.01), 
protein (55 vs. 49 g, p= 0.03), vitamin B1 (1.7 vs. 1.5 mg, p= 
0.002), vitamin B2 (0.9 vs. 0.7mg, p= 0.03), calcium (490 vs. 421 
mg, p= 0.04) and iron (18 vs. 15 mg, p= 0.001) the day before the 
interview. No differences in daily intake of vitamin B12, C, D, E, 
selenium and zinc were detected. 
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Table 1. Characteristics of probiotic yogurt- and control group 
Characteristics  Control  
% (n) 
Yogurt 
% (n) 
p 
 
Gender Female 85% (70) 81% (55) 0.5 
  Male 15% (12) 19% (13)  
Marital status Widow/Divorced 66% (54) 54% (37) 0.1 
  Single 13% (11) 9% (6)  
  Married 21% (17) 37% (25)  
Water source Pipe 68% (56) 56% (38) 0.1 
  Well 32% (26) 44% (30)  
BMI <18.5 9% (7) 10% (7) 0.7 
  18.5 + 92% (75) 90% (61)  
Age (years)* <18 2% (2) 5% (3) 0.5 
  18-45 73% (60) 64% (43)  
  45+ 24% (20) 31% (21)  
Education* No schooling 21% (17) 9% (6) 0.1 
  Grade 1-7 69% (56) 79% (52)  
  Form 1-4 or higher 10% (8) 12% (8)  
Living with HIV* < 1 year 24% (20) 13% (9) 0.1 
  1+ year 76% (62) 87% (58)  
Antiretroviral medication No 31% (25) 24% (16) 0.3 
 Yes 70% (57) 77% (52)  
* Numbers don’t add up due to missing values 
BMI = Body Mass Index 
 
Within consumer differences 
Before starting consumption, the 68 yogurt consumers 
experienced an average increase in CD4 count of 0.16 cells/µl/day 
[95% CI; 0.06 - 0.27, p= 0.002]. This increased an additional 0.23 
cells/µl/day [95% CI; 0.02 - 0.44, p= 0.04] after the start of yogurt 
consumption. After adjusting for ARV use which was associated with 
an increase of 0.30 cells/µl/day [95% CI; 0.07 - 0.16, p= <0.001], 
the increase observed before the start of yogurt consumption was 
fully explained, as no significant increase remained after adjusting 
(p= 0.6). Furthermore, commencing yogurt consumption also was not 
associated with an increase in CD4 count (p = 0.3) after adjusting for 
ARV use. However, without the development of CD4 count over time 
as a variable, commencing yogurt consumption was again associated 
with an increase in CD4 count of 0.16 cells/µl/day [95% CI; 0.0 - 
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0.31, p= 0.05]. This indicates significant co-linearity between the 
variables threatening their individual contribution; hence a control 
group was included that did not consume yogurt at any point in time. 
Within consumer and between group differences 
 Taking into account the correlated nature of the repeated CD4 count 
measures within individuals, no differences were noted of CD4 count 
levels before the start of yogurt consumption between the yogurt 
consumers (mean 376 cells/ųl) and non-consumers (mean 366 
cells/ųl, p = 0.8). Among the yogurt consumers before use and the 
non-consumers an average increase in CD4 count of 0.13 cells/ųl/day 
[95% CI; 0.07 - 0.20, p= <0.001] was seen.  After commencing 
consumption, yogurt consumers experienced an additional increase of 
0.28 cells/ųl/day [95% CI; 0.10-0.46, p= 0.003]. When adjusting for 
length of time using ARV medication, the additional increase 
explained by yogurt consumption remained 0.17 cells/ųl/day [95% 
CI; 0.01-0.34, p= 0.04] and the increase seen before yogurt 
consumption and among the control group was fully explained by ARV 
treatment, as no significant increase remained after adjusting (p= 
0.6) (Figure 1). Treatment with ARV medication was associated with 
an increase of 0.27 cells/ųl/day [95% CI; 0.17-0.38, p= < 0.001]. 
Time living with HIV was not associated with CD4 count development 
(p = 0.3) nor was the medical centre at which treatment was 
received (p = 0.6). This indicates that no differences in treatment 
existed between the centers that significantly affected CD4 count 
development. When allowing for a different CD4 count development 
before and after 70 days, we found that before the start of 
consumption and among controls, an increase of 0.13 CD4 
cells/ųl/day [95% CI; 0.06-0.20, p= <0.001] occurred. Among 
consumers, after commencing consumption an additional increase of 
0.73 CD4 cells/ųl/day [95% CI; -0.02-1.50, p= 0.6] during the first 
70 days was seen. After this initial period the CD4 count continued to 
rise an additional 0.2 CD4 cells/ųl/day [95% CI; 0.03-0.4, p= 0.02]. 
Using a Log link with a Poisson distribution provided similar 
inferences as well as using a generalized linear model. 
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Figure 1. Increased CD4 count after commencing consumption of probiotic 
yogurt. Additional increase of 0.17 CD4 cells/ųl/day [95% CI; 0.01-0.34, p= 0.04] 
after start probiotic yogurt consumption when adjusting for anti-retroviral treatment. 
General health questionnaire 
All participants, except one consumer, completed the interview. 
Probiotic yogurt consumers reported the ability to work 8 hours a 
day, compared to 6 hours reported by non-consumers (p= 0.01). 
Furthermore, consumers reported 1 day of fever a month compared 
to non-consumers who reported a median of 2 days a month (p= 
0.01). Regarding gastrointestinal symptoms, among those consuming 
yogurt, 56 of 67 (84%) participants did not report any diarrheal 
symptoms; nor did 57 of 82 (69%) participants among the non-
consuming group (p= 0.05). Also, 45 of 67 (52%) consumers did not 
reported any impact (intermediate or severe) of gastrointestinal 
symptoms on everyday life compared to 24 of 82 (39%) among the 
non-consumers (p= 0.004).  
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Discussion 
The study site is typical of many low-income communities in the 
developing world where access to daily nutrition and medical care is 
limited, and HIV infection is highly prevalent (24). The introduction of 
a locally produced highly nutritious food (yogurt) supplemented with 
a probiotic strain, not only provides an economic stimulus for farmers 
and those producing the yogurt, but may also improve the immune 
function among those living with HIV and their ability to work.  
The present study is, to our knowledge, the first to report the 
long-term effects of probiotic yogurt on CD4 count among people 
living with HIV/AIDS. The more pronounced increase of CD4 count 
during the first 70 days of consumption corresponds to another study 
at this site, in which intake of Lactobacillius rhamnosus GR-1 and 
Lactobacillus reuteri RC-14 in capsule form increased CD4 count at 10 
weeks moreso than at 25 weeks (Hummelen et al. submitted). The 
mechanism by which ingested lactobacilli can cause a boost in 
peripheral CD4 count is worthy of investigating as well as determining 
if the increase in CD4 count can be further stimulated by switching 
the type of lactobacilli used. 
An important strength of this study is the long period (3 years) in 
which we assessed the development of the immune function, an asset 
that would have been difficult to achieve using a prospective study 
design. Also the observational nature of the study is a strength as we 
were able to assess the impact of probiotic yogurt  at a grassroots 
level among a wide range of patients, as opposed to the perfect 
conditions created for a homogenous group of participants to access 
and consume an intervention in a clinical trial setting. 
Although selection bias may have occurred due to the 
unstandardized sampling of the groups, the similarities between the 
groups indicates that this bias was limited. We were able to adjust for 
potential confounders such as length of time living with HIV and 
antiretroviral medication use, but not for co-trimoxazole use. When 
using the subject as his/ her own control, a significant increase in 
CD4 count was also found which validates the differences seen when 
including the control group in the analyses. Because the intervention 
in this study both included a probiotic strain and a nutritious carrier 
(micronutrients and high quality protein) we were limited in 
distinguishing the individual contribution of each component. 
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However, two randomized controlled trials have compared regular 
yogurt to a yogurt combined with probiotic strains and showed a 
significantly beneficial impact on the CD4 count when the yogurt was 
supplemented with additional probiotic strains (21, 22). Therefore, it 
is likely that the probiotic component of this intervention exerted 
beneficial affects on the immune system independently from its 
nutrient carrier. 
Studies conducted in Africa have estimated the average annual 
increase in CD4 count of 90 cells/µl with ARV treatment (25) and an 
average decline of 20-50 cells/µl/year without ARV treatment (26, 
27). In this study a similar rate of increase was observed of 99 
cells/µl with ARV treatment (0.27 cells/ųl/day), while no significant 
decrease was observed without ARV treatment.  The results of this 
study indicate that probiotic yogurt consumption is associated with an 
overall increase in CD4 count of 62 cells/µl/year (0.17 cells/ ųl/day). 
This could be due to an accelerated immune reconstitution after 
initiation of ARV treatment,  thus shortening the time of severe 
immune deficiency, or, may be due to an increase in CD4 count 
among those not yet eligible for ARV treatment, which may 
potentially delay the need for ARV medication. This hypothesis will 
require future assessment as our sample size did not allow for this 
subgroup analyses. 
The differences in symptoms experienced between the groups 
suggest that probiotic yogurt might alleviate gastrointestinal 
symptoms among people living with HIV. However, due to the 
subjective nature of a questionnaire these results need to be 
confirmed in a blinded setting. In conclusion; probiotic yogurt was 
significantly associated with beneficial long term effects on the CD4 
count and may provide an effective intervention to delay the 
deterioration of the immune system or potentiate ARV treatment 
among those living with HIV. 
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Abstract 
Aim: To evaluate the safety and impact on the immune function of 
long term probiotic use among women with HIV.  
Methods: A pilot study was performed with a double blind, placebo 
controlled trial design among 65 women with HIV who were naïve and 
non-eligible to anti-retroviral treatment. Women were randomized to 
receive oral capsules containing Lactobacillus rhamnosus GR-1 and 
Lactobacillus reuteri RC-14 (2x109 colony forming units) or placebo 
twice daily for 25 weeks. CD4 count and biochemical parameters 
(Albumin, Alanine transaminase and creatinine) were measured and 
adverse events assessed at baseline, 10 and 25 weeks. The immune 
markers IgG, IgE, IFN-γ and IL-10 were measured at baseline and 10 
weeks follow-up and the occurrence of diarrhea was reported daily.  
Results: Ten participants were excluded post-randomization due to 
non-eligibility for inclusion when their status was re-assessed. Thirty 
participants were assigned placebo of whom 25 completed the study. 
Twenty-five participants were assigned probiotics of whom 19 
completed the study (p = 0.5). Two participants did not return for 
any follow-up visit and were therefore not included in the analyses. 
From baseline to 10 weeks follow-up, the CD4 count declined on 
average with –3 CD4 cells/ųl [95% Confidence Interval: -97; 91] in 
the placebo group versus an increase of 50 cells/ųl [95% CI: -61; 
162] in the probiotics group (p = 0.5). From baseline to 25 weeks, 
the CD4 count increased in the placebo group with 19 cells/ųl [95% 
CI: - 90; 129] versus an average increase of 46 cells/ųl [95% CI: -
100; 192] in the probiotics group (p = 0.8). The occurrence of 
diarrhea was low in both groups and no differences between the 
groups could be observed. Among the placebo group 10 of 29 
participants reported at least one adverse event, versus 5 of 24 
reporting an adverse event in the probiotics group (p = 0.3). The 
biochemical measures remained stable during follow-up and no 
differences were observed between groups.  
Conclusion: Lactobacillus GR-1 and RC-14 may be safely consumed 
at 2x109 CFU/day by moderately immune compromised HIV patients 
but this did not universally preserve immune-function.  
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Introduction 
The majority of the body’s immune cells resides in the gut [1], a 
compartment that is disproportionally affected by HIV infection. 
During the early stages of infection, the virus depletes gut associated 
lympoid tissue (GALT) including CD4+ lymphocytes [2,3] and 
dendritic cells [4]. These detrimental changes appear to lead to a 
reduced gut barrier function [5], aberrant intestinal microbiota [6,7]  
and translocation of microbial products to the peripheral bloodstream 
[8,9]. The latter is associated with increased levels of inflammatory 
cytokines and immune cell activation [8-10], which in turn can drive 
HIV progression [8,11].  
Though anti-retroviral treatment (ART) can reverse the detrimental 
changes to the GALT in most HIV patients [8], in a sub-group of 
patients the damage cannot be undone [9,12]. The use of ART has 
significantly increased in the developing world, yet still approximately 
one in three patients does not have access to this therapy [13]. 
Moreover, ART is only initiated when a moderate immune 
compromised state is reached (< 350 CD4 cells/µl).  
Studies in Nigeria, Brazil and Tanzania have suggested that 
probiotic organisms, defined as “live microorganisms which, when 
administered in adequate amounts, confer a health benefit on the 
host” [14], may be able to delay damage to, or help preserve, the 
immune function of HIV patients [15-17]. Potential mechanisms 
include stimulating Natural Killer cell activity [18], improving 
intestinal barrier function [19,20] and lowering systemic inflammation 
[21,22].  However, no studies have been conducted to assess 
whether a preserved immune-function can be maintained for longer 
than two months. Furthermore, although the safety of probiotic use 
among HIV patients has been investigated [7,23], the longer term 
safety has not been established. Therefore, we initiated a 
randomized, placebo controlled trial to assess the impact of 25 weeks 
probiotic L. rhamnosus GR-1 and L. reuteri RC-14 on immune 
function in moderately immune compromised HIV patients (> 200 
cells/ µl), and confirm the safety of probiotic use among this 
population. 
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Materials and methods 
Participants and procedures 
The primary outcome of the trial was the change in CD4 count 
from baseline to 25 weeks. Secondary outcomes included the effect 
of probiotic supplementation on the vaginal microbiota of women 
living with HIV, results which were reported elsewhere [24].  Between 
October 2007 and February 2008, HIV seropositive women attending 
the HIV care and treatment clinic at Sekou-Toure regional hospital, 
Mwanza, Tanzania, were enrolled. Inclusion criteria were confirmed 
HIV infection, not eligible to be treated with antiretroviral medication 
(i.e. CD4 count > 200 cells/µl), not-normal vaginal microbiota 
according to the Nugent score [25], and being 18 - 45 years old. 
Exclusion criteria were pregnancy, lactation, menstruation at time of 
screening, hypersensitive to metronidazole and presence of sexually 
transmitted diseases [24]. 
Participants visited the clinic for a screening which included CD4 
cell count, serum storage, and a physical and gynecologic 
examination performed by a physician. Participants diagnosed with 
bacterial vaginosis [25] were treated with metronidazole for 10 days 
(twice daily 400mg orally). Within one week of screening, eligible 
participants were interviewed using a structured questionnaire to 
collect information on demographics, medical history and drug use, 
According to a computer generated block randomization list, 
participants were supplied with a tube of capsules containing freeze-
dried L. rhamnosus GR-1 and L. reuteri RC-14 (2 x 109 viable 
organisms/capsule) or identical looking placebo capsules. The tube 
sets, only bearing the identification number of each participant, had 
been prepared by a statistician not involved in the data collection, to 
ensure blinding of participants and study staff. Tube-sets were 
supplied at each follow-up visit and capsules had to be taken twice 
daily for 25 consecutive weeks. Viability testing after transport on dry 
ice from Denmark and storage on site for eight months confirmed a 
minimum of 109 colony forming units per probiotic capsule. 
During follow-up, participants were interviewed at 2, 5, 10, 15, 20 
and 25 weeks to evaluate adverse events, assess gastrointestinal 
symptoms, and to count remaining capsules. The participants 
recorded the occurrence of diarrheal episodes using a diary, which 
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was collected at each visit. Diarrhea was defined as three or more 
loose or watery stools in a 24-hour period [26]. At baseline and after 
10 and 25 weeks the CD4 was measured using the Partec FACS 
(Partec GmbH, Münster, Germany). At baseline and 10 weeks, ELISA 
assays were used to measure serum levels of IgE, IgG, (E80-108 & 
E80-104, Bethyl Laboratories, Montgomery, USA) and IFN-γ, IL-10 
(99-7799, eBioscience, San Diego, USA). Alanine transaminase (ALT), 
creatinine and albumin were measured at baseline and twenty-five 
weeks using a Beckman CX5 biochemistry machine (Beckman coulter, 
Brea, USA). All laboratory tests were performed on site at National 
Institute for Medical Research (NIMR), Mwanza Research Centre, 
according to good laboratory practices. 
Ethics 
The ethics boards of Erasmus University Medical Centre, 
Rotterdam, The Netherlands, and NIMR, Tanzania, approved the 
study design and protocol. Participants were informed of the purpose 
of the trial and had to give their signed or thumb printed informed 
consent before participation. This trial was registered at 
clinicaltrials.gov NCT00536848. 
 
Sample size and statistical analyses 
We calculated that a sample size of 30 participants per treatment 
arm would be required  to detect a 15 cells/ųl difference in CD4 count 
(from baseline to 25 weeks) with 90% power and a two-sided alpha 
of 0.05, a 25% loss to follow up and a standard deviation of 10 CD4 
cells/ųl of within subject differences [15]. Laboratory parameters 
were analyzed as continuous data using within-subject differences 
from baseline to 10 or 25 weeks, and tested using an unpaired t-test. 
When non-parametric data was analyzed using a Wilcoxon-rank-sum, 
this is indicated in the text. Gastro-intestinal symptoms’ data were 
analyzed as dichotomous data by taking into account the correlation 
between measurements using generalized estimating equations, with 
an exchangeable correlation structure and a logit link. Baseline 
variables were analyzed using a χ2 test; Fishers exact test was used if 
one or more sub-groups had fewer than five participants. All tests 
were performed two-sided at the α = 0.05 level with no adjustments 
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made for multiple comparisons. Data was stored in an Access 
database and analyzed using SPSS 15.0 software.  
Results 
A total of 229 women were screened of whom 65 were randomized 
to receive probiotics (n = 32) or placebo (n = 33) for 25 weeks 
(Figure 1). A total of 10 women were excluded from analyses due to 
a missing CD4 count at baseline (n = 2), a CD4 count lower than 200 
at baseline (n = 6), or a HIV-negative test during follow-up (n = 2). 
Two other participants, one in each group, were not included in the 
analyses after failing to return for any follow-up visit. At baseline, no 
clinically relevant differences could be detected between the placebo 
and probiotics group (Table 1). Overall, half of the women had low 
albumin levels (< 36 gram/ml), indicating malnutrition or systemic 
inflammation. Furthermore, 43 of 48 women had levels of IgG higher 
than normal (≥ 18 gr/l), and 35 of 48 women had abnormally high 
IgE levels (≥ 400 ng/ml, figure 2) [27]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Trial profile 
a 86 normal vaginal microbiota (Nugent score 1-3), 15 sexual transmitted infection 
and 18 eligible for ART (CD4 count < 200 cells/µl).  
b 2 losses due to travelling, and 1 for unknown reasons.  
c 2 baseline CD4 < 200 cells/µl, 1 baseline CD4 invalid.  
d 2 losses due to travelling, and 2 for unknown reasons.  
e 4 baseline CD4 < 200 cells/µl, 1 baseline CD4 invalid, 2 HIV negative. 
33 assigned placebo  32 assigned probiotics 
3 lost to follow-upb 
2 started ART 
3 excludedc 
4 lost to follow-upd 
2 started ART 
7 excludede 
25 completed study  19 completed study 
65 women randomised 
229 women screened 
119 not meeting 
inclusion criteriaa  
45 not willing to 
participate 
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From baseline to 10 weeks follow-up the CD4 count dropped on 
average with –3 CD4 cells/ųl [95% CI: -97; 91] in the placebo group 
versus an increase of 50 cells/ųl [95% CI: -61; 162] in the probiotics 
group (p=0.5). At 25 weeks, the CD4 count increased from baseline 
in the placebo group with 19 cells/ųl [95% CI: - 90; 129] versus an 
average increase of 46 cells/ųl [95% CI: -100; 192] in the probiotics 
group (p = 0.8). Changes in the immune parameters IFN-γ, IL-10, 
IgG and IgE did not differ between the groups (Figure 2).  
Table 1. Baseline characteristics 
Characteristic  Placebo  
(n = 29) % (n) 
Probiotic  
(n = 24) % (n) 
p 
Age (years) < 30 31 (9) 38 (9) 0.8 
  ≥ 30 69 (20) 63 (15)  
Education (years) 0 3 (1) 4 (1) 1.0 
  ≥ 1 97 (28) 96 (23)  
Marital status Single 79 (23) 63 (15) 0.2 
  Married 21 (6) 38 (9)  
HIV diagnosis (years) < 1 69 (20) 79 (19) 0.5 
  ≥ 1 31 (9) 21 (5)  
CD4 count (cells/ųl) < 350 59 (17) 67 (16) 0.6 
  ≥ 350 41 (12) 33 (8)  
Any HIV symptoma None 76 (22) 75 (18) 1.0 
 Present 24 (7) 25 (6)  
Co-trimoxazoleb No 66 (19) 46 (11) 0.2 
 Yes 35 (10) 54 (13)  
BMI (kg/m2)c < 18.5 12 (3) 23 (5) 0.4 
 ≥ 18.5 89 (23) 77 (17)  
Albumin (gr/ml)c < 36 67 (16) 59 (10) 0.7 
 ≥ 36 33 (8) 41 (7)  
 SD=Standard Deviation, BMI= Body Mass Index,  
aAny HIV related symptoms: Defined as having any of the following symptoms; 
diarrhea, coughing, fever for > 1 month, weight loss > 4,5 kg or skin rash during 
past year.  
bCo-trimoxazole use as prophylaxis for ≥ 30 days during follow-up.  
cNumbers do not add up due to missing values. 
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Figure 2. Immune parameters at baseline and 10 weeks follow-up. The 
horizontal lines in the IgG and IgE graphs indicate the upper reference values [28]. 
Individual values are shown as dots with the short horizontal line representing the 
mean and the 95% confidence intervals displayed as the error-bars. 
The median number of days reported with diarrhea was low in both 
groups with two days in the placebo group (median 151 days 
recorded) versus five days in the probiotic group (median 148 days 
recorded) (p = 0.4, Wilcoxon rank-sum test). The average length of 
each episode was similar with in both groups a median of 1 day 
diarrhea per episode (p = 0.2, Wilcoxon rank-sum test). The odds of 
having stomach pain at any time during follow-up (Odds Ratio for 
probiotics group (OR) = 0.7; 95% CI: 0.4 – 1.3), flatulence (OR = 
0.9; 95% CI: 0.5 – 1.7), nausea (OR = 1.3, 95% CI: 0.7 – 2.5) and 
the impact of gastro-intestinal symptoms on daily life (OR = 0.7, 
95% CI: 0.4 – 1.2) did not differ between groups.  
Adherence estimates based on pill counts indicated that the 
product was well-tolerated and that compliance was good with a 
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median of 92% [range 47–100%] of days compliant in the placebo 
group versus 94% [range 84–100%] of days in the probiotics group 
(p = 0.5, Wilcoxon rank-sum test). Furthermore, loss to follow-up 
was similar between groups with 4 of 29 in the placebo group not 
returning for a follow-up visit versus 5 of 24 in the probiotics group (p 
= 0.5). 
A total of 15 participants reported at least one adverse event, of 
which 10 of 29 among the placebo group and 5 of 24 among the 
probiotics group (p = 0.3). One participant in the placebo group 
reported constipation, two diarrhea, three nausea, two itching or 
peeling skin, one dizziness and one vaginal odour as main adverse 
event. In the probiotic group one participant reported abdominal 
discomfort, three nausea and one reported vomiting as adverse 
event. A physician rated all events mild or moderate and none was 
rated severe. Over the course of 25 weeks probiotics 
supplementation, no differences in ALT, albumin and creatinine level 
were detected between the groups, indicating no adverse effect on 
liver or kidney function (Table 2).  
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Discussion 
To our knowledge, this is the first randomized, placebo controlled 
study to assess the impact of long-term probiotic use on immune 
function among people living with HIV. Previous trials have shown a 
preservation of the immune function with probiotic use among 
children treated with, or non-responsive to ART with Bifidobacterium 
bifidum and Streptococcus thermophilus in Brazil [16], and among 
women naïve to ART with L. rhamnosus GR-1 in Nigeria [15]. The 
present study did not show a significant impact of L. rhamnosus GR-1 
and L. reuteri RC-14 on the immune function. The disconcordance of 
this finding has three potential explanations; the daily ingestion of 
probiotic L. rhamnosus GR-1 and L. reuteri RC-14 did not have a 
long-term impact on the immune function of people living with HIV; 
the variability in CD4 count fluctuations was higher among this study 
population than the one from which the sample size was calculated 
[15], resulting in a potential too small sample size; the populations 
previously studied, children in Brazil, and women with diarrhea in 
Nigeria, differed in their immune response to the probiotic 
formulation due to a different and less acute disease state of the 
host. Of note, within our population, those who were moderately 
immune deficient at baseline (CD4 count 200 – 350 cells/ųl) 
experienced an increase of 34 cells/ųl [95% CI: -37; 105] in the 
placebo group versus a mean increase of 158 cells/ųl [95% CI: 35; 
281] in the probiotics group at ten weeks (p = 0.1). In the six 
participants who were not included in the main analyses because of a 
baseline CD4 count < 200 cells, the four participants receiving 
probiotics experienced a mean increase of 93 cells/ųl [95% CI: 26; 
159] while the two placebo participants experienced a mean decrease 
of –69 cells/ųl [95% CI: -95; -42] (p = 0.04). In both subgroups, 
these effects were not sustained at 25 weeks. These findings suggest 
that probiotics may have a different impact among sub-populations, 
with those who have a more compromised immune state responding 
better to the probiotic interventions. This emphasizes the importance 
of trying to increase the chance of patients responding to therapy, by 
using biological or genetic markers when available to stratify the 
patient population before enrollment and decide at what point 
intervention will provide the best outcome (for example, in subjects 
with a starting CD4 count less than 350 cells/ųl) [28]. 
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The immune markers IgE, IgG, IFN-γ and IL-10 did not show a 
significant impact of probiotic supplementation. Markers that are 
more specific for the intestinal barrier including plasma 
lipopolysaccharide (LPS), plasma total bacterial DNA and urine 
lactoferrin: mannitol ratio, may be more useful in future studies [8, 
29]. The finding that IgE is elevated compared to reference values 
[27] confirms previous findings of a Th-2 dominated immune-state 
among this population [30, 31]. The increased levels may be partly 
due to helmintic colonisation (IgE), though this effect is likely to be 
limited as previous studies show levels do not significantly increase 
among HIV patients harbouring helminths [30]. Elevated levels of IgG 
among HIV patients have been previously reported, although these 
may have been due to sub-clinical opportunistic infections [32]. 
This is one of few studies to examine the safety of long-term use 
of probiotics, and the first to do so in a population with HIV [33]. No 
adverse events were associated with the long term use of probiotics. 
Minor adverse events were reported by twice as many participants in 
the placebo group than in the probiotic group. Given the challenges of 
living in this impoverished community, participants’ compliance was 
remarkable with 80% (n = 44) completing the 25-weeks trial. This 
might partly be explained by the selection of participants who were 
keen to take prolonged action that they believed might improve the 
course of their HIV infection.  
This study shows that long term probiotic supplementation is 
feasible in HIV patients in sub-Saharan Africa. Unfortunately, so-
called ‘probiotic’ products that have never been tested in humans, 
never shown to provide measurable benefits, and with strain 
combinations that have not been assessed in malnourished or HIV-
positive subjects, are now becoming available in countries including 
Zambia and South Africa.  This is not unexpected given that similar or 
identical products have not yet been either banned in the developed 
world, or instructed to not use the term probiotic until their health 
benefits have been substantiated [14]. For people in developing 
countries who face the day-to-day challenges from malnutrition, 
infectious diseases and poverty, alleviation of gastro-intestinal 
symptoms, improvement in immunity and increased ability to work 
could contribute significantly to their life and that of their family. The 
potential to provide benefits through probiotic food or supplements, is 
worthy of further study, but selling untested products is tantamount 
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to an unethical practice. As shown herein and as mechanistic studies 
would support the rationale for probiotics for HIV management [34], 
there are some encouraging signs that well-documented probiotics 
may have potential [15-17,35]. This has to be proven in targeted 
large randomized trial. Just as important, if certain probiotics do not 
have a tangible effect on the health (as assessed by immune 
parameters, diarrhea incidence, other markers) of subgroups of HIV 
patients, there is no reason for them to be recommended.  
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Abstract 
Background: Women living with HIV and co-infected with bacterial 
vaginosis (BV) are at higher risk for transmitting HIV to a partner or 
newborn. It is poorly understood which bacterial communities 
constitute BV or the normal vaginal microbiota among this population 
and how the microbiota associated with BV responds to antibiotic 
treatment.  
Methods and Findings: The vaginal microbiota of 132 HIV positive 
Tanzanian women, including 39 who received metronidazole 
treatment for BV, were profiled using Illumina to sequence the V6 
region of the 16S rRNA gene. Of note, Gardnerella vaginalis and 
Lactobacillus iners were detected in each sample constituting core 
members of the vaginal microbiota. Eight major clusters were 
detected with relatively uniform microbiota compositions. Two 
clusters dominated by L. iners or L. crispatus were strongly 
associated with a normal microbiota. The L. crispatus dominated 
microbiota were associated with low pH, but when L. crispatus was 
not present, a large fraction of L. iners was required to predict a low 
pH. Four clusters were strongly associated with BV, and were 
dominated by Prevotella bivia, Lachnospiraceae, or a mixture of 
different species. Metronidazole treatment reduced the microbial 
diversity and perturbed the BV-associated microbiota, but rarely 
resulted in the establishment of a lactobacilli-dominated microbiota. 
Conclusions: Illumina based microbial profiling enabled high though-
put analyses of microbial samples at a high phylogenetic resolution. 
The vaginal microbiota among women living with HIV in Sub-Saharan 
Africa constitutes several profiles associated with a normal microbiota 
or BV. Recurrence of BV frequently constitutes a different BV-
associated profile than before antibiotic treatment. 
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Introduction 
The human vaginal microbiota plays an important role in the 
maintenance of health of a woman, partner or newborn [1]. Until 
very recently, the composition and dynamics of these organisms was 
poorly understood due to limitations of culturing methods. 
The advent of PCR based techniques and pyrosequencing has 
made it possible to further examine this complex microbial niche 
(reviewed in [2]). Herein, we describe the development and 
utilization of a novel metagenomic approach based on Illumina 
sequencing to profile the vaginal microbiota. Illumina has fewer 
errors than 454 sequencing [3] and therefore we hypothesized that it 
could provide a higher phylogenetic resolution than 454 based 
approaches [4]. Furthermore, the advantage of Illumina to provide 
30-times more reads would enable us to perform in depth sequencing 
of hundreds of samples in one run at a fraction of the costs, making it 
an excellent tool for large microbiome studies. We chose to sequence 
the V6 variable region of the 16S rRNA gene as it was adequate to 
resolve the majority of the expected organisms in the vaginal 
microbiota to the genus level [5] and provided resolution for a 
number of organisms in our samples to species and in some cases to 
strain level (Gloor et al. submitted). In selecting the population to 
study, we were struck by the extremely high prevalence of bacterial 
vaginosis (BV) in women living with HIV in Sub-Saharan Africa [6–9]. 
This condition is generally characterized by a depletion of lactobacilli 
and overcolonization by a range of anaerobic bacteria [10]. The 
apparent absence of lactobacilli and their by-product lactic acid 
increases vaginal pH, thereby disrupting physiological mechanisms 
that might inactivate or contain the virus [11–14]. These factors 
presumably result in an increased risk of transmission to a newborn 
child or partner associated with BV [15]. Knowledge of the microbiota 
profiles among women living with HIV is important as different 
microorganisms may be indicative of distinct risk-profiles in the 
transmission of HIV and severity of BV. Another consideration for 
selecting this study population was that BV appears to be more 
recalcitrant to antibiotic treatment in HIV patients and treatment is 
ineffective in reducing HIVshedding from the vaginal tract [6,16]. 
Assessing the response of the BV-associated microbiota to antibiotic 
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treatment may yield further insight in factors contributing to the 
failure of treatment. Therefore we sought to define (1) the microbial 
communities of women living with HIV, (2) their association with the 
vaginal pH and (3) their relation with the Amsel criteria and Nugent 
scoring system commonly used to diagnose BV [17,18].  
Results 
A total of 272 samples were sequenced using a single lane of a 
paired-end Illumina run resulting in >18 million reads of 76 
nucleotides. Of these >12 million bar-coded V6 16S rRNA sequences 
were identified that completely covered the V6 region and that had 
intact barcodes and primer sequences (see Gloor et al, submitted, for 
a complete description of the workflow used to extract these 
sequences). Individual samples were covered with a median of 
40,931 reads (range 7,018–129,054). The Chao1 measure of 
biodiversity estimation was the most conservative estimate and 
predicted that the reads covered >90% of the expected diversity in 
235 of 272 samples (Table 1). After clustering in operational 
taxonomic units (OTUs) based on a >95% sequence similarity cut-off, 
which permitted up to 3 substitutions per V6 sequence, a total of 60 
OTUs representing phylogenetic groups were identified (Tables S1, 
S2, Figures S1, S2). Of those, 30 were assigned to specific species 
based on sequence identity to a well-annotated organism and 18 to a 
genus. Strikingly, within some OTUs distinct strains could be 
separated. For example, within OTU 1 the sequences could be 
annotated as Gardnerella vaginalis 409-05, G. vaginalis NML060420, 
and as two unique uncultured G. vaginalis sequences. All four of 
these sequences differed from each other by a single diagnostic 
nucleotide. 
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Table 1. Coverage estimates 
Method N>0.9 N>0.95 
Rarefaction 272 255 
Ace 241 169 
Chao1 235 181 
The number of samples in which >90% and 95% of the expected diversity was 
sampled using rarefaction, Ace and Chao 1 estimates [34, 35]. Analyses were 
performed using the VEGAN package for biodiversity analyses [36]. 
 
L. iners and G. vaginalis constitute core members of the 
vaginal microbiota 
Figure 1 shows the composition of the microbiota clustered by the 
similarity of the relative abundance of the organisms. We found that 
207 of the 272 samples could be grouped into 8 major clusters with 
relatively uniform microbiota compositions. Across all clusters, G. 
vaginalis and Lactobacillus iners were detected in each sample, 
constituting core members of the microbiota. Two major clusters 
were associated with a normal vaginal microbiota, one dominated by 
L. iners and one dominated by L. crispatus. Four clusters were 
strongly associated with BV, and were dominated by Prevotella bivia 
or Lachnospiraceae, or comprised a mixture of different species. The 
remaining clusters were notable in that they contained normal, 
intermediate and BV samples and were composed largely of G. 
vaginalis and L. iners and a mixture of other species. 
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The vaginal microbiota and pH 
Figure 1 shows that all 13 samples within the L. crispatus cluster, 
but only 29 of 39 samples in the L. iners cluster had a pH ≥4.5 (Table 
2). We used two independent methods to examine the strength of 
this association. Table 2 shows that the proportion of L. iners alone 
was only weakly associated with the vaginal pH. The strength of this 
association increased when the proportion of L. crispatus was added 
to the model. Figure 2A shows that L. crispatus is associated with a 
low pH, but if L. crispatus is not present, a large fraction of L. iners is 
required to predict a low pH. However, lack of both L. iners and L. 
crispatus is strongly predictive of high pH.  
 
Table 2. Correlation Amsel and Nugent score with microbiota 
clusters. 
Organisms n pH Clue cell Odor Nugent score 
  ≤4.5 >4.5 n y n y 0-3 4-6 7-10 
L. iners 39 29 10 33 6 35 4 38 1 0 
L. iners & 
 G. vaginalis 
21 9 12 11 9 16 4 7 8 6 
L. crispatus 13 13 0 11 2 10 3 13 0 0 
Lachnospiriceae 
& Veillonellaceae 
14 1 12 4 10 1 13 0 1 13 
G. vaginalis 64 9 50 16 46 35 29 9 19 36 
Prevotella bivia 20 0 18 4 14 7 11 3 4 13 
Multiple species 15 2 10 2 11 3 10 0 3 12 
Lachnospiraceae 21 0 21 0 21 5 16 0 1 20 
This table summarizes the number of samples for each cluster (corresponding to 
Figure 1) with a specific Nugent or Amsel diagnostic characteristic. Categories do not 
always count up due to missing data (Figure 1). 
 
The vaginal microbiota and the Amsel criteria 
Table 3 shows that the various components of the Amsel criteria 
vary in their strength of association with the vaginal microbiota. In 
particular, the presence of a milk-like discharge did not appear to 
have any correlation with the resident microbiota and was a 
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confounding factor within the set of four Amsel criteria (Tables 3,S3). 
The presence of odor was moderately associated with the vaginal 
microbiota. Of note, two Lachnospiriceae clusters, and the multiple 
species cluster appeared to be most strongly associated with the 
presence of an amine odor (Figure 1 and Table 2). Figure 2B show 
that Atopobium vaginae and Veillonellaceae were most clearly 
associated with odor across clusters. 
 
Table 3. Correlation proportion of lactobacilli with Amsel criteria 
and Nugent score. 
Variable Proportion Pairs R1 p Strength2 
pH L. iners 254 -0,2469 0,0000 83 
pH L. iners & L. crispatus 254 -0,2311 0,0000 35 
Nugent score L. iners & L. crispatus 272 -0,2423 0,0000 34 
Amsel score L. iners & L, crispatus 242 -0,1531 0,0012 31 
Odor L. iners & L. crispatus 265 -0,1473 0,0034 231 
Clue cells  L. iners & L. crispatus 262 -0,1927 0,0001 55 
Discharge L. iners & L. crispatus 259 0,0514 0,3131 418 
1 Kendall rank correlation coefficient and p-value.  
2 Strength of the association is indicated by estimating the number of subjects that 
would be required to show the correlation between the variables with ≥ 95% 
confidence. 
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Figure 2. Association of vaginal pH and odor with members of the vaginal 
microbiota. The flow chart explaining the relationship between microbiota and 
diagnostic criteria were generated using data mining techniques (Materials and 
Methods). To obtain the prediction about a clinical sample, follow the arrows like a 
flow chart from the organisms (rectangular boxes) to the prediction (ovals). Each 
decision in the tree is split on the proportion of the organism above; thus, if a clinical 
sample has proportions less than 13.6% L. crispatus and less than 48.8% of L. iners it 
is predicted that the sample is taken from a vaginal environment with a pH≥4.5. The 
accuracy of the decision tree is reported for the entire dataset and for 10- folds cross 
validation, which is an attempt to estimate the accuracy of the decision tree on new 
clinical samples. 
Impact of Metronidazole treatment 
Of the 132 women enrolled at baseline, 47 had a normal 
microbiota, 22 intermediate and 67 had BV as defined by the Nugent 
score [17]. The microbiota of BV patients were composed a larger 
diversity of taxa than normal subjects (Figure 3). All subjects with BV 
were treated with metronidazole and 39 subsequently returned for 
follow-up visits. After 2 weeks, 57% of these patients still had BV. 
Treatment with metronidazole reduced the diversity at two weeks but 
the diversity increased slightly at later follow-up time-points 
indicating a tendency to return to a more diverse microbiota (Figure 
3). Metronidazole frequently caused a shift from one BV-associated 
microbiota profile to another, but rarely resulted in a lactobacilli-
dominated microbiota (Figure 4). L. iners was the only organism with 
an increase in relative abundance (from a median of 25% to 46%) 
after metronidazole intervention (p =,0.0001, Wilcoxon rank test). 
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The effect of metronidazole on two patients is presented in Figure 5, 
to illustrate the dynamics of microbiota changes with antibiotic 
intervention. 
 
 
Figure 3.  Diversity of the vaginal microbiota and the impact of antibiotics. 
The species diversity was measured by calculating Shannon’s Diversity index [31]. 
The data was partitioned either by Nugent category [17], or by treatment time-point. 
Metronidazole treatment (week 0) reduced the diversity at two weeks but a slightly 
higher diversity was observed at later follow-up time-points indicating a return to a 
more diverse microbiota. 
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Figure 4.  Changes in microbiota profile after antibiotic intervention. The 
network depicts the profile of the vaginal microbiota before (time = 0) and after 
metronidazole intervention. A thin line represents one subject while a thick line 
represents two. Only women were included with a complete follow-up and when a 
microbiota was present similar to the major profiles at baseline (Figure 1). Gv 
indicates G. vaginalis, MS = Multiple species, LV = Lachnospiraceae & Veillonellaceae, Ls= 
Lachnospiraceae, Pb= P. bivia and U = minor clusters. 
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Figure 5. Dynamics of the vaginal microbiota after antibiotic intervention. The 
line graphs depict the changes in relative abundance for a select number of species 
after metronidazole intervention (week 0). After two weeks both patients are cleared 
of BV along with an increase in the relative abundance of L. iners at two weeks. 
However patient 43 experiences a recurrence and receives another course of 
metronidazole at 5 weeks. Of note, after an L. crispatus profile is established, BV does 
not recur in this subject. 
Discussion 
To our knowledge, we report the first successful attempt to nearly 
completely sample the diversity of the vaginal microbiota. Compared 
to 454 sequencing, the Illumina method provided 30-fold more reads 
with a 10-fold reduction in costs, enabling hundreds of samples to be 
processed in one run. This method could be adapted to sequence the 
V3 or V5 region suitable for uncovering the intestinal microbiota [5]. 
The reduced costs of microbial profiling ($10/sample) might enable 
the use of this technology in a diagnostic setting and allow large 
studies to be carried our on the human microbiota. 
Based on similarity of the relative abundance, we have 
demonstrated in an HIV population of African women, that there are 
several microbiota profiles associated with BV, and two with a 
normal, healthy status. For BV cases, there was a dominant 
abundance of P. bivia or members of the order Clostridiales and 
family Lachnospiraceae. Interestingly, in a culture based study of 
African women, P. bivia was also found to be the dominant organism 
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[7], unlike Caucasian and black women from North America, in whom 
Atopobium vaginae and genera of the order Clostridiales, such as 
Megasphaera sp., were dominant [10,19].  
A recent 454 pyrosequencing study of a healthy cohort of 
American women including African Americans, showed the Prevotella 
genus to be the most abundant in one of five clusters [20]. Prevotella 
bivia is a well known pathogen that has been reported to invade 
epithelial cells, cause inflammatory responses, endometritis, pelvic 
inflammatory disease, and peri-rectal abscesses [21]. Its presence in 
the vagina of HIV patients warrants efforts to treat and eradicate it; 
however, this was not achieved by the use of metronidazole in the 
present study. 
The common finding of Clostridiales organisms, presumably 
originating from the gut, indicates an ability to adapt easily to the 
vaginal environment. The two clusters in which Lachnospiraceae were 
heavily represented, were associated with the presence of an amine 
odor. Although many cases of BV can be asymptomatic, odor is a 
major reason for women deciding to seek treatment. It is unpleasant 
and adversely affects quality of life [22]. The association of 
Clostridialis organisms and A. vaginae with odor warrants the 
evaluation of interventions specifically directed against these 
organisms. 
The presence of L. crispatus or a high abundance of L. iners was 
clearly associated with a healthy (≥pH 4.5). The fact that L. iners was 
detected in all the vaginal samples, along with G. vaginalis, indicates 
they have some core functions or at least a well developed means to 
persist in the fluctuating environment of the vagina. It would be 
worthwhile examining a larger sample pool of women colonized by L. 
crispatus, to verify what appears to be an important role in lowering 
the vaginal pH. The ability of L. crispatus, unlike L. iners, to produce 
hydrogen peroxide may also be a factor in maintenance of health 
[23]. The low prevalence of L. crispatus and the virtual absence of L. 
jensenii relative to non-African populations [10,19,23–25] might in 
part explain the high occurrence and low cure rates of BV among this 
cohort of Tanzanian women with HIV. 
Treatment with metronidazole was associated with a shift in 
microbial profiles without necessarily a recurrence of the same 
profile, and poor efficacy at establishing a lactobacilli-dominant 
microbiota. The treatment caused a shift in abundance of L. iners, but 
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did not induce a recovery of L. crispatus. This is interesting for 
several reasons. The emergence of BV causes a displacement or 
killing of L. crispatus, while it does not eradicate L. iners. The genome 
of the latter contains exogenously acquired elements that appear to 
aid persistence and survival (Macklaim et al. manuscript submitted), 
but how they achieve this when confronted by biofilms of BV 
pathogens, remains to be determined. If such mechanisms are 
identified, it may be possible to try and up-regulate them in probiotic 
strains such as L. crispatus CTV05, L. rhamnosus GR-1 or L. reuteri 
RC-14. By surviving BV and antibiotic treatment, L. iners may be able 
to proliferate (as shown by its increased abundance following 
metronidazole treatment) and create an environment conducive to 
later re-colonization by L. crispatus via the rectum and perineum. 
This remains to be verified. 
In summary, we report a novel, inexpensive, highly practical 
technique for profiling the human microbiota at a high phylogenetic 
resolution. The study identified 60 OTUs in the vagina of African 
women with HIV and L. iners and G. vaginalis were found to be core 
members of the vaginal microbiota. Four bacterial clusters were 
associated with BV, and two clusters with a normal vaginal 
microbiota. L. crispatus was more strongly associated with a low 
vaginal pH than L. iners, suggesting a different ecological function. 
Treatment failed to eradicate BV and only transiently reduced the 
diversity of the BV-associated microbiota. 
Materials and Methods 
Clinical study and sample collection 
Women visiting the HIV clinic of Sekou-Toure Regional Hospital in 
Mwanza, Tanzania, were invited to participate in the study. Subjects 
were included when: their HIV infected status was confirmed, they 
had not yet initiated antiretroviral treatment, and they were between 
18 and 45 years old. Participants were not included when pregnant, 
lactating, menstruating at time of screening, hypersensitive to 
metronidazole, had Trichomoniasis detected by saline microscopy, 
had budding yeast indicating Candida colonisation seen on Gram stain 
or had cervical inflammation noted during gynaecologic examination. 
The medical ethical review committee of Erasmus University Medical 
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Centre, The Netherlands, and the medical research coordinating 
committee of the National Institute for Medical Research, Tanzania, 
approved the study design and protocol. Subjects were informed of 
the purpose of the study and gave their signed informed consent 
before participation. The study was registered at clinical trials.gov 
NCT00536848. 
A total of 132 women were screened of whom a sub-group of 
women (n =39) diagnosed with BV (Nugent score ≥7) were treated 
with metronidazole (400mg orally, twice daily for 10 days) (Aventis), 
and followed at 2, 5, 15 and 25 weeks. If symptoms and signs of BV 
in addition to a Nugent score of ≥7 were present at any follow-up 
visit from week 5, subjects were again prescribed metronidazole. At 
each visit, vaginal samples were collected for Gram staining, pH, 
saline microscopy and KOH preparation. 
Samples for DNA extraction and PCR were obtained by brushing a 
polyester swab against the mid-vaginal wall after insertion of a non-
lubricated speculum. The swabs were placed in a cryovial and stored 
at 22oC until analysis. BV was diagnosed at each visit by rating a 
gram stained smear by Nugent scoring [17] and Amsel’s criteria [18]. 
A Nugent score of 1–3 was defined as normal, 4–6 as intermediate 
and 7–10 as BV. Also, the presence of trichomoniasis was diagnosed 
by saline microscopy and the presence of budding yeast by Gram 
stain to indicate Candida colonisation. 
PCR amplification 
The primers L-V6 (5’-CAACGCGARGAACCTTACC-3’) and R-V6 (5’-
ACAACACGAGCTGACGAC-3’) were chosen to amplify the V6 
hypervariable region of the 16S rRNA gene. The primers were tested 
in silico using a custom made database including all entries in the 
RDP with taxonomic information and longer than 1400 nucleotides. Of 
all those sequences the left primer matched over 96% and the right 
primer over 98% of the sequences in the dataset. The taxa Sneathia, 
Leptotrichia, Ureaplasma and Mycoplasma could only be amplified if 
up to 4 mismatches were allowed outside the first 5 nucleotides of 
the left primer, and therefore we suggest that our data are biased 
against these taxa. We developed different barcodes of 3–6 
nucleotides long, to be attached to the 5’ end of the primer that 
would give a relatively even mixture of the 4 nucleotides at the first 
several positions. The barcodes were between 3 and 6 nucleotides 
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long to reduce the likelihood that adjacent spots on the Illumina solid 
support would be scored as one spot during the sequencing of the 
amplification primers. For the left primer we developed 18 different 
barcodes (5’-3’ CATGCG, GCAGT, TACGT, GACTGT, CGTCGA, GTCGC, 
ACGTA, CACTAC, TGAC, AGTA, ATGA, TGCA, ACT, TCG, GTA, CTA, 
TGA, GCTA) and for the right primer 16 different barcodes (5’-3’ 
CGCATG, ACTGC, AGCTA, ACAGTC, TCGACG, GCGAC, TACGT, 
GTAGTG, GTCA, TACT, TCAT, TGCA, AGT, CGA, TAC, TAG). A-priori 
the primers and DNA extraction procedures were tested using the 
amplification conditions described below on L. iners, L. rhamnosus, A. 
vaginalis and G. vaginalis.  
DNA extraction and amplification 
Swabs were vigorously agitated in 1 mL of PBS (pH 7.5) to 
dislodge cells after which the DNA was extracted using InstaGene 
Matrix (Biorad #732-6030) according to the protocol of the 
manufacturer. After extraction, 10 µl of the Instagene supernatant 
was used as template for a 50 µl PCR reaction. The following PCR 
reaction conditions were used: 5 units Taq platinum: 1.7mM MgCl, 
210 mM dNTPs and 640 nM of each primer. A touchdown protocol was 
employed with: initial denaturation 940C for 2 min; denaturation 
940C; annealing starting at 610C and dropping with 10C over 10 
cycles with the remaining 15 cycles at 510C; extension at 720C; all for 
45 seconds and a final elongation step for 2 min. A negative control 
including all ingredients but with water instead of DNA template, and 
a positive control with a lower limit of detectable DNA, were 
performed alongside all test reactions. PCR-products were used when 
the negative control was free of PCR product and the positive control 
amplified. A constant volume aliquot of each amplification product 
was run on a 1.5% agarose gel to determine the approximate amount 
of product. The amount of product was scored on a 4 point scale and, 
based on this scale, between 2 and 40 µl of the PCR products were 
mixed together to give the final sample sent for Illumina sequencing 
at The Next-Generation Sequencing Facility in The Centre for Applied 
Genomics at the Hospital for Sick Children in Toronto. The library was 
prepared without further size selection. All new sequencing data have 
been deposited in GenBank under accession numbers: HM585291-
HM585350. 
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Taxonomic classification of sequence reads 
The number of reads and the short nature of the reads precluded 
the use of the data analysis pipelines currently in use for microbial 
community profiling by the 454 pyrosequencing method. We 
developed a data analysis pipeline and programs in-house (Gloor et al 
submitted). A shell script plus the Perl and R scripts able to run on OS 
X to recapitulate the analyses are available from the authors. 
Sequences present at >1% abundance in any sample were clustered 
by similarity to a seed sequence at 95% identity using UCLUST [26]. 
All clustering methods present a trade-off between sensitivity and 
specificity. The 95% identity cut-off was chosen because it was the 
best compromise between clustering of sequences derived from PCR-
based sequencing errors and true taxonomic relatedness (See figure 
S1 for full justification of clustering cut-off). The most abundant 
sequence of each OUT was chosen as seed sequence. Each resultant 
seed sequence was first compared using mega BLAST against non-
redundant bacterial nucleotide sequences in the NCBI database while 
excluding environmental samples. The best scoring hit was selected 
to represent the seed sequence if it displayed 100% identity and 
coverage. If multiple hits fulfilled these criteria, a common higher 
taxonomic rank was assigned. When no hits were present at >90% 
identity, uncultured samples were included in the search (Tables S1, 
S2, Dataset S1). Preference was given in taxonomic assignment to 
sequences derived from fully sequenced bacterial genomes, then to 
sequences derived from characterized organisms and finally to 
environmental isolates. 
Association analyses 
Kendall’s Tau was used to test nonparametric rank association 
between lactobacilli fractions, the Nugent and Amsel criteria primarily 
for its simple interpretation [27,28]. The magnitude of association 
between the interval-scale Lactobacillus population fraction and 
ordinal-scale diagnostic criterion was quantified by a novel technique 
based on information theory [29]. To ensure invariance to 
distribution, population fractions were converted to ranks. Sampling 
variance was preserved by noting that the joint percentile distribution 
of all variables follows a Dirichlet distribution [30]. The Kullback-
Leibler divergence of the uniform density to the empirical density was 
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used to estimate the expected accuracy for distinguishing 
populations. To facilitate interpretation, the information divergence 
was converted to an estimate of the number of patient evaluations 
required to determine with ≥95% confidence whether or not those 
patients came from a population where no association was present. 
The more patients needed, the smaller the association between 
variables.  
Hierarchical clustering among samples 
Samples were clustered for similarity of relative abundance by 
calculating a generalized angle between proportions, as given by their 
Euclidian inner product [31]. Such a distance is equivalent to 
minimum Fisher information connecting two points. From a biological 
perspective, this angle can be loosely interpreted to measure how 
much a mixture of the two populations would have in common with 
each of its components. Small angles imply that two samples are 
virtually identical, while large angle imply thatsamples are maximally 
distinct. 
Diversity estimations 
Diversity was calculated using Shannon’s Diversity Index which 
calculates the entropy or variability of the system [32]. It is 
calculated as follows: Hs = −Σni ln ni where H is the entropy, and we are 
summing the species proportions multiplied by the log of those 
fractions. The diversity index has a minimum value when there is only 
one species and a maximum when all species are equally and 
identically distributed. 
Decision trees 
Decision trees were generated using the j48 implementation of the 
C4.5 decision tree algorithm from the Weka machine learning 
workbench [33]. The C4.5 algorithm attempts to create the most 
effective decision tree to create accurate predictions by using 
information theory. At each step in the process, the program splits 
the dataset on an attribute (eg. the relative abundance of an 
organism) to maximize the information gained about an important 
predicted variable (eg. the likelihood of a pH >4.5); the split is then 
entered into the decision tree like an entry in a flowchart and the 
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process is repeated until no more information can be gained. The 
decision trees were created using default C4.5 parameters and were 
pruned to prevent over-fitting the training set. The C4.5 decision 
trees were validated using 10-folds cross validation.  
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Abstract 
We developed a low-cost, high-throughput microbiome profiling 
method that uses combinatorial sequence tags attached to PCR 
primers that amplify the rRNA V6 region. Amplified PCR products are 
sequenced using an Illumina paired-end protocol to generate millions 
of overlapping reads. Combinatorial sequence tagging can be used to 
examine hundreds of samples with far fewer primers than is required 
when sequence tags are incorporated at only a single end. The 
number of reads generated permitted saturating or near-saturating 
analysis of samples of the vaginal microbiome. The large number of 
reads allowed an in-depth analysis of errors, and we found that PCR-
induced errors composed the vast majority of nonorganism derived 
species variants, an observation that has significant implications for 
sequence clustering of similar highthroughput data. We show that the 
short reads are sufficient to assign organisms to the genus or species 
level in most cases. We suggest that this method will be useful for 
the deep sequencing of any short nucleotide region that is 
taxonomically informative; these include the V3, V5 regions of the 
bacterial 16S rRNA genes and the eukaryotic V9 region that is gaining 
popularity for sampling protist diversity. 
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Introduction 
Microbiome profiling is used to identify and enumerate the 
organisms in samples from diverse sources such as soil, clinical 
samples and oceanic environments [1–3]. This profiling is an 
important first step in determining the important bacterial and protist 
organisms in a biome and how they interact with and influence their 
environment. 
Microbiome profiling is usually achieved by sequencing 
PCRamplified variable regions of the bacterial 16S and of the 
protistan small subunit ribosomal RNA genes [4,5]. Other sequences, 
such as the GroEL genes may also be targeted for independent 
validation [6]. The microbial profile of a sample may be determined 
by traditional Sanger sequencing, by terminal restriction length 
polymorphism analysis or by denaturing gradient gel electrophoresis 
(reviewed in [7]). The recent introduction of massively parallel 454 
pyrosequencing has resulted in a radical increase in the popularity of 
microbiome profiling because a large number of PCR amplicons can 
be sequenced for a few cents per read [4,8]. However, while 
constituting a tremendous improvement over previous methods, 
pyrosequencing is constrained by cost limitations and a relatively high 
per-read error rate. The high error rate has led to some discussion in 
the literature about the existence and importance of the ‘rare 
microbiome’ [9]. New methods for analyzing pyrosequencing output 
suggest that much of the raremicrobiome is composed of errors 
introduced by the sequencing method [10]. 
Until recently, the Illumimna sequencing-by-synthesis method of 
parallel DNA sequencing was thought to be unsuitable for microbiome 
profiling because the sequencing reads were too short to traverse any 
of the 16S rRNA variable regions. This can be partially circumvented 
by identifying maximally informative sites for specific groups of 
organisms (eg. [11]). A recent report demonstrated that short 
sequences derived from Illumina sequences could be used for robust 
reconstruction of bacterial communities. This group used Illumina 
sequencing to determine the partial paired-end sequence of the V4 
16S rRNA region in a variety of samples using single-end sequence 
tagged PCR primers [12]. 
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Here we report the methods used to perform microbiome analysis 
of the V6 region of 272 clinical samples using the Illumina sequencing 
technology. We used paired-end sequencing in combination with 
unique sequence tags at the 5’ end of each primer. The overlapping 
paired-end reads gave us complete coverage of the V6 region. The 
combination of sequence tags at each end of the overlapped reads 
allowed us to use a small number of primers to uniquely tag a large 
number of samples. The Illumina sequencing method generated >12 
million useable reads at a cost of ~0.03 cents per read, an 
approximate order of magnitude cheaper than the per-read cost of 
pyrosequencing. The cheaper per-read costs allows economical 
experiments on large numbers of samples at very large sequencing 
depths. Since Illumina sequencing is now capable of ~100 nt long 
reads from each end of a DNA fragment, the methods described here 
can be easily adapted for paired-end sequencing of the microbial V3, 
V5, V6 and the eukaryotic V9 rRNA regions. Similarly to others [12], 
we found that methods used to analyze pyrosequencing microbiome 
data were often unsuitable for reads generated by Illumina 
sequencing and we present a workflow that can be used for rapid and 
robust generation of the relative abundance of organisms in each 
sample. 
Importantly, we found that the Illumina sequencing method has an 
exceedingly low error rate and that the majority of errors arise during 
the PCR amplification step. We argue that the error profile has 
profound implications for choosing the appropriate seed sequence for 
clustering using the data generated by Illumina sequencing. 
Results 
Description of the Data 
The DNA samples analyzed by this method were derived from 
a study designed to examine the vaginal microbiota in HIV+ women 
in an African population. A separate manuscript details the clinical 
findings of the study [13]. In all we analyzed 272 clinical samples by 
a single Illumina paired-end sequencing run.  
The Illumina sequencing platform is currently restricted to read 
lengths of ~100 nucleotides from each end of a DNA fragment, and 
was limited to ~75 nt at the time of experimental design. Thus, a 
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paired-end sequencing run could only traverse the short 16S variable 
regions: V3, V5 and V6. The expected distribution of amplified 
fragment sizes, including the primer, for each variable region is 
shown in Figure 1. We decided to use the V6 region for two main 
reasons. First, the V6 region was expected to produce amplified 
fragments between 110 and 130 bp, ensuring that the majority of 
paired-end reads would overlap. Secondly, the V6 region provided 
resolution for a number of organisms of interest in our samples down 
to the species and in some cases the strain level [14]. The Illumina 
platform currently provides reads long enough to overlap in either the 
bacterial V3 [1,14] or V5 regions or in the eukaryotic V9 region [5]. 
We suggest the region(s) chosen for sequencing should be 
characterized for the resolution of taxa of interest, and several 
studies have examined this in detail [7,11].  
 
Figure 1. Expected amplified product size using constant regions flanking 
eubacterial variable regions. 
Chapter 7 
 150 | 
PCR Primer Characterization 
The primers were located within two conserved 16S rRNA 
segments that flanked the V6 region. The left and right primer 
sequences mapped to the 967–985 (CAACGCGARGAACCTTACC) and 
1078–1061 (ACAACACGAGCTGACGAC) using the coordinates on the 
Escherichia coli 16S rRNA segment, and were chosen to amplify the 
majority of species expected to be found in the vaginal environment. 
The potential ability to amplify the regions flanking the V6 region was 
tested computationally by two methods. First, the primers were 
assessed using the probematch service from the Ribosomal Database 
Project [15]. The forward and reverse primers were found to match 
96.8% and 99.3% of the good quality, long 16S rRNA sequences with 
2 or fewer mismatches. The forward primer was strongly biased 
against amplification of sequences in the Tenericutes and 
Thermotogae phyla, amplifying 201/1438 and 8/82 in these groups. 
The reverse primer was unbiased. Secondly, we used a method 
similar to Wang and Qian [16]. Unaligned 16S rRNA sequences were 
downloaded from the Ribosomal RNA Database Project [15] and the 
187260 sequences longer than 1400 nucleotides were extracted. 
Sequences of this length are nearly-full length and are expected to 
contain the V6 region. These sequences were filtered to remove 
entries where the only entry on the annotation line was ‘unidentified 
bacterium’ or ‘uncultured bacterium’, leaving 97987 entries. 
Approximate string matching (agrep) with the TRE regular expression 
library [17] was used to determine that the left and right primers 
matched 94101 and 96432 of 97987 sequences with the 
requirements of perfect matching at the 5 nucleotides at the 39 end 
and up to 2 mismatches in the remainder of the primer. Using this 
measure, the left primer matched over 96% and the right primer over 
98% of the sequences in the dataset. However, as shown in Table 1, 
either the left or right the primers did not match the majority of 
sequences annotated as Sneathia, Leptotrichia, Ureaplasma or 
Mycoplasma. We found that relaxing the parameters somewhat 
resulted in matching to the majority of species in these groups (Table 
1). We suggest that these primers would allow amplification of the 
majority of species in each of these groups, but that amplification 
may occur at lower efficiencies in some groups. 
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The primers were tested for their ability to amplify the 16S rRNA 
V6 region of Lactobacillus iners, Lactobacillus rhamnosus, Gardnerella 
vaginalis and Atopobium vaginae. All were amplified equivalently 
using the following PCR parameters: denaturation 940, annealing 510, 
extension 720 all for 45 seconds over 25 amplification cycles. 
 
Table 1. Number of species matching each primer in a RDP dataset. 
Taxon Total species Left1 Righta 
Escherichia 322 320 318 
Citrobacter 113 111 110 
Bacteroides 275 265 270 
Streptococcus 1249 1243 1244 
Staphylococcus 704 696 694 
Lactobacillus 1922 1908 1910 
Lachnospiraceae 82 82 82 
Peptostreptococcus 28 28 28 
Anaerococcus 29 29 29 
Megasphaera 38 38 38 
Dialister 21 21 21 
Candidatus 579 377 566 
Mobiluncus 25 25 25 
Propionibacteriaceae 12 12 12 
Bifidobacterium 146 145 143 
Porphyromonas 111 109 111 
Prevotella 269 264 264 
Fusobacterium 103 102 103 
Sneathia 4 4 0(4)b 
Leptotrichia 60 60 1(58)b 
Gardnerella 3 3 3 
Ureaplasma 36 0(34)c 36 
Mycoplasma 414 95(331)d 336 
anumber of hits with identity at the 3’ 5 nucleotides and up to 2 mismatches in the 
rest of the primer: 
bnumber of hits requiring identity at the 3’ 4 nucleotides: 
cnumber of hits allowing 3 mismatches and identity at the 3’ 5 nucleotides: 
dnumber of hits allowing 4 mismatches and identity at the 3’ 5 nucleotides. 
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Sequence Tag Choice 
The Illumina sequencing platform uses dye-terminated primer 
extension to sequence DNA  [18] and the base-calling algorithm uses 
the intensities from the first several nucleotides incorporated to 
normalize the fluorescent signal from subsequent nucleotide 
incorporation events [19,20]. Thus, we chose sequence tags to 
ensure all 4 nucleotides were represented in each of the first four 
positions of the primers using parameters similar to those in the 
barcrawl program [21]. This was achieved, in part, by varying the 
length of the tags between 3 and 6 nucleotides long. The tag length 
variation was expected to reduce the likelihood that adjacent spots on 
the Illumina solid support would be scored as one during the 
sequencing of the amplification primers [19,20]. All sequence tags 
were checked with a primer design program to ensure that they 
would not induce primer-dimer formation [22]. The sequence tags are 
given in Table 2. The right-side sequence tags can be uniquely 
identified if they are full-length, or if they are truncated by 1 
nucleotide, as commonly occurs during oligonucleotide synthesis. 
Three of the left-side sequence tags (GTA, CTA, TGA) could derived 
from three longer left-side sequence tags (AGTA, GCTA, ATGA) by N-
1 truncation. Only reads with full-length sequence tag sequences 
were used in this analysis. The three nucleotide-long sequence tags 
have been redesigned for subsequent experiments to remove any 
ambiguities that arise from N-1 truncation. The sequence tags were 
incorporated at the 5’ end of the PCR primers.  
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Table 2. Sequence tag and primer sequences. 
L-tag Name R-tag Name 
catgcg 0-v6L cgcatg 0-v6R 
gcagt 1-v6L actgc 1-v6R 
tagct  2-v6L  agcta  2-v6R 
gactgt  3-v6L  acagtc  3-v6R 
cgtcga  4-v6L  tcgacg  4-v6R 
gtcgc  5-v6L  gcgac  5-v6R 
acgta  6-v6L  tacgt  6-v6R 
cactac  7-v6L  gtagtg  7-v6R 
tgac  8-v6L  gtca  8-v6R 
agta  9-v6L  tact  9-v6R 
atga  10-v6L  tcat  10-v6R 
tgca  11-v6L  tgca  11-v6R 
act  12-v6L  agt  12-v6R 
tcg  13-v6L  cga  13-v6R 
gta  14-v6L  tac  14-v6R 
cta  15-v6L  tag  15-v6R 
tga  16-v6L   
gcta  17-v6L   
 
Extracting Sequence Reads and Sample Assignment 
As stated by others [12] the large number of sequences and the 
short sequence reads present a challenge. The number of and the 
short length of the reads prevented the application of many common 
pyrosequencing data analysis pipelines. We therefore developed the 
data analysis pipeline shown schematically in Figure 2. A full 
description of each step is given below. All programs to extract the 
sequence reads and to index them into individual sequence units 
(ISUs) were developed in-house. A Bash shell script referencing C, 
Perl and R programs and scripts that are able to recapitulate this 
analyses on OS X are available from the authors.  
We received 18047860 reads that were 76 nt long from each end 
of the PCR amplified region. Of these, 6236435 and 5491692 reads 
contained one or more low quality positions in the left and right end 
reads (defined as having the lowest base quality scores). However, 
there were only 53598 and 88498 reads that contained one or more 
‘N’ character in the sequence calls.  
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A custom program was written in C to identify the overlapping 
segments of the forward and reverse reads. The program first 
identifies perfect overlaps between the two reads, and then finds 
reads that overlap if a single mismatch is allowed. The quality score is 
used to identify the most likely nucleotide in the overlapped segment, 
and a new fastq formatted file is generated for the combined reads. 
With this strategy 14960488 reads were obtained that had a perfect 
overlap between 10 and 50 nucleotides and an additional 1922084 
reads had a single nucleotide mismatch in the overlapped region. The 
extraction of overlapping reads with proper primer sequences and 
correct sequence tags was performed with a custom Perl program. 
We found that 12035329 sequences contained two valid sequence 
tags and both primer sequences; allowing up to 3 mismatches per 
primer. The sequences derived from the perfectly overlapping reads 
form the basis of the remainder of the analysis. 
 
 
Figure 2. Conceptual workflow of the data analysis. PCR products derived from 
the eubacterial V6 rRNA region were sequenced on a single paired-end Illumina run. 
Reads were filtered for quality, overlapped and clustered as outlined in the text. Only 
reads with 0 mismatches in the overlapping region were used for further analysis. 
Inspection of sequences with incorrect sequence tags showed 
that the single largest contributor to the difference between the 
number of reads with proper primer sequences and the number of 
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reads with proper sequence tag sequences was an N-1 truncation of 
the sequence tag, which presumably arose during the primer 
synthesis. The next largest class of sequence tag error was complete 
lack of the left or right end sequence tag. Together, these classes 
account for slightly more than half of the missing reads. The 
remaining missing reads are composed of a large number of classes 
of sequence tag sequences each containing small numbers of errors 
including additional 5’ bases, misincorporated bases or difficult to 
classify errors that presumably arose during the PCR amplification. 
Sequence Clustering 
Clustering was used to group identical sequences into ISUs, and 
these ISUs were further clustered into operational taxonomic units 
(OTUs). The variation in an OTU can come from sequence differences 
between closely related taxa in the underlying population, through 
errors introduced into the amplified fragment from the PCR 
amplification, or from DNA sequencing errors.  
ISUs were produced by collecting and collapsing identical 
sequences located between the primers and collapsing. A custom Perl 
program was written that associated each ISU with the number of 
identical sequences in it, that indexed each read to the appropriate 
ISU and, later the OTU. The 12035329 reads were collapsed into 
126832 ISU sequences, with the most abundant ISU containing 
4321348 identical reads. 
The occurrence of chimeric sequences was examined using 
UCHIME, a part of the UCLUST package. Chimeric sequences can 
arise during PCR [23] or because of overlapping spots on the solid 
support when imaged during DNA sequencing [18]. The default 
settings of UCHIME identified 5211 putative chimeric ISUs, containing 
18614 reads. Thus, 5.6% of the ISUs were putative chimeric 
sequences, but these composed only 0.15% of the total reads. There 
were 21 abundant putative chimeric ISUs that contained >100 reads; 
the most abundant contained contained 1271 reads. 
Each of the abundant putative chimeric ISUs were tested for 
chimerism with BLAST using the ISU sequence as the query and using 
the bacterial subset of nucleotide sequences at NCBI as the database. 
We found only two putative chimeric sequences had sequence derived 
from two different species and had a UCHIME chimera score >10, the 
other 19 putative chimeric ISU sequences matched multiple 
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independent sequences in the dataset with ≥98% identity for their 
entire length. Thus, the occurrence of chimeric sequences was re-
evaluated using a chimera score cutoff of 10 and only 497 ISUs 
containing 1834 total reads (0.015% of the dataset) were above this 
threshold. We concluded that chimeric sequences composed a very 
small subset of the total number of ISUs, probably because the 
primers amplified across a variable region only. The dataset was used 
without further regard to chimeric sequences because putative 
chimeric sequences composed a minuscule fraction of reads. 
The ordered ISU sequences were clustered into OTUs, operational 
taxonomic units, by UCLUST which clusters each ISU to a seed 
sequence at a fixed sequence identity threshold using sequences as 
seeds in the order they are encountered in the file. We ordered the 
ISU sequences from the most to the least abundant, under the 
assumption that read abundance correlated with the abundance of 
the sequences in the underlying population.  Several lines of analysis 
were used to decide on appropriate clustering values. 
It is expected that the abundance of sequence variants per OTU 
will decrease according to a power law if the variants are generated 
stochastically. However, if a variant represents a distinct taxon in the 
underlying microbial population, the frequency of the variant is 
expected to reflect the proportion of the bacterial DNA in the sample. 
Figure 3 shows a plot of the number of reads in an OTU having n 
mismatches compared to the most frequent read in the OTU at a 
cluster percentage of 92%. For an OTU with a length between 72–80 
bp this corresponds to ~5 mismatches with the seed sequence. The 
red line in Figure 3 shows the plot for the 37 bp concatenated left and 
right primer sequences, which are expected to have half the per-
nucleotide PCR-dependent error rate as the sequence between the 
primers, because 50% of the sequence is not derived de novo but is 
contributed by the primer sequence. Because the concatenated 
sequence is about one-half the length of the sequence between the 
primers, the overall slope of the primer line should approximate the 
slope of a single-species OTU that includes errors arising only from 
the PCR and sequencing. Note that the line for the primer sequence is 
nearly linear and, in line with our expectations, the number of reads 
having additional differences with the seed sequence for the OTU is 
far less abundant than the reads with one fewer difference. Also 
plotted are the results for the 25 most abundant OTUs, with OTU 0, 
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the most abundant OTU comprising 51% of the total reads, shown in 
blue. The line for OTU 0, and several other OTUs closely follow the 
line for the concatenated primers until 4 or 5 differences with the 
seed sequence are included. The simplest interpretation is that one or 
more additional rare taxa having 4 or more mismatches with the seed 
sequence for OTU 0 are now being included at this level of clustering. 
The lines for 11 of the 25 OTUs show a similar pattern with a sharp 
increase at 4 or more mismatches. Only 3 of the OTUs show a 
continuous decline for all number of mismatches with the seed 
member of the OTU suggesting that clustering at 92% identity was 
including sequences not derived from PCR or sequencing error.  
 
 
Figure 3. The proportion of reads in the 25 most abundant OTUs clustered at 
92% identity as a function of the number of differences with the seed ISU. 
The red line shows the plot for the concatenated primer sequences, and the blue line 
shows the plot for the OTU containing the most abundant ISU. 
We next calculated the Levenshtein distance — the minimal 
number of substitutions, insertions or deletions needed to convert 
one sequence into another — for all pairs of the 108 ISU sequences 
that occurred with a frequency of >1% in any of the 272 samples. 
Examination of the neighbour-joining tree drawn from these distances 
showed that there was a continuum of distances between ISU 
sequences, but that there seemed to be a natural distance cutoff of 
three substitutions in this dataset. This is illustrated in Figure 4 where 
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the branches sharing red nodes connect ISU sequences that clustered 
together at 95% identity, and branches sharing green nodes connect 
ISU sequences clustered at 92% identity. Several of these are 
instructive. The clade at 2 o’clock is anchored around ISU 0. The 
other ISU sequences in this clade differ from ISU 0 by one or two 
substitutions, and, as we show below, represent substitutions 
because of PCR error. All the members of this clade are wellseparated 
from all other clades. The other extreme can be illustrated by the 
clades at 4 and 6 o’clock. Here, as shown below, the grouping at 95% 
identity includes differences derived from PCR errors and from 
underlying sequence diversity in the microbial sample. However, 
grouping at 92% identity (Levenshtein distance of 5) clearly groups 
outlier clades with the main group. It is standard to assume that 
clustering at 97% identity represents species units [12]. However, 
taking the two extremes as examples, clustering at greater than 95% 
identity would result in splitting clades that contain differences 
derived only from PCR error (i.e. ISU 0 and associated ISUs) and 
clustering at less than 95% identity would group sequences that 
should be distinct.  
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Figure 4. Neighbour-joining tree derived from Levenshtein distance 
between the 108 most abundant ISU sequences. ISUs clustered into OTUs at 95% 
identity are connected with red branches and ISU sequences clustered at 92% identity 
are connected with green branches. The seed sequence for each 95% identity OTU 
cluster is identified by a red dot. 
 
Based on these analyses a cluster percentage of 95% was used for 
the analysis given below because it allowed up to 3 nucleotide 
differences with the seed sequence per OTU. At the 95% clustering 
threshold, 15 of the OTUs showed ISU mismatch frequency decay 
characteristics similar to that expected for errors introduced only via 
PCR or sequencing error; i.e., their abundance profiles decayed at a 
rate similar to that seen for errors in the primer sequences. This 
indicates that these 15 OUT sequences may be well differentiated 
from their neighbours at this level of clustering and may represent 
distinct sequence species in the underlying population. On the other 
hand, the most abundant ISU in several OTUs was outnumbered by 
clustered ISU sequences. In the most extreme cases, OTUs 46, 97 
and 119, ISU species with 2 and 3 differences from the seed ISU 
outnumbered the seed ISU by 2–3 orders of magnitude. An example 
of this characteristic profile is labeled with an arrow in Figure 3. As 
shown below, these OTUs represent clusters of errors derived from 
very abundant organisms in the underlying population. 
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Assignment of OTUs to Taxonomic Groups 
The tools used for taxonomic assignment are not designed to work 
with the short sequences derived from this type of analysis [15]. 
Therefore, similar to others we designed a simple classification 
scheme based on sequence comparison with BLAST [12,24] vs. 
eubacterial sequences (taxid 2), excluding uncultured and 
environmental samples, in the GenBank database [25]. In essence, 
sequences were identified at the species level if a fully-sequenced or 
classified type-species sequence matched the OTU with 100% identity 
and 100% coverage and no other sequence matched with >97% 
identity. Sequences that matched with less than 100% identity were 
classified at the genus level if another genus matched with a lower 
percent identity. Sequences with less than 95% identity were 
matched to the taxonomic level supported by the groups of reads. 
With these rules we were able to assign the 63 OTU sequences that 
were at an abundance of >1% in any of the 272 samples 
unambiguously. As discussed below, three of the OTUs were derived 
from PCR errors from the G. vaginalis strains and were classified 
accordingly. The classifications of these OTUs, and the supporting 
evidence for each is shown in Supplementary Table S1. The sequence 
of the seed ISU for each OTU has been deposited in Genbank with 
sequential accession numbers between HM585291–HM585350 
inclusive. 
Systematic Sources of Error 
Recently, Quince et al [10] examined the effect of pyrosequencing 
errors on the classification of organisms in high-throughput 
microbiome analyses. They concluded that a large fraction of the ‘rare 
microbiota’ was composed of pyrosequencing errors and introduced a 
method to accurately cluster the reads based on their expected 
errors. Since the Illumina sequencing platform has a substantially 
lower error rate than does the 454 pyrosequencing platform, and the 
read length is deterministic rather than random [19] we were thus 
interested in identifying the sources of error in the ~13 million 
overlapping reads in our dataset. Most notably the Illumina platform 
is not susceptible to miscalling the number of nucleotides in 
homopolymeric regions; this type of base-call error is more 
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pronounced in pyrosequencing reads when sequence coverage is 
relatively low [19]. 
If the major source of error in the data came from DNA 
sequencing, we would expect that errors should increase as a 
function of distance from the sequencing primer until the region of 
overlap and that the errors should be much less frequent in the 
overlapped region. This hypothesis can be assessed by comparing the 
Q, or quality, score assigned by the Illumina base-calling algorithm in 
the overlapped 16S sequences with the error frequency per position. 
Figure 5 shows a box-plot of the Q scores for the reads of length 120 
nt, which composed 24% of the ~12000000 overlapping reads. 
Similar results were obtained for reads between 113 and 126 nt, 
which together compose >99% of the overlapping reads. Two 
important conclusions can be drawn. First, as expected, the median Q 
score decreases and the range of scores increase as the distance 
from the sequencing primer becomes greater. Second, the Q scores, 
and the variability in these scores for the region of overlap are 
greater than for the region of single coverage.  
 
Figure 5. Quality scores for all overlapped 120 bp composite reads. The Q 
scores a log-odds score of the likelihood of error in the base call, higher Q scores 
represent lower likelihoods of error [40]. They are expected to decrease with distance 
from the left or right sequencing primer, and to be highest in the region of perfect 
overlap because Q scores are additive. 
 
Initally, the concept of stochastic error contributing to sequence 
variation was examined by measuring the frequency of occurrence of 
each nucleotide in the left and right primers. Figure 6 shows a plot of 
the number of times that each nucleotide occurred at each position in 
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the left and right V6 primers. This figure illustrates several points. 
First, the most frequent variant at each position is usually a transition 
rather than a transversion, although several positions did not follow 
this pattern. Secondly, the frequency of the residues differing from 
the primer sequence are found in a relatively consistent range. 
Thirdly, position 9 in the left primer, which was synthesized as a 
mixture of G and A, shows a strong deviation from the background 
frequency. Thus the underlying nucleotide frequency in the population 
of molecules being amplified strongly affects the nucleotide frequency 
at the polymorphic position. Finally, the variation is constant across 
the entire length of the primers except for position 9 and is not 
dependent on the distance from the sequencing primer. These 
observations support the hypothesis that stochastic errors may 
contribute significantly to sequence variation in our dataset. 
The relationship between the Q scores and the abundance of 
sequence variants for each OTU was examined by mapping the 
variants onto seed ISUs as was done for the primer sequences. All 
ISU sequences in each OTU were used to make a BLAST database for 
that OTU and the OTU seed sequence was used as the query 
sequence. An additional 6 nucleotides were added onto both ends of 
both the OTU sequence and the ISU sequences because of the edge 
effects in the BLAST algorithm [26]. These nucleotides were later 
trimmed for the analysis. The number of sequence variants at each 
position, weighted by the number of reads that the variant occurred 
in was tabulated and converted into graphical representations of 
nucleotide counts at each position in the OTU.  
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Figure 6. The frequency of each nucleotide observed at each position in the 
left and right primers derived from the Illumina dataset. There are >12 million 
sequences, and the difference in frequency between the correct and altered nucleotide 
is relatively constant. Note that the errors are at the same frequency at each end of 
the primers. 
 
Two representative examples for the rRNA V6 region are given in 
Figure 7, and a summary of the distributions is given in Figure 8. 
Figure 7 shows the number of reads that contain an individual residue 
at each position plotted in color. The entropy of each position is 
plotted as open or filled diamonds; higher entropy values correspond 
to greater variability at the position. Both of these OTUs contain 
several million reads, and the predominant nucleotide corresponds to 
the OTU seed sequence. However, there are many variants that were 
clustered together in these OTUs. 
Figure 8 shows a summary plot of the distribution of differences in 
the frequency across each OTU between the most commonly 
occurring residue and the other 3 residues at each position. The OTUs 
are arranged approximately from those with the most to the least 
number of reads. Several interesting observations can be made from 
these bar-plots. First, the frequency differential varies between 10-2 
and 10-5 for the vast majority of sequence variants from the seed ISU 
sequence. Second, about half of the OTUs contain one or more 
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strongly outlying values. These correspond directly to the common 
variant residues seen in Figure 7. Compare, for example, the uniform 
distribution of variants in the top panel of Figure 8 (OTU 0) and the 
three outlying variants in the bottom panel (OTU 1) with the 
nucleotide distributions in Figure 7 for these OTUs. Third, the 
evidence for outlying positions becomes progressively weaker as the 
the number of sequences in the OTU decreases.  
 
Figure 7. The sequence variation in OTU 0 and OTU 1. The plot shows the 
number of times that each nucleotide occurred at each position in two example OTUs. 
 
The data in these two figures can be summarized numerically by 
examining the distribution of the entropy of the positions in each 
OTU. Skew in the entropy values is calculated by: 
SK=Hmedian-Hmeanx100. The SK value tells us if the distribution of 
entropies is strongly skewed by the occurrence of highly variable 
positions. Values near or greater than 1 indicate a strongly skewed 
entropy distribution and represent a situation where several to many 
positions are highly variable. 
Z and ZQ both measure how different the maximum entropy value 
is to the central tendency of the entropy distribution, and are 
calculated as follows: Z=(Hmax-Hmean)/ơH and ZQ~(Hmax-
Hmedian)/(H95thpercentile-Hmedian). Thus Z represents the number of 
standard deviations that the maximum entropy value is from the 
mean, and ZQ is the number of 95 percentile deviations of the 
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maximum entropy value from the median. Both values are required 
since Z is not informative if a distribution has a large variance. ZQ has 
extreme values in the instances of a skewed distribution with small 
number of extreme values. Inspection of the plots suggests that 
values of SK>1, Z>6 or ZQ>6 represent situations where the 
nucleotide distribution for a suggests a mixed population of reads. 
Conversely, OTUs where all 3 values are less than these cutoffs 
strongly suggest that the variability seen in the OTU arose from 
stochastic errors inherent in the experimental protocol. 
 
 
Figure 8. Boxplot summaries of the difference between the frequency of 
the most in common residue at each position and the frequency of each 
sequence variant. The OTU numbers are given at the top of the graph. 
 
Supplementary Table S2 summarizes these statistics for each OTU. 
The complete set of Figures, shown in Supplementary Figure S1, and 
the associated summary statistics provide information about the 
potential mixture of sequences found in each OTU. 
The information in Figure 7 and in 8 and the associated entropy 
information, allow us to classify the OTUs into groups that contain a 
homogeneous population of reads that differ from each other only 
because of variations introduced during the PCR step (eg. OTU 0) and 
OTUs that contain sequence variants derived from the underlying 
population (eg. OTU 1). As an example, the top panel in Figure 7 
corresponds to OTU 0, and the seed sequence in this OTU is identical 
to the V6 region of Lactobacillus iners in both the RDP and NCBI 
nucleotide databases. The bottom panel corresponds to OTU 1, and 
the seed sequence is identical to one annotated as Gardnerella 
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vaginalis 409-05. The second most common sequence is identical to 
one annotated as G. vaginalis NML060420, and the third and fourth 
most common sequences are identical to sequences annotated as 
uncultured G. vaginalis sequences. All four of these sequences differ 
from each other by a single diagnostic nucleotide, and the variant 
counts match the counts of the 4 major ISUs. These 4 ISUs make up 
the 88.9% of the reads in OTU 1. Based on the analysis of these two 
OTUs and the similar analyses of the remaining OTUs, we conclude 
that OTUs that exhibit the pattern of variation seen in OTU 0 
represent distinct sequence entities in the underlying dataset and 
that those exhibiting a pattern of variation similar to OTU 1 represent 
the grouping of sequence entities in the underlying dataset based on 
sequence similarity. In the case of OTU 0, no sequence in the RDP 
database [15] could be clustered with it without including at least 5 
nucleotide substitutions, leading us to conclude that OTU 0 represents 
a distinct taxonomic group at the sequence level. In the case of OTU 
1 there are several sequences, all annotated as different strains of 
the same species that are grouped together, and like OTU 0, all are 
well-separated from other V6 sequences. Thus, we conclude that OTU 
1 is a cluster of distinct G. vaginalis strains. 
OTUs 46, 97 and 119 in the dataset, had distinct distributions 
when plotted as in Figures 7 and 8. The nucleotide frequency 
difference between the seed sequence and the nucleotide variants in 
these three OTUs was much smaller than in the other 61 OTUs. 
Inspection of the sequences making up these OTUs showed that they 
were most similar to one or more of the G. vaginalis strains. We 
propose that these OTUs are composed of ISU sequences derived 
solely from PCR errors that failed to cluster with the seed sequence in 
OTU 1. We are currently working on a clustering procedure that 
explicitly accounts both for edit distance and read abundance to more 
accurately cluster sequences derived by very high throughput 
sequencing. 
Organism Diversity and Data Reproducibility 
We found that one right-end tag, GCGAG, was composed of a 
mixture with the ratio 69.5/30.5 of the full-length and the unique N-1 
truncation-derived GCGA tag. This oligonucleotide synthesis error was 
exploited to determine the effect of the number of reads on within-
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sample variability; in essence the N-1 truncated tag allowed an 
examination of the technical replication of the experiment. The 
GCGAC tag was used in 17 samples. The black-filled circles in Figure 
9 show the number of reads from the full length GCGAC tag 
compared to the truncated GCGA tag in these samples. The red open 
circles in Figure 9 show an example of the read replication observed 
from independent samples. The replication of the read numbers in the 
full length and N-1 samples is extremely high for reads occurring at 
least 30 times in the fulllength tag set, and at least 10 reads in the N-
1 tag set. As expected the read replication for independent samples is 
much poorer. The correlation coefficients for the 17 full-length and N-
1 samples ranged from 0.97 to 0.99 when the N-1 sample contained 
at least 10 reads. Thus, we conclude that the number of reads in a 
sample is reproducible, if at least 10 reads are observed. Similar 
conclusions about the minimum read abundance have been drawn 
from RNA-seq experiments [27].  
 
  
Figure 9. Plot of the reproducibility between and within samples. The black-
filled circles plot within-sample variation, and the red circles plot the between-sample 
variation for the GTCGC tag. The count of sequences composing OTUs clustered at 
95% identity for samples containing the GTCGC tag and the GTCG N-1 tag are in black. 
This shows the technical replication of the data when amplified from the same sample 
in the same tube. The open red circles plot the correspondence for between-sample 
OTU counts. 
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Rarefaction Curves 
A second way to examine reproducibility is to generate rarefaction 
curves where the number of species sampled per unit of effort is 
estimated by resampling the dataset [28,29]. Rarefaction curves for 
the dataset from each sample were generated by performing 10000 
random samples with replacement [30] on the complete set of OTUs 
or ISUs or by including only those OTUs and ISUs that occurred in a 
sample more than twice. The values for resampling without 
replacement will approach the observed value (i.e. will saturate) only 
if the sample is of sufficient size to encapsulate all possible diversity 
[30]. Thus, if the values do approach saturation when resampling 
with replacement, we can be confident that we have sampled most, if 
not all, of the available sequence species [30,31].  
Figure 10 shows rarefaction curves generated for ISUs and OTUs in 
sample 1 using different protocols for a representative sample in our 
dataset; it is worth pointing out that this rarefaction curve is one of 
the few curves that does not reach saturation. The white-filled 
symbols show curves generated for unclustered ISUs in this sample, 
and the black-filled symbols are for OTUs generated at 95% sequence 
clustering. Here, the effect of removing rare sequence species is 
clear. The curve saturates when sampling only 50% of the reads if 
either rare ISU or rare OTU sequences are removed, but does not 
saturate for either the ISUs or OTUs even with the full set of reads. 
Inspection of the full set of rarefaction curves shows that this failure 
to reach the limit is commonly observed when the sample is 
dominated by one or a few species, which is the case in many of the 
microbiota samples in our complete dataset. Samples containing a 
broader range of species show rarefaction curves that generally reach 
the limit near 20000 reads, suggesting that this is an appropriate 
number of reads to sample the microbiome in the vaginal 
environment. Rarefaction curves for each of the 272 samples are 
given in Supplementary Figure S2. 
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Figure 10. An example rarefaction curve. The top panel shows rarefaction 
curves generated for sample 1 by resampling with replacement either all OTUs or ISUs, 
or OTUs and ISUs where at least 3 reads were observed. The bottom panel shows the 
rarefaction curve and the 95% and 99% confidence interval for all OTUs in sample 1. 
Rarefaction curves for all 272 samples are given in Supplementary Figure S2. 
 
Estimating Species Richness 
Another method of examining species richness is to use the Chao1 
or ACE methods to estimate the number of unseen species in the 
sample [32,33]. We used both methods to determine the number of 
species expected in each of the 272 samples with the VEGAN package 
for biodiversity analysis [34]. There were 37 and 31 of 272 samples 
where the Chao1 and ACE estimates indicated that we observed 
<90% of the real species. The correspondence between the Chao1 
and ACE measures is plotted in Figure 11 and it is clear by these two 
measures that the vast majority of samples were expected to contain 
the majority of the available species. Included in this plot is the 
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fraction of species found when the rarefaction analysis was performed 
with the number of reads in the sample. Rarefaction with a saturating 
number of reads again showed that the 206 of 272 samples identified 
all or almost all of the available species. 
 
 
Figure 112. Correspondence between Chao1, ACE and rarefaction curves 
for the 272 samples. The X and Y axes show the fraction of species that were found 
in each sample for the two estimates. Red-filled circles highlight those samples where 
the limit rarefaction value was less than 0.97. 
 
Diversity vs. Number of Reads 
Finally, species richness can be examined as a function of the 
number of reads across all 272 samples. This is plotted in Figure 12 
for ISU and OTU sequences. In this case the white-filled symbols 
represent populations derived from samples classified as ‘normal’, 
and are expected to be dominated by one or a few species, and the 
red or blue-filled symbols represent populations classified as bacterial 
vaginosis (BV), where there is expected to be a more even 
distribution of species [35,36]. There are strongly diminishing returns 
when more than 20000–25000 reads are obtained regardless of the 
diversity of the population; sampling more than 50000 reads was 
Microbiome profiling by Illumina sequencing 
 | 171  
sufficient to sample all the available OTU diversity in the samples. 
Interestingly, the number of distinct ISU sequences increases linearly 
with the number of reads, providing further evidence that increasing 
the number of reads increases the background number of ISUs that 
contain PCR-derived errors. Taken together with the rarefaction, 
Chao1, ACE data, we conclude that the number of reads obtained by 
this Illumina sequencing is adequate to sample nearly saturating 
numbers of species in this environment. 
 
 
Figure 12. Plot of the number of distinct ISU or OTU classes in each sample 
as a function of the number of reads. The number of ISU classes increases with 
the number of reads, but the number of OTU classes becomes constant above 20000–
30000 reads. 
Comparison with DGGE 
Results from Illumina sequencing were compared to those from 
dideoxy chain termination sequencing of bands isolated from 
following denaturing gradient gel electrophoresis (DGGE) analysis of 
amplified PCR products; a method traditionally used for the 
separation of bacterial species. A total of 20 samples were selected 
that were expected to have a diverse population of organisms by 
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extrapolation from the 272 samples sequenced by Illumina. DNA 
fragments from the bands were sequenced and each OTU sequence 
and each sequence from the DGGE bands were assigned to taxonomic 
groups by BLAST using the GenBank nucleotide database as 
described above. OTU sequences were assigned to species if they 
matched 100% of their length at 100% identity, and to genus or 
other groups as outlined in Supplementary Table S3. DGGE was 
found to detect only those bacterial species of greatest abundance in 
the sample, with a minimal Illumina read abundance of 11%. In two 
cases, one shown in Figure 13A-lane 89, a distinct band was excised 
and sequenced that had an Illumina abundance of between 2–3%. 
Figure 13B shows that a total of 8 organisms were detected through 
DGGE analysis, compared to 59 organisms detected through Illumina 
analysis in the same 20 samples, and that the organisms identified by 
DGGE analysis were a strict subset of those identified by Illumina 
sequencing. 
 
Microbiome profiling by Illumina sequencing 
 | 173  
 
Figure 13. DGGE analysis of selected samples. Panel A shows representative PCR 
amplicons from 3 of 20 clinical samples (Subjects 40, 48 and 89) were 
electrophoresed on a denaturing gradient gel. Bands were excised, sequenced and 
identified as in the Materials and Methods. Bands are labeled as follows: le = 
Leptotrichia amnionii; in=Lactobacillus iners; ga=Gardnerella vaginalis; 
cr=Lactobacillus crispatus; pr=Prevotella amnii (also named P. amniotica). Panel B 
shows a Venn diagram of the organisms identified by Illumina sequencing of the V6 
rRNA region and by sequencing DGGE bands amplified from the V3 rRNA region. 
Discussion 
We present and characterize a low-cost, high throughput method 
for microbiome profiling. The method uses combinatorial sequence 
tags attached to the 5’ end of PCR primers that amplify the rRNA V6 
region, but may be easily adapted for use in other bacterial and 
eukaryotic sequences. Illumina paired-end sequencing of the 
amplified sequences generates millions of overlapping reads. The 
combinatorial sequence tags allow the investigator to examine 
hundreds of samples with far fewer primers than is required for 
single-end bar-code sequencing. We propose that this method will be 
useful for the deep sequencing of any short sequence that is 
informative; these include the V3 and V5 regions of the bacterial 16S 
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rRNA genes and the eukaryotic V9 region that is gaining popularity 
for sampling protist diversity. The use of the V3 and V5 regions is 
currently being attempted by our group. Two other groups recently 
used strategies similar to ours. One collected overlapping paired-end 
reads, but without the sequence tags, to examine genomic DNA from 
mixed bacterial populations [37]. The other used a small number of 
sequence tags on one of the two amplification primers to examine 
microbial diversity using paired-end Illumina sequencing [12]. 
However, their method required three Illumina sequencing reads 
instead of two: two of the reads to sequence each end of the 
amplified product and a third using a custom primer to identify the 
sequence tags. In contrast, in our study, we attached very short 
sequence tags to both the left and right primers and read the 
sequence of the tags directly in the paired-end run. Furthermore, we 
used a simple set of rules to choose short sequence tags that 
balanced the nucleotide composition in the first 4 positions of the 
reads, that maximized the stagger in the primer sequences when 
attached to the solid surface and that minimized the possibility of 
primer-dimer formation. Using these simple principles and avoiding 
the N-1 generation of nonunique sequences, short sequence tags 
should be easily derived that are suitable for primers specific to any 
small region of interest. Sequence tags can be chosen automatically 
using the barcrawl program [21] or can be chosen by hand. 
We observed very few chimeric sequences in our dataset. There 
are several reasons. First, we used a relatively small amount of input 
DNA and used a small number of PCR cycles for amplification [23]. 
Secondly, many chimeric sequences may have been removed 
because of the strict requirement for proper sequence tag and primer 
sequences on the left and right ends, and because of a requirement 
for long overlapping segments of a defined length. In this case, the 
deterministic read lengths of the Illumina protocol combined with our 
narrow window for overlapping segments would have resulted in 
many chimeric sequences being filtered out. Indeed, inspection of a 
fraction of the read pairs that failed to overlap, or that failed to pass 
the sequence tag and primer requirements showed that many of 
these were chimeric or deleted at one or both ends (data not shown). 
Thus, while the Illumina sequencing protocol is limited to short 
segments these can be combined into longer segments using the 
paired-end approach as long as there is a significantly overlapping 
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segment. The utility of the method is further demonstrated by the 
nearsaturating number of ISU and OTU sequences obtained from a 
large number of clinical samples. We used several lines of evidence to 
show that 20000 reads are sufficient to capture all or virtually all of 
the sequence diversity in the vaginal microbiome, and that obtaining 
over 50000 reads results in no new sequence species. Thus, 
assuming a requirement for 50000 reads, up to 200 samples can be 
combined into a single Illumina lane, while up to 500 samples are 
possible if only 20000 reads are required. This is much greater depth 
at a much lower cost than is possible with current pyrosequencing 
technology. Strikingly, we observed that none of our samples 
contained the full range of species in the microbiome as a whole, and 
that we found fewer species than in a recent report that used 
pyrosequencing in the same niche [38], despite averaging 20-fold 
greater sequence coverage. We suggest that the higher fidelity 
Illumina sequencing may have resulted in fewer taxa because of a 
lower error rate contributing to fewer ‘rare microbiome’ taxa. 
Finally, we showed that the spectrum of errors could be examined 
for each OTU to help determine if the OTU was derived from a single 
underlying sequence in the sample population. The large number of 
reads presented a challenge for sequence-based clustering because 
sequencing millions of reads ensured that much of the read variation 
was derived from PCR-amplification. We show that sequence 
clustering of the large number of reads derived from Illumina 
sequencing would be more accurate if it took both the sequence 
variation and the underlying error rates into account. We are 
currently working on developing methods to cluster that use both 
sequence similarity and read abundance. 
Materials and Methods 
Ethics Statement 
The medical ethical review committee of Erasmus University 
Medical Centre, The Netherlands, and the medical research 
coordinating committee of the National Institute for Medical Research, 
Tanzania, approved the study design and protocol. Subjects were 
informed of the purpose of the study and gave their signed informed 
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consent before participation. The study was registered at 
www.clinicaltrials.gov NCT00536848. 
Sample Preparation and Amplification 
DNA was prepared from clinical swabs as part of a clinical study 
[13]. Amplification was initiated with a 610 annealing temperature 
that dropped to 510 in 10 increments followed by 15 cycles of: 
denaturation 940, annealing 510, extension 720 all for 45 seconds with 
a final elongation for 2 minutes. A constant volume aliquot of each 
amplification was run on a 1.4% agarose gel for to determine the 
approximate amount of product. The amount of product was scored 
on a 4 point scale and, based on this scale, between 2 and 40 µl of 
the PCR products were mixed together to give the final sample sent 
for Illumina sequencing at The Next-Generation Sequencing Facility in 
The Centre for Applied Genomics at the Hospital for Sick Children in 
Toronto. The library was prepared without further size selection. 
Denaturing Gradient Gel Electrophoresis Analysis 
Clinical samples were amplified using eubacterial primers flanking 
the V3 region of the 16S rRNA gene: HDA-1 (5-
ACTCCTACGGGAGGCAGCAGT-3) at position 339–357 (with a GC 
clamp located at the 5 end), and HDA-2 (5-
GTATTACCGCGGCTGCTGGCA-3) at position 518–539, with an 
annealing temperature of 560C. PCR reactions were carried out in 50 
µl reactions for 30 cycles using the profile: 940C, a gradient of 
annealing temperatures 71{510C at 45sec each, elongation 720C all 
for 45sec. 
Preparation of the 8% polyacrylamide denaturing gradient and gel 
electrophoresis was done according to the manufacturers instructions 
for the D-Code Universal Detection System (Bio-Rad) with a 30–50% 
gradient of urea and formamide. The gel was run in Tris-acetate 
buffer and pre-heated to 590C. The gel was run at 130V for 2 hours 
or until the xylene cyanol dye front reached the lower end of the gel. 
DNA was visualized by UV irradiation following stain with ethidium 
bromide. Bands were excised and reamplified, using the same 
primers and profile but without the GC clamp. This second PCR 
product was purified and sequenced with the HDA forward primer via 
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dideoxy chain termination. Analysis of results was carried out using 
the GenBank nucleotide database and BLAST algorithm [39]. 
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Abstract 
Importance of the field: Urogenital infections are on average the 
number-one reason for women to visit the doctor. Yet, treatment and 
preventive strategies have gone unchanged for close to 50 years. 
With prevalence rates for bacterial vaginosis at more than 29%, 
depending on the population, and similarly high incidences of vulvo-
vaginal candidiasis and urinary tract infections, plus HIV, new 
therapies are urgently needed to improve the health of women 
around the world.  
Areas covered in the review: This review discusses the vaginal 
microbiota, our improved understanding of its composition, and its 
role in health and disease. It also discusses the progress made in the 
past 10 years or so, with the development and testing of probiotic 
lactobacilli to improve vaginal health and better manage urogenital 
infection recurrences. 
What the reader will gain: The reader will have an understanding 
of the clinical data obtained so far, and the potential mechanisms of 
action of probiotics. Despite the need for more clinical studies, the 
review illustrates a case for inclusion of probiotics as part of the 
approach to disease prevention, and as an adjunct to antimicrobial 
treatment. Challenges remain in optimizing clinical benefits, selecting 
new strains, preparing new products and having them tested in 
humans then approved with informative claims, and making products 
readily accessible to women in the developed and developing world. 
Take home message: The vaginal microbiota is a complex structure 
that can change quickly and dramatically and significantly impact a 
woman’s health. New health-maintenance and disease-treatment 
approaches are badly needed, and probiotics should be considered. 
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The vaginal microbiota 
The vagina is a dynamic environment colonized by a wide range of 
microorganisms that are collectively referred to as the vaginal 
microbiota. The most important constituent of the microbiota in 
healthy women are members of the genus Lactobacillus.  
A decade ago, L. crispatus and L. jensenii were viewed as the 
predominant vaginal species [1]; however, with recent advances in 
culture-independent community profiling, the nutritionally fastidious 
L. iners is emerging as a dominant organism, present in both healthy 
and lactobacilli-deficient aberrant vaginal environments [2]. Bacterial 
migration from the rectum, across the perineum to the vagina occurs 
naturally in women and is a source of both pathogens as well as 
lactobacilli. The latter are believed to offer protective effects against 
pathogens through displacement, modulating immunity, production of 
antimicrobial substances and lowering vaginal pH [3,4]. 
Estrogen levels confer a wide range of effects on the vaginal 
environment, including influencing the microbiota [5,6]. Estrogen 
stimulates glycogen production by vaginal epithelial cells, and the 
glycogen is then metabolized to glucose, which can then be 
fermented by lactobacilli as an energy source. Lactic acid, as a 
byproduct of metabolism, is released and functions to acidify the 
vaginal environment from a pH of 5 to 3.8 - 4.2. The lactic acid is a 
key antimicrobial agent in the vaginal fluid and has been shown to 
affect uropathogenic Escherichia coli surfaces [7,8]. During ovulation, 
an increase in lactobacilli numbers has been observed with a sub-
sequent decrease during menses, resulting in a higher incidence of 
bacterial vaginosis (BV) [9,10]. At present, it is not possible to know 
to what extent a depletion of lactobacilli per se is associated with the 
clinical exacerbation of postmenstruation, but certainly BV is one 
factor.  
In prepubescent girls, estrogen levels are low and the vaginal 
epithelium is thin and lacking in glycogen. This is associated with a 
low abundance of lactobacilli replaced by mostly anaerobic Gram-
negative rods and Gram-positive cocci. Similarly, in postmenopausal 
women with low estrogen levels, lactobacilli are less dominant, but 
become restored when hormone replacement therapy is administered 
[11]. The replenishment of the lactobacilli may involve an increase in 
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receptor sites that allow more transient binding of the organisms to 
epithelial cells [12]. 
The microbiota may vary among racial groups. Zhou et al. [13] 
observed, in a group of 144 North American caucasian and black 
women, that 33% of black women had communities that were not 
dominated by lactobacilli, while only 7% of caucasian women 
displayed communities that were not dominated by lactobacilli. They 
speculated that the lack of a protective microbiota might explain the 
increased susceptibility to BV in the black population. The problem 
can carry forward to complications associated with an aberrant 
vaginal microbiota, as illustrated in a study of 11,910 women enrolled 
at 23 - 26 weeks’ gestation in which the proportion of preterm birth 
associated with lower genital tract infection was 21% among African 
Americans and 5% among whites [14]. In a study of 531 women at 
high risk of unplanned pregnancy, BV and sexually transmitted 
infection was shown to be significantly more associated with African 
American than white women, although race and color per se do not 
explain this finding [15]. 
Bacterial vaginosis 
Bacterial vaginosis is a common infectious condition, affecting an 
estimated one third of all women at any given time and is 
characterized by a depletion of lactobacilli and a resulting alteration 
of the vaginal microbiota [16]. The reduction in lactobacilli makes for 
a more conducive vaginal environment for the proliferation of many 
anaerobic bacteria, such as Gardnerella vaginalis, Atopobium vaginae 
and Mobiluncus curtissi. Recent molecular techniques have allowed 
for a more thorough detection of bacteria than traditional culture, 
with the result of increased bacterial diversity associated with BV 
[17]. 
Current diagnosis of BV can be achieved by the Amsel criteria 
based upon the presence of a milk-like discharge, odor, a pH of > 4.5 
and epithelial cells covered in Gram- negative rods. Another 
diagnostic test involves microscopic examination of a vaginal smear 
and a scoring system that is based upon the presence or absence of 
lactobacilli, Gram-negative rods and various bacterial morphotypes 
[18]. Some rapid diagnostic systems have been developed, primarily 
based upon elevated pH [19,20]. The symptoms and signs of BV do 
Probiotics and the vaginal microbiota 
 | 185  
significantly impact the quality of life of women [21] but are only 
reported in the minority of cases [22]. Irrespective of 
symptomatology, BV has been associated with an increased 
susceptibility to preterm labour perhaps owing to inflamma- tory 
processes [23], sexually transmitted infections including HIV 
infection, perhaps due to a damaged epithelial layer or altered 
expression of protective compounds like elafin [24,25], and pelvic 
inflammatory disease caused by pathogens [26]. These sequelae of 
BV are difficult to manage and many are not resolved with current 
therapeutics. This places an increased importance on developing new 
ways to treat and prevent this condition, with the use of probiotics 
being one such option. 
The selection of urogenital probiotic strains 
The criteria used to select bacterial strains for potential use as 
urogenital probiotics have evolved with time. From 1987 to 2002, the 
criteria included production of antimicrobial substances such as 
bacteriocins and hydrogen peroxide (H2O2), adhesiveness to epithelial 
cells and in vitro inhibitory activity against known BV pathogens [27-
30]. This was based on the premise that probiotic bacteria have to 
adhere to or colonize epithelial cells and inhibit the adhesion and 
growth of pathogens in order to be beneficial. The inclusion of H2O2 
production was based on lactobacilli isolated from healthy women 
often producing this substance [31]. The concept of adhesion led to 
the isolation of strains that were highly adherent to epithelial cells, 
with the expectation that they would then persist better in the host. 
There has only been one study correlating in vitro predictability with 
in vivo persistence [32], and thus it is difficult to say that this is a 
definitive criterion for clinical success with all probiotics. Today, the 
ability to persist in the vagina and produce metabolites that benefit 
the host are more important than adhesion scores to cells and/or 
mucus, and this process probably involves the ability to survive pH, 
cope with hormonal and modulate host responses, as well as use 
various compounds for growth, and somehow outcompete organisms 
already present. The most extensively tested probiotic combination 
for vaginal health, L. rhamnosus GR-1 and L. reuteri RC-14, has been 
detected in the vagina for up to 19 days after vaginal administration, 
whereas intestinal probiotic L. rhamnosus GG also inserted vaginally 
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was only detected for up to 5 days post-administration [33]. This 
would indicate that mining the genes of these organisms might 
identify factors that allow some strains to take advantage of certain 
biological niches. One study implanted L. rhamnosus GR-1 into the 
vagina and showed some upregulation of host defenses [34], while 
another showed an ability to displace BV pathogens [35]. 
The ability to inhibit pathogenic bacteria can be achieved through a 
number of different mechanisms. A study of 60 vaginal Lactobacillus 
isolates showed that the four strains exhibiting the greatest activity 
against BV-associated bacteria were all capable of producing H2O2 
[29], although it was unclear that this compound was solely 
responsible. Clearly, it is possible to inhibit urogenital pathogens 
without the necessity for H2O2 [28,36]. In addition, while hydrogen 
peroxide is toxic to G. vaginalis at high concentrations [37], it is 
ineffective or irrelevant against G. vaginalis biofilms [38,39]. 
The ability of a probiotic to survive passage through the 
gastrointestinal tract becomes an important selection criterion when 
oral administration is intended. While it perhaps seems most logical 
to deliver probiotics by direct vaginal administration, studies have 
shown that oral delivery is also feasible to deliver the lactobacilli to 
the vagina [40-42], and the finding of indigenous lactobacilli in the 
rectum and vagina further supports this delivery concept [43]. Direct 
vaginal application may be preferable for treatment of BV; however, 
the ability to deliver probiotics orally could be more convenient for 
long-term prevention. 
Regardless of the initial selection criteria used in vitro to identify 
potential probiotics, the evidence so far highlights the importance of 
ultimately selecting probiotic strains from clinical trials. Also, the 
differences in activity observed, even between strains of the same 
species, disproves a common misconception that all strains of L. 
rhamnosus or L. acidophilus are probiotic. Just because one strain (or 
combination of strains) has been proven as a probiotic, it does not 
necessarily follow that all strains of the same species are equally 
effective. 
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Probiotics for the treatment of bacterial 
vaginosis 
The current approach to the treatment of BV is through the 
application of antibiotics such as metronidazole or clindamycin. 
Although these treatment options yield a reasonable cure rate 
immediately following treatment, recurrences are common within 
weeks and months, and side effects including drug resistance are also 
common [44,45]. The potential for probiotics to enhance the cure 
rate of antibiotics is therefore appealing. Numerous clinical trials have 
been undertaken with the aim of assessing the effectiveness of 
probiotic intervention to treat BV. A number of trials have 
investigated the use of probiotics or candidate probiotics to treat BV 
(Table 1).  
A recent small trial performed by Mastromarino et al. [46] tested 
the effectiveness of three candidate probiotic strains used in 
combination to improve cure rate and symptoms of BV in 34 women. 
BV was diagnosed by Nugent score (7 - 10), Amsel criteria (3 - 4 
criteria) and vaginal symptoms (discharge and/or malodor). Subjects 
were randomized to receive one vaginal tablet containing L. brevis 
CD2, L. salivarius subspecies salicinius FV2 and L. plantarum FV9 at ≥ 
109 colony-forming units (CFU) each (18 of 34 subjects; 53%) or 
placebo (16 of 34 subjects; 47%) once daily for 7 days. Cure of BV 
was defined by Nugent score (1 - 6). Immediately following therapy, 
18 of 18 subjects (100%) in the probiotic group were free of BV, with 
15 (83%) and 3 (17%) subjects having a normal and intermediate 
vaginal microbiota, respectively. Of the placebo group, only 2 of the 
16 subjects (12%) were free of BV and had an intermediate 
microbiota (p < 0.001). An improved BV cure rate was maintained in 
the treatment group 14 days after termination of therapy, with 11 of 
18 subjects (61%) free of BV in the probiotics group com- pared with 
3 of 16 (19%) in the placebo group (p < 0.05). Subjects taking the 
probiotics also experienced reduced symptoms, including discharge 
and malodor. This study thus substantiates the evidence for 
lactobacilli to treat BV, although future trials with larger sample sizes 
will need to be conducted. 
Similarly, Hallén et al. [47] investigated the potential of lactobacilli 
to treat BV in 57 women. BV was defined by Amsel criteria (3 - 4 
criteria). Subjects were randomly assigned to receive suppositories 
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containing 10 8 - 109 CFU of lyophilized L. acidophilus (28 of 57 
subjects; 49%), or placebo capsules (29 of 57 subjects; 51%), 
inserted intravaginally twice daily for 6 days. Immediately following 
therapy, 16 out of 28 women (57%) in the treatment group had 
normal vaginal wet smear results compared with 0 of 29 (0%) in the 
placebo group (p < 0.005), as defined as lactobacilli content of wet 
smears. The definition of BV cure as an improved vaginal microbiota 
is unclear, however, and should also include the Amsel criteria as 
used in the initial screening of this trial. It 
should also be noted that the bacteria tested, L. acidophilus, was 
not strain-specific and thus cannot be considered a probiotic. 
Rossi et al. [48] investigated the effectiveness of certain bacteria 
to normalize vaginal pH and improve symptoms associated with BV, 
at a longer term of therapy relative to the other trials discussed. 
Subjects included 40 women with BV as defined by the Amsel criteria 
(3 - 4 criteria). All subjects were given vaginal tablets containing L. 
rhamnosus at > 106 CFU - 1 tablet once daily for 6 days, then 1 tablet 
twice a week for 2 months and then 1 tablet once a week until 24 
months. No placebo group was included in the trial. Following 
therapy, vaginal pH was < 4.5 in 24 out of 40 subjects (60%) after 
12 months and in 32 out of 40 (80%) after 24 months, compared 
with only 4 out of 40 (10%) before treatment (p < 0.001 and p < 
0.02 for 12- and 24-month follow-up, respectively). Subjects also 
reported a decrease in itching, vaginal discharge and burning at the 
12-month and 24-month follow-up visits. Investigators of this trial did 
not consider differences in the subjects in terms of the length of time 
from treatment with antibiotics to enrolment into the trial. Also, 
results of this study cannot infer the effect of this treatment on BV 
cure because standardized tests such as the Amsel criteria or Nugent 
scoring were not used to determine prevalence of BV following 
treatment. 
In the only study published so far comparing the BV cure rate of 
intravaginal probiotics and antibiotics, L. rhamnosus GR-1 and L. 
reuteri RC-14 were administered each night for 5 days versus 0.75% 
metronidazole gel applied vaginally twice a day to 40 women, and the 
probiotic proved to be more effective [49]. The subjects were 
randomized, but because of the treatments they were not blinded to 
what they received. Nevertheless, the measure of cure was not 
primarily based upon subject perception, but rather on Nugent 
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scoring and a BV-Blue test for sialidase. Whilst it is always feasible 
that discomfort and irritation could be swayed by subjects believing 
that a new therapy (i.e., probiotics) works and the old one (antibiotic) 
might not, the clinical presentation of odor and discharge is more 
definitive in combination with Nugent and BV-Blue scoring. Thus, the 
likelihood of bias is remote. Follow-up at days 6, 15 and 30 showed  
cure of BV in significantly more probiotic-treated subjects (16, 17 and 
18/20, respectively) compared with metronidazole treatment (9, 9 
and 11/20: p = 0.016 at day 6, p = 0.002 at day 15 and p = 0.056 at 
day 30). Confirmatory studies are needed, but some might argue that 
the cure rate with metronidazole in the previously mentioned study 
was much lower than normally expected. However, metagenomic 
studies are now showing that, at least in African women, 
metronidazole is poorly effective in curing BV and at best only useful 
in changing the abundance of pathogens (Hummelen et al., 
unpublished data). 
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Secondary prevention of bacterial vaginosis 
Two clinical studies examined whether probiotics could treat 
infection and prevent recurrences. The first was a study by Anukam 
et al. [50] which showed in 125 women that probiotic L. rhamnosus 
GR-1 and L. reuteri RC-14 augmented cure of BV with 500 mg 
metronidazole therapy. The combination therapy doubled the cure 
rate of BV (88 vs 40%; p < 0.001) and did not lead to recurrent 
infection, albeit the follow- up was short.  A second independent 
study by Martinez et al. [51], showed similar results (87.5 vs 50% 
cure; p < 0.05) using the same probiotic lactobacilli orally (2 
capsules/day of 1 X 109 CFU for each strain) plus 2 g tinidazole to 
treat 64 women diagnosed with BV. In addition, at 5-week follow-up, 
75% of women in the probiotic group had a normal vaginal 
microbiota compared with only 34.4% in the placebo group. 
A larger trial (n = 100) was undertaken by Larsson et al. [52] 
which also tested two strains, L. gasseri Lba EB01-DSM 14869 and L. 
rhamnosus Lbp PB01-DSM 14870, each at > 108-9 CFU/capsule 
administered once daily for 10 days during three consecutive 
menstrual cycles, as a means to reduce recurrences of BV following 
2% clindamycin cream therapy for 7 days. The initial cure rate in 
each group as determined by a score of 1 in the Hay/Ison scoring 
system was 37 of 48 women (77%) in those who subsequently 
received lactobacilli and 39 of 50 (78%) in those randomized to then 
receive placebo. Women who remained positive for BV after the first 
menstrual cycle were treated with antibiotics and discontinued from 
the study. At the 6-month follow-up, 24 of 37 subjects (64.9%) in 
the lactobacilli group remained BV-free compared with 18 of 39 
subjects (46.2%) in the placebo group (p = 0.027). The investigators 
also isolated lactobacilli from subjects in the treatment group and 
verified that these matched the strains that were administered. This 
study therefore demonstrates the potential for these strains to help 
reduce the occurrence of BV, although more investigation is 
warranted. 
A large trial (n = 255) conducted by Eriksson et al. [53] 
investigated the use of lactobacilli-containing tampons (L. gasseri, L. 
casei var. rhamnosus and L. fermentum, total of 108 bacteria) 
following 3 days of clindamycin ovule administration for BV. Following 
treatment, there was no improvement in cure rate of BV (51 of 91 = 
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56% with lactobacilli and 59 of 96 = 62% with placebo). The failure 
indicates that only certain strains of lactobacilli have the ability to 
augment antibiotics and reduce the risk of BV recurrences. The use of 
vaginally applied L. casei var. rhamnosus Lcr35 daily for 7 days, 
following treatment with 2 X 300 mg oral clindamycin for 7 days [54] 
in 190 women resulted in 83% showing a marked reduction in Nugent 
score by ≥ 5 grades (mean difference of 6.61), compared with only 
35% in the control group (mean difference of 4.13; p < 0.001). It is 
important to note that this trial was observer-blind only, and so 
subjects from the control group were aware of the contents of their 
capsules and thus cannot be considered placebo. Nevertheless, this 
study demonstrated a beneficial effect of lactobacilli administered 
with clindamycin and raises the question of whether this remedy 
worked because of the strain or the route of administration, 
compared with the study using tampons [52]. A genomic comparison 
study might prove useful to compare the L. rhamnosus Lcr35 used 
here versus the L. casei var. rhamnosus used in the tampon study. In 
addition, it is feasible that the strains contained in the tampon 
countered each other through either bacteriocin production or by one 
strain negating a beneficial effect of another on host immunity. 
A study by Shalev et al. [55], albeit with groups too small to be 
clinically significant, investigated the effect of yogurt enriched with 
bacteria to prevent recurrent BV in 46 women who have had ≥ 4 
documented episodes in the past year. BV was defined by pH > 4.5, 
positive amine test and presence of clue cells in microscope analysis 
of vaginal secretions. Subjects were randomly assigned to two 
groups. In group 1, 23 of 46 subjects (50%) consumed 150 ml yogurt 
enriched with L. acidophilus (> 108 CFU/ml) daily for 2 months, 
followed by no yogurt for 2 months, and then 150 ml pasteurized 
yogurt daily. In group 2, 23 of 46 subjects (50%) consumed 
pasteurized yogurt for 2 months, followed by no yogurt for 2 months, 
and then consumed yogurt enriched with L. acidophilus. A significant 
reduction in the episodes of BV was seen in the first group, from 60% 
before treatment to 25% after the first month, while group 2 saw a 
decrease in episodes from 70 to 50% (p = 0.004). An increase of L. 
acidophilus in both the vagina and rectum was also seen in the first 
group compared with the second group. There was a considerable 
dropout rate in both groups for reasons unclear, which made it 
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difficult to specify the number of participants treated successfully at 
each follow-up. 
A study of 84 BV patients randomized to receive either oral 
metronidazole 500 mg twice a day for 7 days, or one vaginal tablet 
containing freeze-dried L. rhamnosus once a week at bedtime for 2 
months starting 1 week after the last antibiotic administration, 
showed a significant improvement long-term effect (up to 90 days) 
with the lactobacilli prophylaxis (p = 0.05) [56]. 
In the first study of its kind of postmenopausal women, 21 of 35 
(60%) who received daily oral L. rhamnosus GR-1 and L. reuteri RC-
14 for 14 days and only 6 of 37 (16%) receiving placebo showed a 
reduction in the Nugent score by at least two grades (p = 0.0001) 
[57]. Although this does not prove cure of BV, the clear displacement 
of BV organisms in favor of lactobacilli shows that probiotic lactobacilli 
treatment can impact vaginal health even when estrogen levels are 
low after menopause. The fact that the microbiota was improved 
within such a short timeframe argues well for adding a new option to 
the management of postmenopausal women at risk of BV. Another 
study with the same probiotic strains in postmenopausal women 
susceptible to urinary tract infections (UTIs), showed that 1 year of 
daily therapy was as effective as daily antibiotic in preventing 
recurrences [58]. The mean number of reported symptomatic UTIs 
the year before the study was 7.0 in the trimethoprim-
sulfamethoxazole (TMP/SMX) and 6.8 in the probiotic group. After 12 
months of prophylaxis these fell to 2.8 and 3.1, respectively. After 1 
month on TMP/SMX, resistance to TMP/SMX, trimethoprim and 
amoxicillin increased from about 20 - 40% to about 80 - 95% in fecal 
and asymptomatic bacteriuria E. coli. This study not only showed that 
long-term safe and effective appli- cation of probiotics to women 
whose vaginal microbiota is the source of uropathogens and infection, 
but also showed that this approach significantly reduced antibiotic 
resistance amongst uropathogens. 
The ability of probiotic lactobacilli to restore and main- tain a 
normal vaginal microbiota is important, given the high prevalence of 
BV [59]. In a study of 64 women, oral treatment with L. rhamnosus 
GR-1 and L. fermentum (reuteri) RC-14 once daily for 60 days 
resulted in the vaginal microbiota being restored from an 
asymptomatic BV state to a healthy state in 37% of subjects 
compared with 13% receiving placebo (p = 0.02). Six of the 25 
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subjects (24%) in the placebo group developed BV at day 35 and 4 
(16%) at day 56 compared with 0 of the 23 (0%) in the treatment 
group (p < 0.05) [42]. This study, like that of Petricevic et al. [54] 
highlights the benefit of the everyday use of these lactobacilli strains 
as they help restore the vaginal microbiota and help prevent 
asymptomatic BV. 
The safety record of probiotic lactobacilli for vaginal application is 
excellent. Hemmerling et al. [60] performed a Phase I dose-ranging 
safety trial for L. crispatus CTV-05, in 12 healthy women. Safety was 
assessed by recording the incidence of adverse events, while 
tolerability was assessed by recording the number of subjects who 
prematurely discontinued themselves from consuming the product 
because of an adverse event. Acceptability was evaluated through the 
use of a self-administered questionnaire. Subjects were instructed to 
insert vaginal applicators containing L. crispatus CTV-05 given at one 
of three doses (5 X 108, 1 X 109, and 2 X 109 CFU/dose; 3/12 subjects 
[25%] for each dose) or placebo (3/12 subjects; 25%) once a day for 
5 days. Overall, 45 adverse events were found to occur evenly across 
the three doses and placebo group. Most events (91%) were mild in 
nature, while the other 9% were unrelated to product use, indicating 
that the product was safe. None of the subjects discontinued 
themselves and most (83%) agreed with statements regarding the 
satisfaction and comfort of the product, which indicated tolerability 
and acceptability of the product. The subjects in this group were 
healthy, unlike one of the target populations of BV women for this 
probiotic product. In addition, the sample size of 12 limits the 
reproducibility of findings from this study. Thus, more investigation 
will be required to test the safety and tolerability of this product in BV 
women. 
Another strain that shows promise as a vaginal probiotic is L. 
crispatus. A company study that was not published in peer-reviewed 
literature showed that vaginal application of L. crispatus CTV-05 in BV 
patients did not statistically improve clinical cure rates at 30 days. 
The strain only ‘colonized’ 70% patients, but when it did there was 
better resolution of BV compared with women who received placebo. 
Although this led to the company terminating commercialization, 
studies on the strain continued. Antonio et al. [61] investigated the 
ability of L. crispatus CTV-05 to persist in 90 healthy young females 
aged 14 -21 years. Quantitative culturing methods were used to 
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measure the abundance of Lactobacillus species, while molecular 
techniques detected the abundance of the CTV-05 strain. Two groups 
of 45 subjects (50%) were randomly assigned to receive intravaginal 
capsules containing either 106- or 108 -CFU L. crispatus CTV-05 twice 
daily for 3 days. The CTV-05 strain showed moderate ability to persist 
in 60 of the 87 participants (69%). The strain was found in 36 of 40 
subjects (90%) who originally lacked L. crispatus, compared with 24 
of 47 subjects (51%) who had been colonized with indigenous L. 
crispatus (p < 0.001), indicating that the indigenous strains 
outcompeted the candidate probiotic. A decrease in colonization of 
the administered strain was linked to protected (p = 0.02) and 
unprotected (p < 0.001) sex.  
Given the lack of advances in managing BV during the past 50 
years, it is perhaps not surprising that women are receptive to the 
idea of using probiotics [62]. One study assessed the satisfaction of a 
product containing L. crispatus CTV-05 in 424 women who suffer from 
BV [63]. Satisfaction was assessed by having the subjects complete a 
standardized questionnaire after randomization to receive either an 
intravaginal capsule containing 1 X 108 CFU L. crispatus or placebo, 
applied twice daily for 3 days, monthly for 3 months. Only 232 of the 
424 subjects (54.7%) completed the three follow-up visits for 
reasons not stated. A total of 175 of 232 subjects (75.4%) stated 
that they were satisfied with the capsule, which was found to be 
associated with improved Nugent score. No significant differences 
were found between the treatment and placebo group, although 
these numbers were not provided. 
Expert opinion 
There is clearly a significant need for new therapeutic and 
prophylactic approaches to the management of urogenital infections. 
Since the clinical observation of Bruce et al. in 1973 [64], efforts 
have been made to understand better not only the composition of the 
healthy vaginal microbiota but also the properties of lactobacilli that 
seem to protect the host from infection. 
Metagenomic and other such techniques are uncovering the 
microbes that can colonize or transiently survive in the vagina. The 
methods used to select candidate probiotic strains are not so 
advanced and still in many cases consist of in vitro assays on 
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adhesion and production of antimicrobial agents, plus species 
commonly found in the vagina. This is somewhat ‘hit and miss’, as 
noted in studies that improve the health of the host, and others that 
seem to make no or little impact. Genomic sequencing of strains will 
help to determine some characteristics that may be beneficial in vivo, 
but the absence of an animal model, and the unsubstantiated 
tightening by regulatory agencies such as the FDA in allowing 
probiotic studies to be done in humans, mean that the development 
of new efficacious vaginal probiotics are some way off, at least in the 
USA. Nevertheless, a number of groups around the world are 
attempting to develop and test lactobacilli strains for vaginal use. In 
doing so, if they decide to use multiple strains, they need to do 
studies that show the benefits and absence of counteractive effects of 
these combinations. At the very least, competitive adhesion, 
bacteriocin and immunological assays should be done for this 
purpose. 
Probiotics to date 
Of the clinical studies carried out in an attempt to administer 
lactobacilli to the vagina, very few have had appropriate sample size 
and trial design, or strains selected with appropriate properties. Even 
though essentially only a handful of strains have been tested so far, 
the data strongly indicate the potential to improve vaginal health with 
probiotic lactobacilli. Studies have now shown that L. rhamnosus GR-
1 and L. reuteri RC-14 can provide a positive impact on the vaginal 
microbiota in pre- and postmenopausal women. These or other 
strains will not colonize the host, nor always actually reach the vagina 
after oral intake, or dominate over time. Rather, the ultimate goal is 
for them to reduce the pathogens that ascend from the rectum and 
counter these and others that enter through sexual contact, in such a 
way as to lower the risk of disease. In addition, the therapy should 
provide a functional milieu that maintains microbial and host-immune 
homeostasis in a manner that optimizes the health of the host. This 
may mean allowing recovery of the woman’s own beneficial 
microbiota, or repriming her natural defenses.  
For a vaginally applied probiotic, current regulations characterize 
them as drugs or medical devices, with the former making the 
development process expensive and the latter difficult to be approved 
with suitable claims. This has delayed (and will continue to delay) the 
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availability of products for use by women, which is unfortunate as 
intravaginal application is needed to treat BV and to displace aberrant 
and recalcitrant microbiota. 
Future studies 
In the future, many new products are envisaged based upon an 
ability to manipulate the vaginal microbiome. Some will comprise 
probiotic strains, either singly or in combinations, others will be 
prebiotic nutrients designed to improve the abundance of 
nonpathogens, and others may target immunomodulatory effects. 
Interventions will probably include the creation of recombinant strains 
that deliver specific anti-infective compounds [65-67] particularly 
against viruses such as herpes simplex and HIV. Challenges for such 
applications will be substantial, including containment, lack of 
adverse effects and an ability to persist in sufficient numbers to 
neutralize the viruses when they enter, especially if they are 
protected by sperm and seminal fluid, and if host cells are present for 
their binding and invasion. 
Challenges also come from scaling up strains from in vitro, animal 
and pilot human studies to a product that is suitable for development. 
These include being able to grow strains that can be fastidious, dry 
and prepare them in a form that survives storage and suitable shelf-
time, and that delivers appropriate live numbers to the target site. In 
some cases, such as if L. iners were to be a developed as a probiotic, 
these problems are insurmountable at present. Companies with the 
expertise in mass culture of bacteria often do not have the time, 
expertise and financial incentive to do the R&D work required for new 
product development. In addition, most companies in the probiotic 
arena are in the food and supplements industry and either not willing 
or able to develop vaginal drugs or devices. Partnerships with 
financiers and biotech or pharmaceutical companies may be required 
to overcome these issues. The extent to which women suffer from 
urogenital infections and complications stemming from them is simply 
too great not to make major efforts to develop new products. 
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Abstract 
Objective: Bacterial vaginosis (BV) among women with HIV is highly 
prevalent, difficult to cure and significantly associated with HIV 
transmission. We aimed to enhance cure and prevention of BV among 
women living with HIV with long term oral Lactobacillus rhamnosus 
GR-1 and Lactobacillus reuteri RC-14 supplementation.   
Methods: We conducted a randomized, double blind, placebo 
controlled among 65 women living with HIV with an aberrant 
microbiota (Nugent score 4-10) who were randomized to receive daily 
probiotics or placebo for 6 months. Those having BV (Nugent score 7-
10) received additionally metronidazole for 10 days (400 mg twice 
daily).  
Results: We did not find an enhanced cure rate of adjuvant 
probiotics to metronidazole treatment of BV. Among those with an 
intermediate vaginal flora, probiotics tended to increase the 
probability of a normal vaginal flora (odds ratio = 2.4, p = 0.1) and 
significantly increased the probability of a beneficial vaginal pH (odds 
ratio = 3.8, p = 0.02) at follow-up.  
Conclusion: We conclude that supplementation of probiotic L. 
rhamnosus GR-1 and L. reuteri RC-14 did not enhance the cure of 
bacterial vaginosis among women living with HIV, but may prevent 
the condition among this population. 
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Introduction 
The vaginal flora is normally dominated by lactobacilli and can 
gradually shift towards a complex mix of anaerobic bacteria, 
Gardnerella vaginalis and Mycoplasma hominis, a condition called 
bacterial vaginosis (BV) [1]. Various observational studies have 
shown that BV is highly prevalent [2] and facilitates the transmission 
of HIV [3-5]. Efforts to reduce the prevalence of BV have been 
unsuccessful [6, 7], and innovative treatment strategies are 
desperately needed. Especially for women living with HIV among 
whom the cure rate of BV appears to be lower and the prevalence 
higher [6].  
Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 have been 
shown to improve the vaginal flora after oral administration [8-11], 
and enhance the cure rate of BV among women treated with 
metronidazole [12].  The apparent safety of probiotics in people living 
with HIV [13-15] led to the design of the current study. Our primary 
aim was to determine whether long term L. rhamnosus GR-1 and L. 
reuteri RC-14 supplementation could enhance the cure of BV among 
women living with HIV treated with metronidazole. In addition, we 
aimed to assess whether long term supplementation could prevent 
women with an intermediate vaginal flora from developing BV.  
Methods 
A randomized, double blind, placebo controlled trial with a follow-
up of 25 weeks was conducted. Primary outcome was the cure rate of 
BV at two weeks follow-up. Secondary outcomes were; recurrence 
rate of BV, the presence of a beneficial vaginal pH (<4.7), symptoms 
(itching, odor, discharge) and prevention of BV among those with an 
intermediate vaginal flora at baseline. 
Participants were randomized to receive either daily capsules of 
freeze dried L. rhamnosus GR-1 and L. reuteri RC-14 (2x109 viable 
organisms) or identical looking placebo capsules, twice daily for 25 
weeks (provided by Chr Hansen, Horsholm, Denmark). Additionally, 
participants diagnosed with BV by Nugent score (7-10) received 
metronidazole for 10 days (Aventis, twice daily 400 mg orally). A 
block randomised list was generated by a computer and a statistician 
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not involved in the data collection prepared a tube set with either 
placebo or probiotics for each participant accordingly.  
The Medical Ethical Review Committee of Erasmus Medical Centre, 
The Netherlands, and the Medical Research Coordinating Committee 
of the National Institute for Medical Research, Tanzania, approved the 
study design and protocol. Participants were informed of the purpose 
of the trial and gave their signed or thumb printed informed consent 
before participation. This trial was registered at clinicaltrial.gov 
NCT00536848. 
 Women who attended the HIV care and treatment clinic at Sekou-
Toure regional hospital, Mwanza, Tanzania, were invited to 
participate. Participants were consecutively enrolled between October 
2007 and February 2008 and the follow-up continued until July 2008.  
Inclusion criteria were, confirmed HIV infection, not eligible to be 
treated with antiretroviral medication, abnormal vaginal flora (Nugent 
score 4 – 10) and being 18 - 45 years old. Exclusion criteria were 
pregnancy, lactation, menstruation at time of screening, 
hypersensitive to metronidazole and presence of cervicitis, genital 
ulcers or Trichomoniasis during gynaecologic examination.  
During screening, a gynaecological examination was performed to 
diagnose cervicitis (mucopurulent endocervical exudate on visual 
inspection) and measure the pH using a dipstick (range: 2.0 – 9.0, 
Merck, Germany). Two swabs from the vaginal wall were taken: one 
sample was used to diagnose Trichomoniasis (presence of motile 
flagellates on wet mount), the other sample was used to make a 
Gram stained smear to evaluate Candida colonization (budding yeast) 
and grade the vaginal flora according to the Nugent score at the 
National Institute for Medical Research, Mwanza, Tanzania. For 
quality control of the Nugent scoring all slides at baseline, 2 weeks 
and 25 weeks were re-evaluated by the microbiological laboratory of 
Weill-Bugando University college of Health Sciences, Tanzania. 
Agreement between the laboratories was substantial (kappa = 0.67, 
95% CI; 0.57 – 0.76). The gynaecologic examination described was 
repeated at follow-up visits at 2, 5, 15 and 25 weeks. At a baseline 
visit information on demographics, gynaecologic history and current 
genital symptoms was collected using a structured questionnaire. 
During follow-up visits at 2, 5, 10, 15, 20, 25 weeks participants were 
interviewed about vaginal symptoms, adverse events and remaining 
capsules were counted to assess compliance. When symptoms and 
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signs of BV were present during follow-up, participants were (re-) 
treated with metronidazole from the follow-up visit at week 5 
onwards.  
To detect a difference in cure rate of BV at two weeks follow-up 
between 80% in the probiotics group and 40% in the placebo group 
the calculated sample size was 46 patients (23 in each group, two 
sided test with α = 0.05 and β = 0.80). While sample size was based 
on a cross-sectional comparison, power was increased in some 
analyses by the use of longitudinal methods for repeated 
measurements.  
We defined cure of BV as a BV Nugent score at baseline (7-10) 
with a normal Nugent score (1-3) during follow-up. Recurrence was 
defined as a BV Nugent score at baseline, a normal Nugent score 
during follow-up (first visit with normal score) and then a BV Nugent 
score again after initial cure (first visit with BV score).  
The prevalence of a normal vaginal flora (Nugent 1-3) was 
compared cross-sectionally between the probiotic and placebo 
groups. Differences were tested using a chi-square test and with a 
Fisher’s exact test when less then 5 participants per sub-group were 
present. To take into account the correlation between measurements 
of the same subject we used generalized estimating equations with a 
binominal outcome, a logit link and an exchangeable correlation 
structure to compare the overall probability of a normal vaginal flora 
and a beneficial vaginal pH during follow-up. 
 Compliance with the study regimen was calculated as the number 
of capsules that had been taken divided by the total number of 
capsules that should have been taken, and tested using a T-test. 
Participants contributed to analyses until participation ended due to 
loss to follow-up or initiation of anti-retroviral medication. Data was 
stored in an access database and analyzed using SPSS version 15.0.  
Results 
Of 229 screened patients, a total of 65 participants were eligible. 
After randomization, 4 participants were excluded from analyses as 2 
were HIV-negative during a re-check, 1 had a normal baseline vaginal 
flora and 1 did not return for follow-up after the baseline visit. Of 
those remaining, 29 received probiotics (20 BV and 9 Intermediate) 
of whom 23 completed the study, and 32 received placebo (23 BV 
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and 9 Intermediate) of whom 28 completed the study (Figure 1).  
Loss to follow-up was similar (p = 0.3) between the probiotic [4 of 29 
(14%)] and placebo group [2 of 32 (6%)], there was also a similar (p 
= 1.0) loss due to anti-retro viral treatment initiation among the 
probiotic [2 of 29 (7%)] and the placebo group [2 of 32 (6%)] 
(Figure 1). No clinically relevant differences were detected between 
groups (Table 1). 
 
 
 
 
  
 
 
 
 
Figure1. Study profile 
ARV: Anti retro-viral treatment 
a 86 Negative Nugent score, 15 sexual transmitted infection and 18 eligible for ARV. 
b 2 losses due to travelling, and 2 for unknown reasons.  
c 2 losses due to travelling, and 1 for unknown reasons. 
d 2 HIV negative, 1 Nugent score 1-3 at baseline 
 
After two weeks follow-up of those having BV at baseline 8 of 20 
(40%) participants were cured among the probiotics group compared 
to 12 of 22 (54%) among the placebo group (p = 0.3) (table 2). 
Cross sectional comparison of the prevalence of a normal vaginal 
flora did not reveal any significant differences (Table 2). At 15 weeks 
a trend was seen (p = 0.08) for a higher prevalence of a normal flora 
among the probiotics group [9 of 17 (53%)] than the placebo group 
[5 of 20 (25%)]. The overall probability of a normal vaginal flora 
during follow-up did not differ between the groups (odds ratio 1.06 
for probiotic group, p = 0.9). No difference (p = 1.0) was detected 
between the recurrence rates of BV among the probiotics group [7 of 
12 (58%)] and the placebo group [9 of 15 (60%)]. The probability of 
119 not meeting 
inclusion criteriaa  
45 not willing to  
participate 
3 lost to follow-upc 
2 started ARV 
65 women randomised 
33 assigned placebo 32 assigned probiotics 
4 lost to follow-upb 
2 started ARV 
3 excludedd 
28 completed 23 completed 
229 screened 
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a beneficial pH (pH < 4.7) (table 3) and the occurrence of vaginal 
symptoms during follow-up were similar between groups (data not 
shown).  
Among those with an intermediate vaginal flora at baseline the 
prevalence of a normal vaginal flora was consistently higher among 
the probiotics group, but did not reach significance with cross-
sectional comparison (table 2). Longitudinal comparison showed a 
trend of a higher probability among the probiotics group of a normal 
vaginal flora during follow up (odds ratio 2.4, p = 0.1). Among those 
receiving probiotics the prevalence of a vaginal pH of < 4.7 was 
consistently higher with cross-sectional comparison, being significant 
(p = 0.04) at 5 weeks of follow-up (Table 3).  Longitudinal 
comparison showed that participants receiving probiotics had a 
significantly higher probability of a pH < 4.7 (odds ratio = 3.8, p = 
0.02), this association remained after adjusting for baseline pH. No 
differences in vaginal symptoms during follow-up were detected.  
Overall, no difference in cure rate was detected between those 
with a CD4 count of < 350 cells/µl [14 of 26 (54%)] and those with a 
CD4 count of > 351 cells/µl [6 of 16 (38%)] (p = 0.3). The 
probability of cervicitis appeared to be lower among the probiotics 
group [2 of 29 (7%)] than the placebo group [7 of 32 (22%)] (p = 
0.1). There was no difference in Candida colonization between the 
probiotic group [13 of 29 (47%)] and the placebo group [9 of 32 
(28%)] (p = 0.2).  
Among those receiving probiotics, 7 participants reported an 
adverse event (6 gastro-intestinal, 1 vaginal) compared to 10 
participants receiving placebo (5 gastro-intestinal, 2 vaginal, 2 itching 
skin and 1 dizziness).  A physician rated all events mild or moderate, 
no severe events occurred and treatment was not interrupted on any 
occasion.  There was no difference (p = 0.2) in compliance between 
the probiotic group (92% of days compliant) and the placebo group 
(89% of days compliant). 
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Discussion 
This study showed that the adjuvant use of Lactobacillus 
rhamnosus GR-1 and Lactobacillus reuteri RC-14 did not improve the 
cure of BV in women with HIV. Treating BV is difficult among women 
living with HIV. This is evidenced by the finding that of the total BV 
group only 11 of 40 women (25%) were cured after metronidazole 
treatment at five weeks. This rate is profoundly lower than among 
non-HIV infected African woman (40%) and non-HIV infected 
Caucasian women (78 - 81%) after 30 days [12, 16].  
A trend was found for a higher probability for a normal vaginal 
flora among those having an intermediate vaginal microbiota when 
taking probiotics and a significantly higher probability of a beneficial 
vaginal pH (< 4.7) at follow-up among the probiotics group. This 
suggests that, as in non-HIV infected subjects, the orally 
administered lactobacilli can reach the vagina or at least influence the 
environment to increase the count of indigenous lactobacilli [9, 17]. 
However, the failure of the antibiotics to eradicate the BV pathogens, 
perhaps as they are invariably in dense biofilms [18], or because a 
fully functional immune system is conjointly required, meant that a 
normal lactobacilli flora was not easily restored. The intransigence of 
BV organisms in HIV infected women needs further investigation as 
the continued presence of these bacteria increases the risk of 
transmission of HIV to a newborn child or partner.  
In summary, this study showed that curing BV in women infected 
with HIV is extremely difficult, and while probiotics did not improve 
this cure, further studies are warranted to explore their use in 
preventing BV among this population.  
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I. What is the long-term impact of probiotic use 
on the immune function of HIV patients?  
Answer: It is not yet proven that use of probiotics, and 
specifically Lactobacillus rhamnosus GR-1, has a long-term impact on 
the immune function of HIV patients.  
 
Comment: Two randomized controlled trials had previously 
suggested a benefit in immune function to HIV patients of probiotic 
consumption of up to two months [1,2] . We examined the impact of 
yogurt supplemented with L. rhamnosus GR-1 by monitoring the 
development of the immune function among a cohort of consumers 
and non-consumers with HIV for up to three years (chapter 4). We 
found that those consuming probiotic yogurt had a modest increase in 
CD4 count compared to the control group. This study therefore 
confirmed previous findings of beneficial effects of probiotics on the 
immune function of HIV patients. An important strength of this study 
was the long period of follow-up, an asset that would have been 
difficult to achieve using a prospective study design. However, due to 
the observational nature of the study, the results observed could 
have been due to selection bias of the intervention and control 
groups. Despite this limitation the similarities between the groups 
indicated that this bias was likely limited.  
To further explore these findings, we conducted a randomized, 
placebo controlled, trial to assess whether an effect on immune 
function would be detectable after 25 weeks of probiotic use, this 
time using L. rhamnosus GR-1 and L. reuteri RC-14 in dried capsule 
form. In contrast to the observational study, no impact on the 
immune function was detected. This leads to three potential 
explanations. Firstly, because the intervention in the observational 
study included both a probiotic strain and yogurt the effect might 
have been caused by an enhanced nutritional status, resulting from 
consuming yogurt. Secondly, the effect observed in the observational 
study could have been due to the fact that the population studied was 
in a more advanced stage of HIV disease. This sub-population could 
have responded better to the intervention as a reduced gut barrier 
and the translocation of microbial products can become more 
profound at a later stage of disease [3]. Thirdly, the limited sample 
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size in the randomized trial may have prevented detection of effects 
with CD4 count as primary outcome (95% confidence interval -158 to 
210 cells/µl).  Trials with a sufficiently long follow-up and an 
adequate sample size are needed to further investigate this concept.  
Following the study of Kaiser and colleagues [4] that showed a 
substantial increase in CD4 counts in HIV subjects given high doses 
of micronutrients, a similar, more physiologically based formula that 
was edible in yogurt was developed and tested in two human studies 
(Hummelen, Hemsworth & Reid, manuscript in preparation). In 
addition, with a view to sustainability and practical translation at the 
local sub-Saharan level, a yogurt formulation was recently developed 
that combines a locally grown vegetable (Moringa Oleifera), 
exceptionally rich in vitamins and minerals, with a yogurt 
supplemented with L. rhamnosus GR-1 (van Tienen, Hullegie, 
Hummelen & Reid, manuscript in preparation).  The potential for such 
an intervention to provide further support for people with HIV and for 
whom access to ARTs is limited, is worthy of testing both from a 
clinical point of view and in terms of practical implementation at 
community kitchen sites being created in Tanzania, Kenya, Rwanda 
and potentially beyond.  
 
II. Which micro-organisms constitute the 
vaginal microbiota among women with HIV? 
Answer: Lactobacillus iners and Gardnerella vaginalis were found 
to be present in all subjects.  In a BV state, the vaginal microbiota 
was dominated by Lachnospiricieae, Prevotella bivia or Gardnerella 
vaginalis. When BV is absent the vaginal microbiota was dominated 
by L. iners or L. crispatus.  
 
Comment: In chapter 6, we describe the development and use of a 
novel technique to identify micro-organisms of the vaginal microbiota 
from a large cohort of Tanzanian women infected with HIV. By the 
use of this technique we acquired an extraordinary insight in the 
vaginal microbiota. Our investigations disproved the long held 
assumption that BV was associated with absence of lactobacilli, while 
pathogens were absent in health. Rather, the presence of 
Lactobacillus iners and Gardnerella vaginalis was detected in every 
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sample.  This finding raises the question of whether these two species 
represent a “core vaginal microbiota” in all women. To address this 
question, we are currently analyzing vaginal samples from a large 
Brazilian cohort and from three Canadian studies, totaling more than 
500 samples. The early results from a cohort in Vancouver suggest 
that depending on how deep the sequence abundance is explored, it 
is possible that these two species can be found in the majority of 
women. Cumulatively, these studies will enable us to compare the 
vaginal microbiota of non-African women with the population studied 
(African women with HIV) using the same technique. Whilst this does 
not allow assessment of how HIV infection impacts the vaginal 
microbiota by direct comparison of HIV+ and HIV- women from the 
same population, we aim to explore this in due course.  
Another assumption previously held was that distinct Lactobacillus 
species (i.e. L. iners, L. crispatus) have a similar function in the 
vaginal tract, for example in maintaining a low vaginal pH. In our 
study, L. iners was found to only exert a modest influence on the 
vaginal pH, in contrast to L. crispatus, which appears to have a more 
profound impact. Interestingly, L. iners was found in an environment 
heavily colonized with pathogens and during antibiotic treatment, 
while L. crispatus appeared to be more easily displaced and killed. 
This suggests that the two Lactobacillus species fulfill different 
ecological functions in the vaginal tract, and have different abilities to 
survive. The recent genomic sequencing of L. iners has identified 
some of the factors that appear to allow this organism to persist so 
well [5].  
The deep sequencing showed that no single pathogen is associated 
with BV. Rather, four different dominating micro-organisms are 
aligned with the current clinical diagnoses. This suggests that either 
the clinical diagnoses are sub-optimal, or the condition is caused by 
certain metabolic functions that can be induced by a range of 
pathogenic organisms. Investigations into these metabolic functions 
of the vaginal microbiota are now underway (Jean Macklaim, personal 
communication).  
It is also possible that BV is caused by, or causes, immunological 
and host defense alterations that pave the way for the displacement 
of lactobacilli and propagation of pathogens. To investigate this, in 
vitro studies were performed to assess whether differences exist in 
the response of vaginal epithelial cells to various lactobacilli and G. 
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vaginalis. Preliminary results indicate that L. iners and G. vaginalis 
both provoke a very modest host response, in contrast to L. crispatus 
which induces the secretion of pro-inflammatory cytokines (IL-6 and 
IL-8) (Bisanz, Hummelen et al. manuscript in preparation). These 
findings suggest that L. crispatus may stimulate a strong host 
response that inhibits pathogen growth and colonization. Further 
studies are being carried out to assess the role of the host response.  
For example, the gene-expression patterns of vaginal epithelial cells 
obtained from women with various compositions of the vaginal 
microbiota are currently being analyzed (Hummelen, Bisanz et al. 
manuscript in preparation).  
This evolving understanding of vaginal health has been made 
possible by the recent development of methods that facilitate the 
large scale sequencing of nucleotides. This has enabled the high-
throughput analyses of genomic information, termed metagenomics, 
present in various human and environmental samples [6]. DNA 
sequencing by syntheses (Roche 454) is currently routinely used for 
metagenomic analyses, as it can sequence relatively long strands of 
DNA. However, it is imprecise as many insertions and deletions occur 
compared to Illumina, which sequences shorter strands of DNA [7].  
For single genome sequencing, this is not a problem with Roche 454, 
but for micro-organism identification it means that analyses can only 
be done to the genus (e.g. Lactobacillus), and not to the species level 
(e.g. Lactobacillus iners). We have been the first to develop and use 
the Illumina sequencing method to identify micro-organisms. We 
describe in chapter 7 its capabilities and demonstrate that hundreds 
of samples can be analyzed at a sufficient depth to sample all 
diversity, at a fraction of the costs of conventional 454 analyses.  
III. Can probiotics prevent or improve the cure 
rate of BV among women with HIV? 
Answer: Additional use of L. rhamnosus GR-1 and L. reuteri RC-
14 with metronidazole treatment does not improve the cure rate of 
BV in HIV patients, but it may help to prevent the condition.  
 
Comment: In contrast to studies on HIV negative women [8,9], 
the probiotic strains did not improve the cure rate of BV among 
women with HIV. One factor that might explain this finding is the 
Chapter 10 
 220 | 
apparent difference in the vaginal microbiota between the studied 
African cohort and non-Africans [10,11,12,13]. The latter showed 
high presence of hydrogen peroxide producing L. crispatus and L. 
jensenii, organisms associated with reduced occurrence of BV [12]. 
The low prevalence of L. crispatus and the virtual absence of L. 
jensenii among our population (chapter 6) could have contributed to 
the inefficacy of the probiotic strains and the rapid recurrence of BV.  
Furthermore, he altered intestinal microbiota of people living with 
HIV, with high numbers of pathogens [14,15], could have prevented 
the probiotic strains from surviving the gut passage. To test this 
theory, the probiotic strains could be instilled directly into the vagina, 
which was shown to be feasible in HIV negative women [9], or 
different probiotics such as L. jensenii or L. crispatus could be tested 
to see if they survive gut passage and transfer to the vagina.  
An additional explanation may be that a functional immune system 
is essential for lactobacilli to help cure BV. This could work via up-
regulation of host-defences in the vagina including of the secretion of 
sIgA which then help dislodge the BV biofilms and allow better 
eradication by the antibiotics [16].  
The finding that probiotic supplementation increased the likelihood 
of having a low vaginal pH during follow-up and a reduced probability 
of acquiring  BV, suggests that probiotics could still have a role to 
play for women with HIV. Currently there is an urgent need to 
develop interventions to counter BV in this population [17]. This 
thesis emphasizes that new interventions need to be tested HIV 
among women with HIV specifically, as the findings from non-infected 
women are not necessarily transferable to this population.   
Further considerations  
Assessment of interventions that target the intestinal 
microbiota in HIV patients 
Drawing from the results and experience obtained in conducting 
the studies described in this thesis, the following recommendations 
can be made. Firstly, before testing the efficacy of interventions on 
clinical outcomes, it would be valuable to identify biological markers 
that could provide insight in the potential of the intervention. Table 1 
summarizes markers that could potentially be used for initial 
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screening of interventions targeting the intestinal microbiota of HIV 
patients.  
 
Table 1.  Biological markers for assessment of interventions that 
target the intestinal microbiota in HIV patients.  
Measurement Outcome References 
Plasma LPS  Microbial translocation [18,19,20,21,22]  
Plasma Total 16s RNA Microbial translocation [18] 
Plasma secreted CD14 Microbial translocation [18,22] 
Urine Lactoferrin:Mannitol ratio Intestinal permeability [23,24] 
Urine Xylose Intestinal absorption [22,24] 
Fecal microbiota Intestinal microbiota [15,25] 
Fecal calprotectin/ lactoferrin Intestinal inflammation [15]  
Plasma CD4/CD25 cells Immune activation [26] 
Natural Killer cells Innate immunity response [26] 
 
Secondly, an intervention targeting the intestinal microbiota may 
have a more favorable outcome among those whose disease 
progression is characterized by leakage of microbial products from 
the intestinal tract. These sequela appear to become more profound 
later during the course of HIV infection [3,18,24]. Although ART 
reduces leakage of microbial products, still 20% of patients have 
persistent inflammation associated with poor CD4 count recovery 
[27]. Among children, ART fails altogether to reduce levels of leakage 
of microbial products [28]. Those characteristic may define the 
outcome of an intervention targeting the intestinal microbiota. For 
example, a Brazillian study on probiotics and HIV had selected a 
subpopulation of children and specifically those not responding to ART 
[2]. This may have selected those whom are likely to have a more 
favorable response to probiotic intervention and therefore, only 
limited inferences can be made for other sub-populations. 
Thirdly, changes to Natural Killer cell cytotoxicity and immune 
activation markers (CD4/CD25) have been observed with a 12 week 
follow-up period and with a limited sample size (n = 57) [25,26]. This 
suggests that immune markers, other than CD4 count, could indicate 
the potential of an intervention to preserve immune function. One 
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criticism of biological markers to screen intervention clinical use, is 
that they have only limited predictive value for clinical outcomes. 
Therefore, when a potential benefit of an intervention is detected, this 
needs to be verified with a trial that has a sufficiently large sample 
size and length of follow-up, that can measure the impact of the 
intervention on defined clinical outcomes (e.g. mortality) or valid 
surrogate outcomes (e.g. CD4 count) [29].  The assessment of these 
outcomes likely requires a longer follow-up and a larger sample size. 
 
Conclusions  
• It is not yet proven that probiotic use, and specifically L. 
rhamnosus GR-1, has a long-term impact on the immune function 
of HIV patients 
• L. iners and G. vaginalis are always present in the vaginal 
microbiota of HIV positive women living in East-Africa. 
• When BV is present, the vaginal microbiota is dominated by 
Lachnospiricieae, G. vaginalis or Prevotella bivia. 
• L. crispatus is strongly associated with a low vaginal pH (<4.5), 
but if L. crispatus is not present, a large fraction of L. iners is 
required to produce a low pH.  
• The use of Illumina sequencing to profile the human microbiota is 
an effective and efficient method to increase the depth of 
microbial analyses. 
• L. rhamnosus GR-1 and L. reuteri RC-14 do not improve antibiotic 
cure BV in women with HIV, but they may reduce the risk of 
developing the condition.  
Recommendations  
The following recommendations are made with respect to future 
directions: 
• We recommend the conduct of a long term (>1 year), sufficiently 
sized, randomized trial to assess the long-term impact probiotics 
on the immune function of people living with HIV. 
• We recommend the development of new interventions to restore 
and maintain vaginal health in women living with HIV.  
• Illumina sequencing with combinatorial barcoding is 
recommended as standard for analyzing the human microbiota.  
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Summary 
The composition of the intestinal and vaginal microbiota has a 
profound impact on the health of the host. With an aberrant intestinal 
microbiota, and a frequent occurrence of a disturbed vaginal 
microbiota, HIV patients are at particular risk to experience adverse 
events. This thesis uncovers the vaginal microbiota of HIV infected 
women and explores whether probiotics can have an impact on 
health. Part I (chapter 2-5) describes whether probiotics can be used 
to target the intestinal microbiota to impact the progression of HIV. 
Part II (chapter 6 -7) describes an assessment of the vaginal 
microbiota of women with HIV. And part III (chapter 8 – 9) provides 
an assessment of probiotics to impact a disturbed vaginal microbiota 
among women with HIV. 
I. What is the long-term impact of probiotic use 
on the immune function of HIV patients? 
Chapter 2 provides a critical assessment of studies conducted of 
nutritional supplements to delay the progression of HIV. It concludes 
that vitamin B, C, E and folic acid can delay the progression of HIV. 
In contrast, vitamin A, iron and zinc have been associated with 
adverse events and caution is warranted for their use. 
Supplementation with selenium, N-acetyl cysteine, prebiotics and 
probiotics has considerable potential but evidence needs to be further 
substantiated. In Chapter 3 a theoretical framework is provided for 
the application of probiotics to ameliorate the impact of HIV on the 
epithelial barrier and the intestinal microbiota. It concludes that 
specific probiotic strains have the potential to counter these 
pathological mechanisms and may help to preserve the immune 
function of HIV patients.  
An observational study is described in chapter 4 on the impact of 
probiotic L. rhamnosus GR-1 in yogurt on immune function of HIV 
patients. A total of 150 HIV patients were followed retrospectively for 
up to three years and their immune function was monitored. An 
increase in immune function was observed in the group who 
consumed the yogurt with Lactobacillus rhamnosus GR-1 compared to 
those who did not. Furthermore, those consuming yogurt had a 
smaller increase in CD4 count before the start of yogurt consumption 
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than after commencing consumption. Hence, the results suggest that 
probiotic yogurt use is associated with a preservation of immune 
function among HIV patients.  This study is followed by a randomized, 
placebo controlled, trial, described in chapter 5, on the impact of 
daily use of encapsulated L. rhamnosus GR-1 and L. reuteri RC-14 for 
25 weeks on the immune function of HIV patients. The effects 
observed in the observational study could not be confirmed in this 
trial. While L. rhamnosus GR-1 and L. reuteri RC-14 can be safely 
consumed at 2x109 CFU/day, the treatment did not universally 
preserve the immune function of HIV patients. 
II. Which micro-organisms constitute the 
vaginal microbiota among women with HIV? 
Chapter 6 provides an in depth investigation of the vaginal 
microbiota in HIV positive women in Tanzania using a novel 
metagenomic technique. This study reveals a core microbiota 
consisting of Garnerella vaginalis and Lactobacillus iners, and 
suggests that L. iners and L. crispatus have two different functional 
roles. Also it describes that antibiotic treatment of BV perturbs the 
vaginal microbiota but rarely results in the establishment of a 
lactobacilli dominant state.  Chapter 7 explores the attributes of the 
technique developed to identify the bacteria of the vaginal microbiota. 
It demonstrates that the technique, based on combinatorial barcoding 
and Illumina sequencing, greatly increases the depth and 
phylogenetic resolution of bacterial identification compared to 
methods currently in use, such as denaturing gradient gel 
electrophoresis or 454 Roche sequencing.  This technique identified 
around 200 species present in the vaginal microbiota in 272 samples 
processed with one sequencing run. This also greatly reduced the 
costs and time involved in microbiota analyses. 
III. Can probiotics prevent or improve the cure 
rate of BV among women with HIV? 
Chapter 8 reviews mechanistic and clinical studies that have been 
performed to assess whether there is a potential for probiotics to 
have an impact on the vaginal microbiota. The review concludes that 
L. rhamnosus GR-1 and L. reuteri RC-14 have been shown to improve 
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the cure rate of BV and positively impact the vaginal microbiota 
among HIV negative women. To test whether probiotics are also 
effective in improving the vaginal microbiota among women with HIV, 
a randomized placebo controlled trial is described in chapter 9. The 
study assessed whether L. rhamnosus GR-1 and L. reuteri RC-14 in 
capsule form administered orally improve the cure rate of 
metronidazole, or reduced the risk of developing BV among women 
with HIV. It concludes that the probiotics did not improve the cure 
rate of BV but may reduce the risk of developing the condition. 
Conclusions  
• It is not yet proven that probiotic use, and specifically L. 
rhamnosus GR-1, has a long-term impact on the immune function 
of HIV patients 
• L. iners and G. vaginalis are always present in the vaginal 
microbiota of HIV positive women living in East-Africa. 
• The use of Illumina sequencing to profile the human microbiota is 
an effective and efficient method to increase the depth of 
microbial analyses. 
• L. rhamnosus GR-1 and L. reuteri RC-14 do not improve antibiotic 
cure of BV in women with HIV, but they may reduce the risk of 
developing the condition.  
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Samenvatting 
De samenstelling van de bacteriële flora heeft een groot effect op 
de gezondheid van de gastheer. Met een afwijkende darm flora en het 
frequent voorkomen van een verstoorde vaginale flora hebben HIV 
patiënten een verhoogd risico om de nadelige effecten hiervan te 
ervaren. Dit proefschrift beschrijft de vaginale flora bij vrouwen met 
HIV en onderzoekt of probiotica een effect kunnen hebben op de 
gezondheid van HIV patiënten. Deel I (hoofdstuk 2-5) beschrijft of 
probiotica ingezet kunnen worden om de darm flora te beïnvloedden 
en hiermee de verslechtering door HIV te vertragen. Deel II 
(hoofdstuk 6-7) geeft een omschrijving van de vaginale flora bij 
vrouwen met HIV. En deel III (hoofdstuk 8-9) bestudeerd of 
probiotica ingezet kunnen worden om een verstoorde vaginale flora 
bij vrouwen met HIV te herstellen.  
I. Wat is het lange termijn effect van probiotica 
op de immuunfunctie van HIV patiënten? 
Hoofdstuk 2 beschrijft studies die hebben geëvalueerd of 
voedingssupplementen de verslechtering van het immuunsysteem 
door HIV kunnen vertragen. Dit hoofdstuk concludeert dat vitamine 
B, C, E en foliumzuur de achteruitgang van het immuunsysteem door 
HIV kunnen vertragen. Vitamine A, ijzer en zink hebben hier geen 
effect op en zijn kunnen bijwerkingen veroorzaken. Hierdoor moet 
kan standaard gebruik van deze supplementen door HIV patiënten 
worden afgeraden. Het gebruik van selenium, N-acetylcysteïne, 
prebiotica en probiotica is veelbelovend maar wetenschappelijk bewijs 
schiet tekort om deze supplementen nu al aan te raden.  
In hoofdstuk 3 wordt uiteengezet hoe probiotica mogelijk een rol 
kunnen spelen het verminderen van de effecten van HIV op de 
epitheliale darmbarrière en de darmflora. Dit hoofdstuk concludeert 
dat specifiek geselecteerde probiotica stammen mogelijk van invloed 
kunnen zijn bij deze pathologische mechanismen en mogelijk een rol 
kunnen spelen bij het langer behouden van een goede immuunfunctie 
bij HIV patiënten. 
In hoofdstuk 4 wordt een observationele studie beschreven naar 
het gebruik van yogurt met L. rhamnosus GR-1 onder HIV patiënten 
en effecten van deze interventie op hun immuunfunctie. De 
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immuunfunctie van 150 HIV patiënten (probiotica en controle groep) 
werd tot 3 jaar retrospectief gevolgd. De studie concludeert dat onder 
deelnemers die de probiotica yogurt consumeerden een verbetering 
werd waargenomen ten opzichte van de deelnemers die geen 
probiotica yogurt consumeerden.  
Een gerandomiseerde, placebo gecontroleerde studie wordt 
beschreven in hoofdstuk 5 waarbij HIV patiënten L. rhamnosus GR-1 
en L. reuteri RC-14 in capsule vorm gebruikten of capsules voor 25 
weken. Hoewel de studie liet zien dat het gebruik van probiotica niet 
geassocieerd was met bijwerkingen konden de effecten van probiotica 
op de immuunfunctie van HIV patiënten niet bevestigd worden.  
 
II. Welke bacteriën maken deel uit van de 
vaginale flora bij vrouwen met HIV? 
Hoofdstuk 6 beschrijft een onderzoek naar de vaginale flora bij 
vrouwen met HIV in Tanzania waarvoor een nieuwe techniek werd 
ontwikkeld en toegepast. De studie laat zien dat Gardnerella vaginalis 
en Lactobacillus iners bij alle Afrikaanse vrouwen deel uitmaken van 
de vaginale flora. Daarnaast laat de studie zien dat Lactobacillus iners 
en Lactobacillus crispatus een verschillende functionele rol vervullen 
als deel van de vaginale flora. Met het in kaart brengen van de 
vaginale flora voor en na behandeling van een verstoorde vaginale 
flora, ook bacteriële vaginose (BV) genoemd, met antibiotica werd 
aangetoond dat de flora wel drastisch veranderde maar dat dit zelden 
leidde tot een Lactobacillus dominante flora.   
Hoofdstuk 7 onderzoekt de karakteristieken van de techniek die 
ontwikkeld werd om de vaginale flora in kaart te brengen. Dit 
hoofdstuk laat zien dat de techniek, die gebaseerd is op het 
combineren van barcodes met de analyse van stukjes bacterieel DNA 
(Illumina sequencing), alle diversiteit in de samples kon waarnemen 
met een hele goede identificatie van bacterie soorten. In vergelijking 
de gangbare techniek (denaturerende gradiëntgelelektroforese 
(DGGE) werd een grotere diversiteit aangetoond en in vergelijking 
met de analyse van langere stukjes DNA (454 sequencing) konden 
bacteriën beter geïdentificeerd worden. De ontwikkelde techniek 
reduceerde ook sterk de kosten en snelheid waarmee flora analyse 
gedaan kunnen worden.  
Samenvatting 
 | 231  
 
III. Kunnen probiotica een bacteriële vaginose 
onder vrouwen met HIV voorkomen of de 
genezinggraad verbeteren? 
In hoofdstuk 8 worden de klinische en mechanistische studies 
beschreven die onderzoeken of probiotica de vaginal flora kunnen 
beïnvloeden. Het hoofdstuk concludeert dat Lactobacillus rhamnosus 
GR-1 en Lactobacillus reuteri RC-14 de genezingsgraad van van 
bacteriële vaginose kunnen verbeteren en de vaginale flora positief 
kunnen beïnvloedden.   Om de vraag te beantwoorden of 
probiotica ook onder HIV-positieve vrouwen de vaginale flora positief 
kunnen beïnvloeden is een gerandomiseerde, placebo gecontroleerde 
trial beschreven in hoofdstuk 9. Vrouwen met HIV en bacteriele 
vaginose werden behandeld met antibiotica voor 7 dagen en 
gebruikten daarnaast dagelijks orale capsules met Lactobacillus 
rhamnosus GR-1 en Lactobacillus reuteri RC-14 of placebo voor 25 
weken. Een andere groep vrouwen met HIV met een minder ernstig 
verstoorde vaginale flora kregen alleen probiotica of placebo voor 25 
weken. Het onderzoek concludeert dat het gebruik van probiotica niet 
de genezingsgraad van bacteriële vaginose verbeterde maar mogelijk 
het risico op het ontwikkelen van bacteriële vaginose verlaagd.  
Conclusies 
• Het is nog niet bewezen dat het gebruik van probiotica, en 
specifiek Lactobacillus rhamnosus GR-1, een lange termijn 
invloed hebben op de immuunfunctie van HIV patiënten. 
• Lactobacillus iners en Gardnerella vaginalis zijn altijd aanwezig 
in de vaginale flora van HIV-positieve vrouwen in Oost-Afrika. 
• Het gebruik van het analyseren van korte stukjes DNA 
(Illumina sequencing) om de humane flora te analyseren is 
een effectieve en efficiënte methode om de diepte van 
microbiële analyse te verbeteren. 
• Lactobacillus rhamnosus GR-1 en Lactobacillus reuteri RC-14 
verbeteren niet de genezingsgraad van antibiotica voor 
bacteriële vaginose van vrouwen met HIV, maar verminderen 
mogelijk het risico op de ontwikkeling van bacteriële vaginose. 

Acknowledgements 
 | 233  
Acknowledgements 
I could not have imagined that an interest in bugs would ultimately 
lead me to a journey on three continents, allow me to collaborate 
with an international team of scientists, and involve hundreds of 
enthusiastic participants. A number of people have been key to 
guiding and accompanying me on this journey, and finally, in this 
section, I get to acknowledge them.    
This journey started off with a conference in Gent, Belgium. 
Prof.dr. Gregor Reid gave a talk on the human microbiota and HIV, 
which immediately sparked my interest. The talk closed with, “turn a 
different corner and we would never have met”. Fortunately, we did 
meet, and an exciting cascade of opportunities has followed since 
then. Gregor, it was only two years ago that we sat down in 
Amsterdam and thought of a plan to further develop this work into a 
PhD thesis. This is just one of the many examples of your passion for 
seeing students succeed. I deeply value your mentorship over the 
past several years, the opportunities that you have created, and 
great times in various pubs on the globe. This is not even to mention 
the upcoming wedding for which you deserve most of the credit 
(though we did a little work too).  
Prof.dr. Dik Habbema, since the day of our first meeting in 2006 I 
have felt privileged to be guided by a highly respected scientist who 
took up the task of leading a student who had more idea’s than tools. 
I have tried to steal some of your sharp reasoning skills and 
facilitative leadership style while working with you. I treasure the 
sparks stolen and know that I will benefit from them for life. Thank 
you for enabling me to find my way and for providing support which I 
could undoubtedly trust. 
Dr. Jan Nouwen, I am thankful for your willingness to act as my 
co-promoter. Thank you for introducing me into the complex world of 
HIV pathogenesis at the out-patient department. It’s incredible how 
you are always ready to pick up new, exciting initiatives and have the 
energy to develop them.  
My sincere thanks to the other members of my PhD committee: 
prof.dr. Eric Claassen, prof.dr. Jan Hendrik Richardus and dr. Janneke 
van de Wijgert. I feel honored that the scientists who have been 
remarkable examples since I started my PhD are willing to be 
members of my committee. 
Acknowledgements 
 234 | 
  
With a project idea, an e-mail address, a tent and a sleeping bag, I 
arrived at Mwanza Airport, Tanzania in July 2006. Not knowing what 
would come of the new adventure, I was introduced to dr. John 
Changalucha, director of the National Institute for Medical Research, 
Mwanza. Dr. Changalucha, your leadership, patience and endless 
support have resulted in solid and interesting projects that we could 
work on together. I admire how altruistically you give your time, 
energy, and advice to those you are working with and many others.  
Dr. Butamanya, I am thankful that I had the opportunity to work 
with such a passionate and hard-working physician. Thank you for 
sharing your knowledge, life experience and for introducing me to 
your important professional network.  
Adrian Cook, the cups of tea at your house and helpful (statistical) 
advice have been a point of rest amidst chaos. Thank you for your 
willingness to join the team and work on the projects.  
I am indebted to the women who were the heart of our clinical 
team: Mama Karoko, Flora and Judith. Thank you for your fearless 
enthusiasm, initiative, and efforts to make our project a success. Our 
lunches together after a full day of hard work are among the best 
memories of my time in Africa. Simon, Oswald, Julius and Aura, 
thank you for your patience, diligence and our good times together.  
I would like to acknowledge the Western Heads East initiative of 
the University of Western Ontario, which provided much of the 
infrastructure and support for my study in Tanzania. Bob Gough, dr. 
Melanie Katsivo, dr. Sharareh Hekmat, I am indebted to your 
willingness to collaborate and am inspired by your continuing efforts 
for people living with HIV in Africa. My house-mates and colleagues, 
Stephanie and Tara, I feel very fortunate to have worked together 
with you in Mwanza and I am looking forward to the many 
adventures that are still in store for us. 
A special thanks to Maimuna Kanymala and her team at Kivulini 
Women’s Rights Organisation in Mwanza. Thank you for your help in 
assembling a research team, connecting me with important people, 
and your kind support. Dear Pendo, thank you for your Swahili, faith 
and cooking lessons plus the joy you brought to our house.  
Joke, you successfully incepted various projects in Mwanza and I 
feel privileged to have worked together with you. Thank you for your 
efforts in getting samples to Canada and too many other things to 
Acknowledgements 
 | 235  
mention. Arja and Yolanda, you have completed a nice project in 
Mwanza at an incredible pace, thank you for our collaboration. 
  
The pain of returning to this swamp we call Holland was greatly 
relieved by my hilarious roommates Jesse and Marleen. Though I was 
not in the office for long, you have always made me feel at home. 
Caspar Looman, thank you so much for your extraordinarily clear and 
helpful support with complex statistical analyses. You are a brilliant 
teacher and have a talent to make really complex things seem 
manageable. Other colleagues from the Department of Public Health -
Sake, Wilma, Natasja, Luc, Gerard, Ton, Farsia, Kees - many thanks 
for the nice conversations and helpful advice. I am also truly grateful 
to the fantastic administrative support team at the Department of 
Public Health, and of course, the miracle workers of the computer 
helpdesk. 
  
I arrived in Canada with some boxes of tediously collected swabs, 
hoping to do a small study. This study evolved into a fascinating 
experiment that has changed the way we analyze and understand the 
composition of the human microbiota. This shift can be largely 
credited to prof.dr. Greg Gloor. Greg, thank you so much for turning 
a simple clinician into a simple clinician who at least appreciates the 
trouble of laboratory work and who can do some PCR. You are an 
excellent teacher.  
Jean, many thanks for your fantastic ideas and efforts in 
developing our projects. I have felt lucky to work with someone with 
so much intelligence and dedication who can make me laugh instantly 
at the same time. Andrew and Russ, despite the vast distance 
between us in mathematical insight, you were brave enough to take 
up our project together. Many thanks for your hard work. 
A special note to Lesley, you have made me feel welcome right 
from the start. I will never forget you cheering for me at my race, 
and our laughs together. Dr. Wayne Miller, I am thankful for all your 
editing work, your strong enthusiasm and great input for the projects 
I was working on (even if it was investigating the health effects of 
Tim Horton’s French Cappuccinos.)   
Jordan, thank you for being at the core of the postmenopausal 
health study, you continue to blow me away with your stellar 
combination of intelligence, creativity and passion for scientific 
Acknowledgements 
 236 | 
questions. Amy, thank you for your amazing input to many aspects of 
the projects we were working on. Rod, among many other things, 
thank you for the manuscript we wrote together; Marc for the 
innumerable slides and great laughs; Sarah, too many practical 
issues to mention; and Kate, for your introduction to the Reid lab. 
Many thanks to the administrative support team at the Lawson Health 
Research Institute and members of the Students Association that 
have made me feel at home. To our Wageningen collaborators: Drs. 
Paul Vos, Belinda van’t Land and Klaske van Norren, I am very 
thankful, and feel indebted to your great input in writing our 
manuscript that is featured in this thesis. It was an absolute privilege 
and pleasure to collaborate with you. 
  
Bouke, finally I get to acknowledge your contribution to the 
figures, and your patience with the innumerable hours of whistling 
while this thesis was finished. Vincent, thank you for your brilliant 
cover art. The cover alone made this thesis worth writing! 
I want to especially mention Greg and Susan Hemsworth; thank 
you for welcoming me into your family and for the many good times 
in Canada. My brothers and sisters, Rob, Jos, Klaske and Ryan, Anne 
and Ruth, Arjen and Froukje, thanks for inspiring me and our 
friendship.  
Dad and Mum, I am deeply thankful for the great examples you 
have been and the safe haven you always have provided. It’s 
extraordinarily how two people teaming up can have such an impact 
on my life and the lives of many others. Mum, you are a remarkable 
woman. Your encouragement and fine intuition have shaped and 
inspired me to become the person I am. Dad, you are a great 
example and mentor. Thank you for sparking of an interest in a 
number of random things including growing vegetables, adventure 
and yes, human health.  
Dear Jaimie, I did not know that there could be such a profound 
connection between two souls. At our first meeting you were the lady 
with Malaria at the back seat, but we very quickly developed a deep 
appreciation and love for each other. I feel very blessed that I can 
look forward to a life together with you as my best friend and soul-
mate. 
Curriculum vitae 
 | 237  
About the author 
 
Ruben Hummelen (1984) was born in 
Ngqeleni, South-Africa, and grew up in 
Ede, the Netherlands. He graduated from 
secondary school (Ichthus College, 
Veenendaal) in 2003 after which he 
enrolled in Medical School at the Erasmus 
University Rotterdam. In 2004 he 
participated in a research project on the 
gut microbiota and inflammatory bowel 
disease (department of immunology, 
prof.dr. H. Drexhage) which sparked of 
his interest in the human microbiota. In 2005 he was selected for a 
research master in Clinical Epidemiology at the Netherlands Institute 
of Health Sciences (Nihes). The studies incepted during this master 
were developed further and are presented in this thesis (promoters: 
prof.dr. G. Reid and prof.dr. J.D.F. Habbema). Studies were 
conducted from 2007 - 2008 at the National Institute for Medical 
Research, Mwanza, (director: dr. J. Changalucha) and Sekou-Toure 
regional hospital, Mwanza, Tanzania (supervision: dr. N. Butamanya). 
Projects were completed and analyzed at the department of Public 
Health, Erasmus University Rotterdam, the Netherlands.  Further 
research was conducted in Canada from 2009 – 2010 at the 
University of Western Ontario, London, Canada. Ruben is founding 
member and past program director of the Students and Fellows 
Association of the International Scientific Association of Probiotics and 
Prebiotics. He currently serves on the editorial board of 
Gastroenterology Research and World Journal of Gastrointestinal 
Pathophysiology. In 2009 he obtained his Masters degree in Clinical 
Epidemiology and is currently completing his clinical internships in 
Rotterdam. Ruben is actively involved in social work in the Tarwewijk, 
Rotterdam, and acts as chair of the foundation friends of House of 
Hope. 

Publications 
 | 239  
International Publications 
1. Irvine SL, Hummelen R, Hekmat S, Looman CW, Habbema 
JDF, Reid G. Probiotic yogurt consumption is associated with 
an increase of CD4 Count among people living with HIV/AIDS. 
Journal of Clinical Gastroenterology. 2010; 44: 201-5 
2. Hummelen R, Hemsworth J, Reid G. Micronutrients, N-Acetyl 
Cysteine, Probiotics and Prebiotics, a Review of Effectiveness 
in Reducing HIV Progression. Nutrients 2010;2:626-51. 
3. Hummelen R, Fernandes AD, Macklaim JM, Dickson RJ, 
Changalucha J, Gloor GB, Reid G. Deep Sequencing of the 
Vaginal Microbiota of Women with HIV. PloS one 2010; 5(8): 
e12078 
4. Gloor G, Hummelen R, Macklaim JM, Fernandes AD, Reid G. 
Microbiome profiling by combinatorial barcoding with Illumina 
sequencing. PloS one 2010; 5(10): e15406 
5. Hummelen R, Changalucha J, Butamanya NL, Cook A, 
Habbema JDF, Reid G. Lactobacillus rhamnosus GR-1 and L. 
reuteri RC-14 to prevent or cure bacterial vaginosis among 
women with HIV. International Journal of Gynaecology and 
Obstetrics 2010: 111(3):245-8 
6. Hummelen R, Vos AP, van't Land B, van Norren K, Reid G. 
Altered host-microbe interaction in HIV: a target for 
intervention with pro- and prebiotics. International Reviews in 
Immunology 2010; 29: 485-513. 
7. MacPhee R, Hummelen R, Bisanz JE, Miller WL, Reid G. 
Probiotic strategies for the treatment and prevention of 
bacterial vaginosis. Expert Opinion in Pharmacotherapy 2010; 
11(18):2985-95.  
8. Shane AL, Cabana MD, Vidry S, Merenstein D, Hummelen R, 
Lynch S, Merenstein DJ, Sanders ME, Tancredi DJ, Vidry S. 
Guide to designing, conducting, publishing and communicating 
results of clinical studies involving probiotic applications in 
human participants. Gut Microbes 2010; 1: 243 - 53. 
Publications 
 240 | 
9. Hummelen R, Changalucha J, Koyama TEK, Butamanya N, 
Habbema JDF, Reid G. Effect of 25 weeks probiotic 
supplementation on immune function of HIV patients. 
Submitted 
10. Hummelen R, Hemsworth J, Changalucha J, Butamanya N, 
Hekmat S, Reid G. Trial of micronutrient supplemented yogurt 
with or without probiotic Lactobacillus rhamnosus GR-1 among 
anti-retroviral naïve HIV patients. Submitted 
11. Monachese M, Cunningham-Rundles S, Diaz MA, Ermond E, 
Guerrant R, Hummelen R, Kemperman R, Kerac M, Kort R, 
Merenstein D, Panigrahi R, Ramakrishna B, Safdar N, Shane A, 
Trois L, Reid G. Probiotics and prebiotics to combat enteric 
diarrheal diseases and HIV in the developing world: a 
consensus report. Submitted 
12. Dols JAM, Boon JA, Bontekoe R, Monachese M, Changalucha J, 
Butamanya N, Varriano S, Vihant O, Hullegie Y, van Tienen A, 
Hummelen R, Reid G.  The challenges of assessing the 
impact of probiotic yogurt on the well-being of HIV positive 
women in Tanzania. Submitted 
13. Hummelen R, Bisanz JE, Macklaim J, MacPhee R, Hammond 
J, Gloor GB, Reid G. The vaginal microbiome of post-
menopausal women and correlation with inflammatory and 
atrophic changes. Submitted 
PhD portfolio 
 | 241  
PhD Portfolio Summary 
Summary of PhD training and teaching activities 
Name PhD student: Ruben Hummelen 
Erasmus MC Department: Public Health 
Research School: Nihes 
PhD period: 2007-2010 
Promotor(s): Prof.dr. G. Reid, 
Prof.dr. J.D.F. Habbema 
1. PhD training Year Load 
Research skills 
- Master of Clinical Epidemiology, Netherlands Institute for 
Health Sciences (Nihes), Rotterdam, The Netherlands 
 
2006-‘9 
 
 
30 ECTS 
In-depth courses  
- Summer course Epidemiology and Biostatistics, Johns 
Hopkins University, USA 
- Course on protection of human research subjects and 
Good Clinical Practices (GCP), London School of Hygiene 
and Tropical Medicine, Mwanza site, Tanzania. 
 
2007 
 
2008 
 
120 hours 
 
40 hours 
Presentations and international conferences 
- European Conference on Probiotics, Krakow, Poland*  
- 6th Meeting of the International Scientific Association for 
Probiotics and Prebiotics (ISAPP), London, Canada*  
- International scientific conference on functional foods, 
Zilina, Slovakia*  
- 5th International Yakult Symposium, Amsterdam, The 
Netherlands# 
- Sackler symposium of the National Academy of Sciences, 
California, USA 
- 7th Meeting of ISAPP, California, USA* 
- TNO beneficial microbes conference, Noordwijkerhout, 
the Netherlands* 
- 8th Meeting of ISAPP, Barcelona, Spain# 
- Human Microbiome Research Conference, National 
Institutes of Health, St. Louis, Missouri, USA$ 
- Bill & Melinda Gates Foundation exploratory meeting 
Enteric and diarrheal diseases, January 5-7, London, UK# 
- 6th international Symposium on Probiotics, Montreal, 
Canada$ 
*Presentation, #Poster presentation, $Abstract 
 
2008 
2008 
 
2009 
 
2009 
 
 
2010 
 
2010 
2010 
 
2010 
2010 
 
2010 
 
2010 
 
32 hours 
36 hours 
 
30 hours 
 
36 hours 
 
 
20 hours 
 
24 hours 
50 hours 
 
32 hours 
1 hour 
 
5 hours 
 
1 hour 
 
Awards and grants 
- Grant in Aid Danone Institute Canada 
- Best presentation European Conference on Probiotics, 
Krakow, Poland 
 
2007 
2008 
 
 
 
PhD portfolio 
 242 | 
- Nominated Young Investigators Award, International 
Scientific Conference on Scientific Foods, Zilina, Slovakia 
- VSB Scholarship 2009 for research 
- Travel Grant for 8th meeting ISAPP 
2008 
 
2009 
2010 
2. Teaching activities Year Load 
- Guest lecture, Scientific meeting National Institute for 
Medical Research, Tanzania  
- Lecture, Symposium Stola, Erasmus University 
Rotterdam, the Netherlands  
- Lecture, Lawson Health Research Institute, London, 
Canada.  
- Lecture, Meeting Canadian Research and Development 
Centre for Probiotics, London, Canada  
- Guest lecture, Department of Nutrition, Fanshawe 
college, London, Canada  
- Guest lecture, Meeting department of Biochemistry, 
University of Western Ontario, London, Canada.  
- Lecture, Staff Conference, University of Western Ontario, 
London, Canada.  
2008 
 
2009 
 
2009 
 
2010 
 
 
2010 
 
2010 
 
2010 
 
6 hours 
 
4 hours 
 
2 hours 
 
2 hours 
 
 
4 hours 
 
2 hours 
 
4 hours 
Supervising theses 
- Bachelor thesis (Nutrition) 
- Bachelor thesis (Microbiology) 
- Master thesis (Medicine) 
- Master thesis (Public Health) 
 
2008-‘9 
2010 
2010 
2008-‘9 
 
80 hours 
24 hours 
24 hours 
90 hours 
3. Other activities 
- Program director Students and Fellows Association (SFA) 
of ISAPP 
- Organiser and chair session at 8th meeting of ISAPP 
2010. 
 
2009-
‘10 
2010 
 
30 hours 
 
14 hours 
 
 
 
